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I Summary 
 
Cancer of the uterine cervix (cervical cancer) represents 6.6% of all female cancers with 
570,000 new cases as of 2018 and is the fourth most frequent cancer worldwide. Human 
papillomavirus (HPV), especially type 16 has been recognized as a necessary and causal 
factor in the pathogenesis of this malignancy. Effective screening for HPV-induced 
precursor lesions plays a huge role in reducing cervical cancer mortality rate globally and 
HPV DNA testing has recently become one of the recommended screening tests. 
However, all the HPV DNA tests available while highly sensitive lack high specificity and 
positive predictive value for advanced lesions and therefore lead to unnecessary anxiety 
and overtreatment in many screen-positive women. Consequently, HPV RNA tests have 
been developed for the intelligible discrimination of low (LSIL) and high grade squamous 
intraepithelial lesions (HSIL). These tests identified a significant upregulation of E1C 
transcripts in HSIL and CxCa. Therefore, E1C has been proposed as a diagnostically 
relevant RNA marker, which is capable of distinguishing LSIL from HSIL. 
In this PhD thesis, HPV16 E1C was characterized to define its role in cervical 
carcinogenesis. Specifically, E1C was overexpressed in four different HPV16-positive cell 
lines to analyze its effect on different HPV16 transcripts involved in cell cycle progression 
and transformation. E1^E4 transcripts showed a significant downregulation upon E1C 
overexpression, whereas E6*I and E7 transcripts remain unchanged. When investigated 
for the presence of endogenous E1C protein, the HPV16 E1C transcript positive cell lines 
tested stained negative in western blot. However, transiently overexpressed E1C protein 
in HEK-293T cells after proteasome inhibition was detectable in western blot and mass 
spectrometry, which points towards the instability of the protein. HEK-293T cells co-
transfected with E1C expression construct and construct expressing a reporter under 
control of the HPV16 upstream regulatory region (URR) demonstrated URR activation by 
E1C transcripts even when E1C translation was abolished by mutation hinting that E1C 
RNA is the biologically active form of E1C. Additional experiments must be performed to 
study further about the viral and cellular changes driven by E1C RNA and to understand 
its upregulation in high-grade lesions. 
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II Zusammenfassung 
 
6.6% aller Karzinome bei Frauen sind Zervixkarzinom. Im Jahr 2018 wurden 570.000 neue 
Diagnosen gestellt, womit es der vierthäufigste Krebs weltweit ist. Effektives Screening spielt 
global eine große Rolle für eine Reduktion der Mortalitätsrate und HPV DNA Tests ist einer der 
empfohlenen Screening tests. Jedoch haben alle bisher verfügbaren HPV DANN Tests schlechte 
Spezifitäten und schlechte positive prädiktive Werte und führen dadurch zu unnötiger 
Verängstigung und Überbehandlung von Frauen. Dementsprechend wurden HPV RNA Tests 
entwickelt, um LSIL und HSIL bzw. CIN Grade zu unterschieden. Ein entwickelter RNA Test 
basiert auf einer singleplex Sequenz-basierten NASBA Amplifikation und analysiert E6*II/E1^E4 
und E1C/L1 Verhältnis und wurde weiterentwickelt zu einer quantitativen Echtzeit-Polymerase-
Ketten-Reaktion zur Identifizierung von E6*I/E1^E4-Verhältnis und/oder der E1C Präsenz in 
HPV16 DANN-positiven Zervixabstrichen. Der ursprüngliche RNA Test hat eine signifikante 
Hochregulierung von E1C in HSIL und im Zervixkarzinom identifiziert, der weiterentwickelte Test 
eine fast ausschließliche Präsenz von E1C in ≥CIN3. So wurde E1C als diagnostisch relevanter 
RNA Marker identifizier, der in der Lage ist, niedrig- und hochgradige Zervixläsionen zu 
unterscheiden. 
In dieser Doktorarbeit wurde HPV16 E1C erstmalig charakterisiert, um dessen Rolle in der 
zervikalen Karzinogenese zu verstehen. E1C wurde in verschiedenen HPV16-positiven Zelllinien 
überexprimiert, um einen Effekt auf andere HPV16 Transkripte (E1^E4, E6*I, E7) zu analysieren, 
die bekannt sind in die Zellzyklusprogression und Transformation involviert zu sein. E1^E4 wurde 
signifikant herunterreguliert, während E6*I und E7 unverändert blieben nach E1C 
Überexpression. Jedoch konnte endogenes E1C mittels Western Blot in HPV16-positiven 
Zelllinien nicht identifiziert werden. Nach der transienten Überexpression von E1C in HEK-293T 
Zellen konnte E1C erst nach Proteasomeninhibition per Western Blot und Massenspektrometrie 
nachgewiesen werden, was auf die hohe Instabilität des Proteins hinweist. HEK-293T Zellen 
wurden neben E1C auch mit HPV 16 URR (vorgelagerte regulatorischer Region) bzw. mit E1C 
Protein, welches für Translation mutiert wurde, transfiziert. Es wurde eine Aktivierung des URR 
ausschließlich von E1C identifiziert, was auf eine biologische Aktivität der E1C RNA hinweist. 
Weitere Experimente müssen in Zukunft durchgeführt werden, um die viralen und zellulären 
Veränderungen getrieben von E1C RNA zu verstehen und herauszufinden, ob dies 
Konsequenzen auf die zervikale Karzinogenese hat.  
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1. Introduction 
 
1.1. Papillomaviruses 
 
Papillomaviruses are DNA viruses that belong to Papillomaviridae family, which consists 
of a diverse group of viruses found in birds, reptiles, marsupials and mammals1. More 
than 150 Human Papillomaviruses (HPVs) have been identified which are divided into 
five genera Alpha, Beta, Gamma, Mu and Delta2,222(Figure 1.1.). Although many HPV 
cause chronic inapparent infections, some can cause serious diseases3.  Among the five 
genera, Alpha-papillomaviruses cause mucosal and cutaneous lesions whereas Beta-
papillomaviruses cause only cutaneous lesions4. Based on their presence as single 
infections in cervical cancer cases mucosal Alpha-papillomaviruses are further classified 
into low-risk and high-risk types4. Low-risk HPV cause only benign lesions whereas high-
risk HPV cause pre-malignant and malignant lesions and immortalize human 
keratinocytes4.  
 
1.2. Human Papillomaviruses (HPV) 
1.2.1. Virus structure 
Papillomaviruses are non-enveloped viruses with an icosahedral capsid of 50-60nm 
diameter (Figure 1.2.). They comprise of 8 kb genomes which are double-stranded and 
can encode for eight or nine open reading frames (ORF)3. Owing to the use of multiple 
promoters and complex splicing patterns, the number of proteins encoded by the small 
HPV genome is much greater5. The virus capsid consists of L1 protein, which are 
arranged into capsomeres. Each capsomere has a beta-jelly core and is made up of 5 L1 
molecules. There are a total of 72 capsomeres on the virus capsid and therefore a total 
of 360 L1 molecules6,7. The virus capsid also contains variable number of L2 molecules. 
Only the N-terminal 120 amino acids (aa) of L2 molecules are exposed on the surface of 
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the virion8,9. During infection, L2 binds to the extracellular matrix and is cleaved by a 
proprotein convertase, furin10.  
 
 
Figure 1.1. Evolutionary tree of HPV. Modified from3. The HPVs are categorised into five genera with the largest 
groups belong to the Alpha and the Beta/Gamma genera. The Alpha low-risk cutaneous HPVs are in the gray region, 
low-risk mucosal in the orange region and high-risk in the pink region. The high-risk types categorised as “human 
carcinogens” are in red text in the pink region and the other Alpha high-risk types are “probable” or “possible” 
carcinogens.  
 
1.2.2. Genome organization 
The ORF of the HPV genome can be classified to early or late categories11. The early 
ORF consist of E1, E2, E4, E5, E6 and E7 and late ORF consist of L1 and L2 (Figure 
1.3.). E1, E2, L1 and L2 genes are well-conserved in papillomaviruses12. E1 is involved 
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in viral DNA replication and amplification and encodes a virus-specific DNA helicase. E2 
protein plays important roles in viral transcription, replication and genome partitioning and 
has binding sites on both viral and cellular genomes3. E4 protein helps viruses to escape 
from epithelial surface13. E5 protein is involved in immune evasion and genome 
amplification14. 
 
 
 
Figure 1.2. Electron micrograph of HPV particles. Modified from86. A negatively stained transmission electron 
micrograph showing HPV particles of 55 nm in diameter. 
 
E6 and E7 proteins drive cell cycle entry in all HPV types and allow genome amplification 
and are therefore called as the oncoproteins. The Upstream Regulatory Region (URR), 
as the name suggests, consists of regulatory elements such as promoters, origin of 
replication, transcription factor binding sites etc. and is located between the end of L1 and 
the start of early region3. L1 and L2 aid orchestration of proper genome packaging6.  
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1.2.3. HPV life cycle 
HPV replication is tightly linked to differentiation of the epithelium it infects15. HPV 
accesses dividing basal epithelial cells through microabrasions or wounds and uses 
heparin sulphate proteoglycans for cell attachment16,17 (Figure 1.4.). In some cases, α6-
integrin is used as the virus receptor18,19 and virus entry is aided via either calveolar or 
clathrin-mediated endocytosis16,20. The viral genome is transported to the cell nucleus 
followed by virus entry. Viral genome is replicated to approximately 50 copies during the 
division of infected cell and attaches to host chromosomes, thereby gets maintained in 
the daughter cells upon segregation of the divided cell. 
 
Figure 1.3. HPV16 genome organization. Modified from86. This is the typical genome organization of all high-risk 
Alpha HPV types. The two arrowheads represent the early and late promoters, P97 and P670 respectively. E1, E2, E4 
and E5 ORF are shown in green and E6 and E7 ORF in red. The late ORF, L1and L2 are shown in yellow. E1, E2 and 
cellular SP1 transcription factor binding sites on the long control region (LCR, also known as URR) are shown.  
 
Normally, during differentiation epithelial cells stop to divide and terminally differentiate15. 
However, cell division is re-activated, apoptosis is inhibited and differentiation is 
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abrogated in HPV-infected epithelial cells by the concerted action of the oncoproteins (E6 
and E7) and tumor suppressors (p53 and pRb)21. Upon division of the infected cell, the 
daughter cells move to the suprabasal differentiating cell layers. The proliferation of the 
infected cells is promoted by the restricted expression of E5, E6 and E7. Late viral gene 
expression, viral DNA replication and formation of capsid proteins such as L1 and L2 are 
initiated in the infected cells of the suprabasal layers22. Assembly and release of the 
infectious virions take place in the upper layers of the epidermis. It is thought that E4 
protein amyloid fibers might play a role in virion release by disrupting the keratin structure 
of the upper epithelial layers3 (Figure 1.4.).  
 
 
Figure 1.4. The life cycle of HPV. Modified from145. Abrasion of the basement membrane (BM) gives HPV, access to 
the basal keratinocytes. During infection, HPV binds to heparin sulphate proteoglycans (HSPGs) on the BM through L1 
which leads to conformational changes in L1 and exposes L2. Extracellular furin cleaves amino terminus of L2 and 
virus entry is initiated. The viral genome replicates to produce ~50 HPV episomes and divides between progeny upon 
cell division. E6 and E7 stimulates the continued proliferation and E1 and E2 drive viral genome replication. E4, L1 and 
L2 are expressed in the upper epithelial layers upon differentiation of the infected cells and orchestrate viral genome 
packaging. With the aid of E4, virions are released by the disintegration of the cytokeratin filaments. No cell 
death/viraemia /inflammation is caused during the completion of life cycle, thus evading local immune responses. APC 
– Antigen-Presenting Cell. 
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1.2.4. HPV gene expression 
1.2.4.1. Transcription 
HPV transcription is initiated at least from two promoters and is polycistronic. It yields 
multiple mRNAs with several ORF (Figure 1.5.). For HPV16, the two well characterized 
early and late viral promoters respectively are P97 and P67015. P97 is located in the URR 
and is constitutively active throughout the virus replication cycle23-26. 
 
 
 
 
 
Figure 1.5. Transcription map of HPV16. Modified from204. Colored rectangles at the top of the figure denote the ORF. 
The numbers on the rectangles denote the following – first number at the upper left end – start nt of the ORF, second 
number at the upper left end – first nt of the first start codon (also marked by dotted line inside the rectangle), number 
at the lower right end  - last nt of the last stop codon. Various spliced mRNA species of HPV16 and their coding potential 
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are shown. Black rectangles are untranslated exons and black lines are intervening introns. Splice donor and acceptor 
nt positions are indicated below each spliced mRNA species146,147. 
 
The late differentiation-regulated promoter, P670 is located within the E7 ORF27. P97 is 
controlled by E2 protein and many cellular transcription factors28. There are four E2 
binding sites in the promoter, E2BS1, E2BS2, E2BS3 and E2BS4. E2BS1 is located in 
the distal promoter region, E2BS2 is located upstream to the keratinocytes enhancer and 
E2BS3 and E2BS4 are near to the TATA box. The P97 promoter is transcriptionally 
repressed by E2 in a normal infection so that E6 and E7 levels remain low and the 
epithelial cells do not progress to tumor. A combination of E2, TATA box and cellular 
transcriptional repressor protein, Sp1 seem to be involved in the repression of P97 
promoter15. During epithelial differentiation, the proteins bound to the URR and the 
strength of their binding are likely to regulate the transcriptional changes required for the 
virus life cycle completion29. In HPV16 many transcription initiation sites have been shown 
to be regulated by P67027,30,31.  Studies have also shown that keratinocyte enhancer 
present in the URR could contribute to P670 regulation15. Other promoters have also 
reported to be present in HPV genomes. Like BPV-1, HPV might also have a similar set 
of promoters in the early region32.  Presence of a late promoter at the start of the E4 ORF 
has been verified by several studies30,33,34.  
 
1.2.4.2. Splicing 
Most HPV mRNAs are produced by constitutive and alternative splicing. As transcription 
progresses, if every intron in the primary RNA transcript is removed, then it is called 
constitutive splicing. Alternative splicing occurs when exons or introns are skipped. In 
HPV, the first and second splice events are generated from the splice donor sites in E6 
and E4 ORFs, which use different splice acceptor sites in the E6, E7, E4 and L1 ORF15. 
Regulation of splicing occurs through cis-acting splicing signals and RNA/protein 
complexes knows as spliceosomes35,36. Some members of the serine-arginine (SR) –rich 
protein family regulate viral RNA splicing37. SR proteins such as SRp20, SC35 and 
SF2/ASF are shown to increase in the mid to upper layers of high-risk HPV infected 
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cervical epithelia38. During infection, E2 controls the expression of these SR proteins. 
During the late phase of virus replication cycle, SF2/ASF is upregulated via E2, which is 
essential for the expression of L1 and L239,40. 
 
1.2.4.3. RNA stability and translation 
HPV gene regulation is controlled post-transcriptionally. Expression of L1 and L2 can be 
regulated through the stability of their mRNAs. In HPV16, a regulatory element is located 
at the end of L1 ORF which extends to the late 3’ untranslated region (UTR)41-51. This 
element blocks L1 and L2 expression in lower epithelial cells by making any transcribed 
mRNAs unstable52. This helps the virus in preventing the cells from triggering any immune 
response as the capsid proteins are highly immunogenic. The regulatory element of 
HPV16 has been shown to bind to a cellular RNA stability regulator, HuR. HuR 
overexpression in undifferentiated HPV-infected epithelial cells increases L1 expression 
and siRNA depletion of HuR decreases L1 expression, which underlies the significance 
of cellular factors in regulating viral late gene expression49,53. 
Few studies have shown that virus mRNA translation is regulated for efficient virus 
replication. A regulatory element which regulates stability of late mRNAs54 has been 
characterized for HPV1. This hints to the possibility that mRNA stability and translation 
could be working hand-in-hand for the regulation of various genes. Also, there could be 
other HPV regulatory elements that are involved in similar processes55. Codon usage also 
controls translation efficiency. HPV mRNAs use rare codons, perhaps a mechanism for 
efficient translation in the background of host cell translation56,57. 
 
1.2.4.4. HPV16 transcripts and proteins 
E1 full length (E1fl) or simply E1protein is an ATP-dependent DNA helicase which is 
essential for replication and amplification of viral genome. It is encoded from E1 ORF and 
is 600-650 aa long. E1 binds to the ori with the help of E2 protein202. A putative E1C 
protein of 82 aa length147, first 5 aa from the amino terminus of E1 and the last 77 aa from 
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the carboxy terminus of E1, could be translated from 880^2582 spliced mRNA (Figure 
1.5., species I-K).  
E2 proteins are sequence specific DNA binding proteins, which are associated with 
transcription and replication of the viral genome. It can be encoded from 226^2709 (Figure 
1.5., species H), 880^2709 (Figure 1.5., species E-G) and 880^2582 (Figure 1.5., species 
I-K) spliced mRNA species64,147. As a transcription factor, E2 regulates the viral promoter 
P97 and thus regulates the expression of oncogenes, E6 and E7. E2 activates the 
transcription of oncogenes at low levels and represses their transcription at high levels65. 
E2C, which is a shorter form of E2 is translated from 1302^3358 mRNA (species N) and 
probably inhibits the function of fl E266. A putative E2M protein could be expressed from 
species O transcript. 
The E1^E4 protein interacts with proteins of the keratin cytoskeleton and helps in virus 
assembly and virus release67. It is translated from 880^3358 spliced mRNA species 
(Figure 1.5., species A-C, L)147. 
E5 protein could be involved in potentiation of EGF receptor signalling pathway. Another 
phenotype, which has been attributed to E5, is assisting cell immortalization and 
transformation by E6 and E7203. The unspliced E2/E5 transcript encodes for E5 protein 
(Figure 1.5., species E-G, M)147. 
The fl E6 ORF encodes for E6 protein (Figure 1.5., species A, G, K) and E7 is translated 
from E6*I mRNA73-75 (Figure 1.5., species B, E, I) or from the fl E6/E7 mRNA23,76,77,147. 
E6 and E7 proteins of high-risk HPVs bind and degrade cellular tumor suppressor 
proteins such as p53 and pRb respectively and thereby promote transformation. 
Either unspliced transcripts or transcripts spliced between nt 1302 and nt 5639 (Figure 
1.5., species P)34 or nt 3632 (Figure 1.5., species O)147 encode for L1 protein. These 
transcripts are initiated by the late promoter P670. L2 protein is expressed only from 
unspliced late transcripts. L1 and L2 proteins are expressed during the late stages of the 
productive infection. However, detection of L1 and L2 RNA in lower epithelial layers79,80 
indicates that their expression is also regulated post-transcriptionally81,82. 
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1.2.4.4.1. Domain structure of E1 and putative E1C proteins 
E1 protein consists of three functional segments58. A regulatory region at the N-terminus, 
an origin-binding domain at the centre and an enzymatic domain (also helicase domain) 
at the C-terminus (Figure 1.6.). The regulatory region is necessary for viral DNA 
replication and is approximately 200 aa long. It contains various sequence motifs such as 
nuclear localization signal and nuclear export signal58. The origin-binding domain is also 
known as the DNA-binding domain and is approximately 150 aa long. It is capable of 
recognizing certain sites of ori58. The helicase domain is roughly 300 aa long which has 
ATPase activity and unwinds viral DNA during replication. It consists of three functional 
regions: the minimal oligomerization domain, the AAA+ ATP-binding module and the C-
terminal brace58. Oligomerization domain is involved in the self-assembly of E1 into 
hexamers during viral DNA replication. AAA+ is an ATPase and therefore as the name 
suggests, AAA+ ATP-binding module is involved in ATP-binding and hydrolysis. C-
terminal brace is a short flexible region. It also helps in assembling E1 to hexamers and 
its stabilization58. 
 
 
 
Figure 1.6. Domain structure of BPV1 E1. Modified from58. Light purple box is the N-terminal regulatory region and 
the nuclear localization signal (NLS) is shown. DNA binding domain (DBD), Oligomerization domain (O), AAA+ ATP-
binding module or ATPase domain and Brace are shown in dark purple boxes. The numbers marked below are aa. 
 
As mentioned earlier, the putative E1C protein comprises of 5 aa from the N-terminus 
and 77 aa from the C-terminus of full length E1 protein. The E1 protein of HPV16 is 649 
aa long204, which means the C-terminus of putative HPV16 E1C protein will have 573 – 
649 aa region of E1 protein. Therefore, last few aa of the ATPase domain and brace 
13 
 
region are present in the E1C protein, which could mean that E1C protein can probably 
hold the function of brace region. 
 
1.3. Cervical Cancer (CxCa) 
1.3.1. Global burden of CxCa 
CxCa is the fourth most common cancer in women and the seventh most common cancer 
overall. 528,000 new cases and 266,000 deaths from CxCa had been estimated 
worldwide in 2012. Around 85% of CxCas occur in the less developed regions, where 
CxCa accounts for almost 12% of all cancers in females. High-risk regions include eastern 
Africa, Melanesia, southern Africa and central Africa. Incidence rates are lowest in 
Australia, New Zealand and western Asia83.  
High-risk HPVs are sexually transmitted and can cause CxCa if they persist. HPV16 is 
the predominant type causing 60% of the invasive CxCas worldwide followed by HPV18 
with 15%84. The histology system used for diagnosis is the Cervical Intraepithelial 
Neoplasia (CIN) scale. Mild dysplasia is categorised to CIN1, moderate dysplasia to CIN2 
and severe dysplasia and carcinoma in situ to CIN3. Majority of CIN1 (90%) regresses 
spontaneously. However only a minority of CIN3 progress to cancer in a lifetime85. The 
Lower Anogenital Squamous Terminology (LAST) is used156 in the United States for 
diagnosis. According to this system, squamous precursor lesions are grouped into low-
grade squamous intraepithelial lesions (LSILs) or high-grade squamous intraepithelial 
lesions (HSILs), and CIN2 category is placed in either one of them based on p16INK4A 
staining. p16INK4A is a marker related to cervical cancer progression. However, LAST is 
unspecific because many HPV infections stain positive for p16INK4A without a precancer86. 
 
1.3.2. Cofactors for HPV persistence  
HPV infections are generally asymptomatic86. More than 90% of the infections are 
undetectable within 5-7 years88 and persistence past 2 years is not common87. The virus 
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is either cleared or suppressed to a low level by cell-mediated immunity. The three major 
classes of cofactors that determine the persistence of an acquired cervical HPV infection 
are viral, host and behavioural variables. Viral variables include genetic differences in 
HPV. For e.g., infection by HPV16 has a precancer risk of one order of magnitude higher 
than other carcinogenic types such as HPV51, HPV56 and HPV5986. Host variables 
include host immune response, for e.g., the influence of HIV infection89. Behavioural 
variables include smoking, multiparity and long-term use of hormonal contraceptives90-92.  
The typical transition time from HPV infection to invasive CxCa lasts decades. Apart from 
age and time, no other strong predictors for invasion have been proven yet. However, 
certain epidemiological and laboratory studies have shown the role of female steroid 
hormones as an aetiological cofactor for CxCa86,91,93-97.  
 
1.3.3. Effects of HPV infection on host cell 
CIN1 lesions support the complete life cycle of HPV98. The deregulated expression of E6 
and E7 from CIN2 onwards promotes cancer progression (Figure 1.7.). E7 proteins 
stimulate host genome instability via binding and degrading multiple members of pRb 
protein family whereas E6 proteins bind and efficiently degrade p53 and interrupt the DNA 
repair pathway3. It is not clear what drives the deregulation of the viral episome; however, 
hormonal changes and/or epigenetic modifications of the infected cell may be the 
drivers99-102. DNA methyltransferases are another targets of E6 and E7 proteins causing 
hypermethylation of CpG islands of the cellular genome which in turn leads to the possible 
silencing of cellular tumor suppressor genes103,104. Interestingly, a mutational signature 
involving APOBEC (apolipoprotein B mRNA editing enzyme catalytic subunit) has been 
reported in HPV associated squamous cell cancers. Increase in E6 and E7 can increase 
cellular APOBEC levels. It has been suggested that APOBEC-mediated mutations might 
lead to the generation of virion variants, providing an evolutionary benefit for the virus105. 
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Figure 1.7. Molecular events during the progression of CxCa. Modified from86. Cell cycle marker minichromosome 
maintenance protein complex (red staining) is almost not present in the first immunofluorescence image.This is an 
example of a productive lesion and here, E6 and E7 are essential for genome amplification in the mid-epithelial layers. 
E4, L1 and L2 expression are mainly in the upper epithelial layers, but can be spreaded (green staining). Such lesions 
are labelled as CIN1 pathologically. In high-grade lesions (or abortive infections) E6 and E7 are further increased (red 
staining) and L1 and L2 are restricted (green staining). Such lesions would be labelled as CIN2 or CIN3 pathologically 
and correspond to precancers.  
 
1.3.4. Host response to high-risk HPV infection 
There is no sign of viraemia during HPV infection. That means, neither inflammation nor 
cell death occurs. In addition, no whole virus is found in the blood. There is no release of 
pro-inflammatory cytokines during the infection and thereby Langerhans cells are not 
recruited or activated. HPV16 E6 and E7 downregulate CC-chemokine ligand 20110 and 
E-cadherin111which are necessary for the function of Langerhans cells. Therefore, 
antigen-specific responses are also not activated and effector cells, which can target and 
kill infected epithelial cells, are not recruited86. Normally, keratinocytes respond with an 
antiviral state in response to viral infection106. Antiviral state constitutes of the expression 
of pattern recognition receptors by keratinocytes, which involves initiation of certain signal 
transduction cascades and activation of cellular transcription factors. These transcription 
factors are responsible for the generation of interferons and inflammatory cytokines107. 
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However, high-risk E6 and E7 directly interfere with the components of these cascades108 
and inhibit the immune response109.  
 
1.3.5. Diagnosis, Screening and Prevention 
The two major cervical cancer prevention strategies based on HPV are primary 
prevention and secondary prevention. Primary prevention is achieved through 
prophylactic HPV vaccines and secondary prevention through HPV assays which detect 
precancerous lesions that can be treated86. 
 
1.3.5.1. Primary prevention 
An effective method of primary prevention to control HPV related cancers is prophylactic 
vaccination. HPV vaccines which are currently in market comprise of Virus-Like Particles 
(VLPs) made of L1112. VLPs are non-infectious and comprise of the native virus particle 
with no DNA. The three licensed HPV prophylactic vaccines are Cervarix 
(GlaxoSmithKline (GSK), London, UK), Gardasil and Gardasil9 (both Merck, Kenilworth, 
New Jersey, USA). Cervarix is a bivalent vaccine and contains HPV16 and HPV18 
antigens113,114. 
Gardasil is a quadrivalent vaccine and provides protection against HPV6, HPV11, HPV16 
and HPV18115,116. Gardasil9 is a nonavalent vaccine and provides protection against 
HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52 and HPV58117,118. All 
vaccines are highly efficacious and confer complete protection when administered as per 
the protocol before virus exposure. The original vaccination administration protocol is 
three doses within six months119. Vaccination programs typically target girls of 9-13 years 
age and increasingly boys121. HPV vaccines had been introduced by 65 countries as per 
2016 statistics, which include high- and middle- income countries and also those that 
participate in GAVI (Global Alliance for Vaccines and Immunization) program120. 
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Systemic immunization with HPV vaccines generates 10-1000 times higher serum 
antibody concentrations than in natural infections116. In contrast to individuals having 
natural infections, those that are vaccinated strongly seroconvert122. Both type-specific 
and cross-neutralizing antibodies are generated, however concentrations of cross-
neutralizing antibodies are 10-100 times lower than type specific ones123,124. 
 
1.3.5.2. Screening 
Screening helps in detecting treatable precancers and early cancers. There are three 
major cervical cancer screening methods: 1) cytology 2) detection of DNA or RNA of high-
risk HPVs 3) cytology-HPV co-testing. In cytology screening, pathologists evaluate cells 
obtained from cervical sampling through a microscope. However, it is less sensitive than 
HPV testing or co-testing. Therefore, in order to achieve good sensitivity, shorter intervals 
between cytology screens are required125,126. HPV testing is capable of detecting 
precancers earlier and thereby can reduce the numbers of cancers in follow-up125,127. 
Therefore, longer intervals between screens can be considered. Compared to HPV DNA 
testing, RNA testing is a bit more specific. However, reassurance after a RNA test 
negative case still needs to be proven128. 
 
1.3.5.2.1. Triage of cervical screening positive women 
HPV-based screening is highly sensitive in detecting viral infection but cannot distinguish 
early stages of infection from advanced precancerous lesions, i.e. the native predictive 
value is high but the positive predictive values is rather low. Therefore, additional triage 
tests are needed to decide whom among the screen-positive individuals more intense 
examination by colposcopy (cervical examination) and biopsy129. During colposcopy, the 
outer surface of the cervix is observed with a magnifying lens and the detection of lesions 
is helped by staining with acetic acid. Colposcopy is used to guide biopsy for obtaining 
lesion tissue for final diagnosis by histology. 
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There are two triage tests available – microscopic or molecular. The microscopic triage 
option for HPV-positive women is cervical cytology. Recent studies suggest that in HPV-
positive women cytology is more sensitive for detecting precancer than in a screening 
situation, although with a possible loss in specificity130-132. 
The dual staining based on p16 and Ki67 is one of the molecular triage tests used in 
cervical screening. p16 is the cellular protein upregulated in transforming HPV infections 
and Ki67 is a marker for cellular proliferation. As per studies, women who stain positive 
for both should be referred to colposcopy and those who stain negative for both require 
only monitoring133-135. Another example of molecular triage is HPV genotyping, which is 
in use in the United States. Here, both HPV16 and HPV18 are genotyped136. Other 
molecular triage tests include checking for methylation of CpG sites in viral (E2, L1 and 
L2) and host genes137-141. 
 
1.3.5.3. Treatment and Management 
Histopathology is the accepted standard for deciding how the triage test-positive women 
should be treated. For e.g., although only some CIN3 lesions are invasive, all CIN3s are 
treated as they are considered as a surrogate of precancer142. By contrast, CIN1 lesions 
are considered as HPV infections and are not treated. CIN2 represents a heterogenous 
mixture of CIN1 and CIN3 and a large proportion of CIN2 regresses. Logically, therefore, 
clinicians decide not to treat CIN2 lesions143. 
The different treatment strategies available for cervical precancers are excision, ablation 
and possibly immunotherapy. The gold standard excision procedures include 1) using a 
cold knife 2) loop electrosurgical excision 3) loop excision of transformation zone. 
However, deep excisions could result in future childbirth complications. Ablation 
technologies include laser, cold coagulation and cryotherapy which are less invasive. 
However, ablation procedure might not be adequate for deep and large precancers86. 
Immunotherapy is still in experimental stage144. 
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The major options for treating invasive CxCas are surgery, external beam radiation, 
brachytherapy and cisplatin-based chemotherapy. Ultimately, the biggest goal is to 
provide vaccination, screening and early treatment to fight CxCa. Maximum coverage for 
HPV vaccines should be achieved as part of the ultimate preventive strategy for CxCa. 
 
1.4. HPV16 E1C  
1.4.1. HPV16 transcript pattern based triaging 
1.4.1.1. Diagnosing CxCa and high-grade precursors by HPV16 transcription 
patterns using NASBA-Luminex assay 
Unlike HPV DNA testing, RNA detection for screening identifies transcriptionally active 
viruses. However, E6/E7 transcript-based tests also in respect to specific detection of 
advanced lesions result in many false-positive results. This leads to overtreatment, 
unnecessary costs and anxiety for women concerned148-152. Therefore Schmitt and 
colleagues152 have developed an assay identifying novel HPV16 transcripts or RNA 
patterns for the intelligible grading of LSIL (low-grade squamous intraepithelial lesion) and 
HSIL (high-grade squamous intraepithelial lesion), which could be used as an improved 
screening tool for CxCa precursor screening programs. The study identifies 880^2582 
transcript (E1C transcript) as one of the useful biomarkers amongst others. 
They employed competitive nucleic acid sequence-based amplification (NASBA) and 
hybridization to oligonucleotide probes coupled to Luminex beads153 to quantify different 
HPV16 transcripts. They analyzed 10 spliced HPV16 RNA sequences (226^409 
(E6*I),226^526 (E6*II), 226^3358 (E6*III), 226^2709 (E6*IV),880^2582, 880^2709, 
880^3358 (E1^E4), 1302^3358,1302^5639, 3632^5639), 5 fl sequences(E6 fl, E7 fl, E1 
fl, E5 fl, L1 fl), cellular p16INK4A, and two housekeeping transcripts (Ubiquitin C (UbC) and 
U1A). The sensitivity of the NASBA assay was a detection limit of 25 to 2,500 copies for 
all transcripts except 25,000 copies for p16INK4A transcript. Regarding specificity, no 
cross-reactivity was observed with highly HPV16-related HPV types 31 and 33152. The 
study was conducted in 79 cervical swabs selected from Reims HPV Primary Screening 
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Cohort Study154,155 and consisted of 25 NIL/M (no intraepithelial lesion or malignancy), 23 
LSIL, 24 HSIL and 7 CxCa cases. 
The study describes two combinations of two viral transcripts to distinguish between LSIL 
and HSIL. The first combination comprises of 880^2582 transcript normalized to 
3632^5639 transcript. The second combination comprises of 226^526 (E6*II) transcript 
normalized to 880^3358 (E1^E4) transcript. The second combination can be analyzed 
when the transcripts of the first combination are negative or their ratio is below the 
threshold. 
This study has observed that 880^2582 transcript is significantly increased in HSIL and 
CxCa patients (Figure.1.8.). This transcript potentially encodes E1C, but also E2. The 
upregulation of this transcript could be due to a) E1C can transactivate virus URR63 b) 
suppression of E2 translation after translation termination of E1C, because both ORFs 
overlap. A repression of E2 is required to repress the URR and thereby repression of E6 
and E7 expression is acquired in cells harbouring HPV16 episomes. Low E2 expression 
is achieved in most cancer cases by integration of HPV16 genome in the E2 ORF region, 
which deregulates E6 and E7 expression and thereby leading the cells to transformation. 
However, in HSIL and CxCa cases where HPV16 genomes are present as episomes, E2 
must still be repressed. It could be that the E1C encoding transcript may counteract the 
E2 protein and promotes E6 and E7 upregulation. This could hint an integration-
independent mechanism for cancer progression in the cervical epithelial cells where 
HPV16 genomes are present as episomes152. 
 
1.4.1.2. HPV16 RNA patterns as triage marker in cervical cancer precursor 
screening 
Detection of HPV16 RNA patterns assay by NASBA –Luminex152 assay is complex as 
well as labour-, time- and cost-intensive85. Therefore, Höfler and colleagues developed a 
second generation HPV16 RNA patterns assay using reverse transcriptase quantitative 
polymerase chain reaction (RT-qPCR) technology which is comparatively less complex 
than NASBA-Luminex assay85. This is the second study that showed E1C transcript as a 
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useful biomarker for distinguishing the severity of cervical lesions. E1C transcript was 
found to be present almost exclusively in high-grade lesions (Figure 1.9.). 
 
 
Figure 1.8. Ratio of viral transcript pairs. Modified from152. Ratio of 880^2582 to 3632^5639 transcripts in different 
cytology grades and the combined groups of CxCa and HSIL (CxCa+HSIL) and LSIL and NIL/M (LSIL+NIL/M) is shown. 
Dotted lines represent median values.  
 
This assay uses two RT-qPCRs for the detection of three spliced HPV16 transcripts E6*I 
(226^409), E1^E4 (880^3358) and E1C (880^2582) and ubiquitin C (cellular 
housekeeping gene). One RT-qPCR is a triplex reaction quantifying E6*I, E1^E4 and ubC 
transcripts and the second RT-qPCR quantifies E1C transcript85. This assay analyzed a 
total of 158 singly HPV16 DNA-positive cervical cell samples obtained from a German 
referral colposcopy clinic and a Mongolian HPV prevalence study and consisted of 36 
NIL/M, 11 CIN0, 11 CIN1, 41 CIN2, 41 CIN3 and 18 CxCa. ≥ CIN3 included Histological 
CIN3 and CxCa samples and ≤ CIN1 included cytological NIL/M and histological CIN0 
and CIN1 samples. CIN2 was considered as intermediate because of the highest inter-
observer variations reported among the pathologists85. 
Out of the 113 E6*I positive samples analyzed in this study, E6*I was significantly 
upregulated in ≥ CIN3. Out of the 95 E1^E4 positive samples, E1^E4 showed an increase 
in CIN3, but decreased in CxCa samples, and the differences were not statistically 
significant. Out of the 34 E1C positive samples, the mean E1C copies per PCR were in 
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CIN2 (40), CIN3 (16) and CxCa (9). The reduction of E1C copies in CxCa was statistically 
significant when compared to CIN2.  
 
 
 
Figure 1.9. HPV16 RNA patterns in 158 cervical cell samples. Modified from85. X-axis shows the different grades of 
cervical lesions. Colour code – grey bars represent E6*I/E1^E4 ratio-positive samples, white bars represent E1C-
positive samples and black bars represent E6*I/E1^E4 ratio- and E1C-positive samples. Number of samples in NIL/M 
= 36, CIN0 = 11, CIN1 = 11, CIN2 = 41, CIN3 = 41, CxCa = 18, ≤CIN1 = 58 (combination of NIL/M, CIN0 and CIN1) 
and ≥CIN3 = 59 (combination of CIN3 and CxCa). 
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1.4.2. HPV16 E1C activates LCR 
Alloul and Sherman63 have identified that cDNAs consisting of E2 and upstream ORFs of 
a (880^2708), a’ (880^2581) and d (226^2708) mRNAs translate E2 protein at different 
efficiencies (Figure 1.10.). They checked whether the differential E2 protein translation 
from a-, a’- and d- type mRNAs affect LCR activity. They also investigated whether the 
co-translation of proteins by these mRNAs has an effect on LCR regulation by E263. 
The transcriptional activities of the polycistronic cDNAs were measured by calcium 
phosphate transient transfections in Cf2Th (Canine foetal thymus) cells using a 
chloramphenicol acetyltransferase (CAT) reporter gene associated to HPV16 LCR. 
Details of polycistronic cDNAs containing E2 ORF and upstream ORFs of a-, a’- and d- 
type mRNAs are described elsewhere157.  
 
Figure 1.10. Structure of HPV16 genome and cDNAs containing E2 ORF. Modified from63. a) Schematic diagram 
of HPV16 genome depicting the ORFs. b) Structures of d-, a- and a’- type mRNA species are shown together with their 
coding potential on the right. Splice donor and acceptor nt positions are marked.  
 
In this study, they have been observed that E2 ORF-containing monocistronic cDNA 
negatively regulated LCR on a dose-dependent fashion and was E2 protein mediated. 
They have also observed that E2 ORF-containing polycistronic cDNAs repress HPV16 
LCR and the repression was mainly due to the E2 ORF function.  
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Figure 1.11.Transcription-modulatory activities of E1C. Modified from63. A) E1C transfections were carried out in 
Cf2Th cells with 0.5, 2 and 5 µgs as indicated on the top. B) Co-transfections of varying amounts (µgs) of E1C and 
constant amounts of LCR-CAT plasmid (2 µg) and E2 plasmid (2 µg) were carried out as indicated on the top. Control 
cells were transfected with pJS55 (backbone vector of E1C) and is indicated as p. The normalized values of acetylation 
percentages are shown at the bottom. 
 
To study the transcription regulatory effects of individual 5’ ORFs, vectors carrying each 
of the individual ORF were constructed and performed the CAT assay. They have found 
that E6 splice variant E6IV from d-type mRNA repressed LCR. From the a-type mRNA, 
E6I weakly activated LCR and E7 did not affect the basal activity of LCR. From the a’-
type mRNA, E1C activated LCR63.  
When E1C expression vector was transfected in increasing amounts in Cf2Th cells, the 
LCR showed dose dependent activation (Figure 1.11. (A)). Also, co-transfection 
experiments of varying amounts of E1C and E2 expression vectors showed a reduction 
of E2-mediated LCR repression (Figure 1.11. (B)). The repression of LCR by a’-type 
mRNA could be due to E2 protein, which is dominant when compared to the activation by 
E1C and E6I proteins. Alloul and Sherman could not detect E1C protein upon a’-type 
mRNA translation in their translation studies157 and speculated that the inability to detect 
the protein could be due to its low expression levels or instability. 
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1.5. Aim of my thesis 
 
Papillomaviruses are ubiquitous DNA viruses, which can cause benign flat warts 
(papillomas) and occasionally, cancer. The high-risk HPVs of Alpha genus are sexually 
transmitted and can cause cervical cancer, one of the most common cancers in women. 
Of the high-risk HPVs, HPV16 is the predominant type causing 60% of the cervical 
cancers and 85% of the non-cervical cancers. Elaborate and intensive research had taken 
place in the field since the discovery of the link between HPV16 and cervical cancer by 
Prof. Dr. Harald zur Hausen in1983, which led to the development of prophylactic 
vaccines for the prevention of cervical cancer. Extensive molecular studies helped to gain 
information about the viral proteins, which plays a role in cervical keratinocyte 
transformation, therefore opening up several therapeutic study approaches. As part of the 
screening program, several diagnostic assays have been developed for the accurate 
stratification of different grades of cervical cancer precursors to avoid unnecessary 
anxiety and overtreatment in women. The diagnostic assay developed by Schmitt and 
colleagues, based on NASBA-Luminex technology and the one developed by Höfler and 
colleagues, based on RT-qPCR technology are two good examples. In both these 
diagnostic assays, HPV16 E1C transcript was found to be almost exclusively present in 
high-grade cervical lesions. This transcript can putatively encode a protein of 82 aa 
length. 
The aim of my thesis was to characterize the diagnostically relevant HPV16 E1C protein. 
The specific questions I addressed were: 
1) What are the effects of overexpression of HPV16 E1C on virus and host? 
2) Does HPV16 E1C transcript encode a protein? 
3) Does HPV16 E1C transcript or HPV16 E1C**protein activate the URR of HPV16 
genome? 
** - HPV16 E1C is designated as E1C from hereafter in the ‘Results’ section. 
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2. Materials  
2.1. Cell lines 
All the cell lines used in the current study were tested for authenticity and contaminations 
by multiplex cell line authentication and multiplex cell contamination tests by the company 
Multiplexion (Felipe Castro 2013 and Markus Schmitt 2009). The table below provides 
the summary and description of the cell lines used in this study together with the sources 
indicated. 
  Table 2.1. Description of cell lines used in this study. 
Name of the cell line Description Source 
CaSki HPV16-positive CxCa  Dr. Michael Pawlita lab223 
SiHa HPV16-positive CxCa  
MRI-H186 HPV16-positive CxCa  
MRI-H196 HPV16-positive CxCa  
HPK-1A Primary human foreskin 
keratinocytes transfected with 
HPV16 genome 
C33A HPV16-negative CxCa  Prof. Dr. Elisabeth Schwarz 
lab223 
W12-epi* (clone 20850) Low grade cervical lesion – HPV16 
genome is present as episome 
Prof.Dr. Paul. F. Lambert lab163 
W12 –int** (clone 20831) Low grade cervical lesion – HPV16 
genome is integrated 
NIH-3T3 Mouse fibroblasts  Prof.Dr. Frank Rösl lab 
HEK-293T Human embryonic kidney cells 
which are adenovirus-transformed 
and are stably expressing SV40a 
large T-antigen 
Prof. Dr. Martin Müller lab 
HeLa HPV18-positive CxCa cell line Prof. Dr. Martin Müller lab 
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2.2. Plasmids 
 
Name of the Plasmid** Description 
pGEX-GST-Tag Glutathione S-Transferase (GST) –Tag  fusion 
proteina 
pGEX-GST-E1C-Tag GST–E1C–Tag fusion protein 
p1-His-GFP Histidine (His) – Green Fluorescent Protein (GFP) 
fusion protein 
p1-His-GFP-E1C His-GFP-E1C fusionprotein 
p-ABCB5 Truncated ATP-Binding Cassette sub-family B 
member 5 (ABCB5) protein with 6x-His tag 
p2 eukaryotic expression vector with an EF alpha 
promoter, GFP sequence driven by SV40 
promoter and zeocin resistance gene 
p2-E1C E1C protein 
pCDNA3.1(+) Eukaryotic expression vector with CMV promoter 
pCDNA3.1(+)-CASIMO CASIMO protein with a Flag tag at the C-
terminus192 
LV lentiviral empty vector with CMV immediate early 
promoter, IRES sequence and puromycin 
resistance gene 
LV-E1C E1C protein 
p-HPV16-URR-FLucd Firefly Luciferase (FLuc) enzyme driven by 
HPV16 URR 
p-TATAbox-RLuc encodes Renilla Luciferase (RLuc) enzyme driven 
by TATA box 
p-EV eukaryotic expression vector with CMV promoter 
and ampicillin resistance gene 
p-HPV16-E2 HPV16 E2 protein 
p-HPV16-E1C HPV16 E1C protein 
p-HPV16-E1C-RNA mutb random RNA sequence with the same GC content 
as that of E1C RNA 
p-HPV16-E1C-Pro mutc mutated E1C sequence with first 3 codons 
replaced by TGA, TAG and TAA respectively 
 
 
 
 
 
 
 
 
 
 
**- vector maps and DNA sequence information are given in the supplementary information 9.2. and 
9.3. respectively. 
a – Tag peptide consists of the carboxy-terminal undecapeptide (KPPTPPPEPET) of simian   virus 40 
large T antigen. 
b – ‘RNA mut’ stands for mutated RNA sequence  
c - ‘Pro’ in ‘Pro mut’ stands for Protein and ‘mut’ for mutated, which means that ‘E1C-Pro mut’ sequence 
cannot encode for E1C protein 
d – HPV16 URR sequence is 7007-102 bp from the HPV16 sequence225, Firefly Luciferase sequence 
is taken from Photinis pyralis225-227. 
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All plasmids containing spliced HPV16 transcripts were kindly provided by Dr. Markus 
Schmitt (Alumnus of Dr. Michael Pawlita lab at DKFZ, Heidelberg, Germany) and are 
described in detail in the doctoral thesis of Dr. Daniela Höfler147 and also given in the 
supplementary information (Table 9.1.). 
 
2.3. Primers and probes 
The primers and probe used for the quantification of HPV16 E7 transcript in reverse 
transcriptase quantitative PCR is given below. Those used for the quantification of E6*I, 
E1^E4, E1C and ubC were designed by Dr. Daniela Höfler85,147 and is protected by patent 
rights and therefore not disclosed. The primers used for sequencing p-HPV16-URR-FLuc 
are M13 forward and reverse primers and were taken from primer repository of Eurofins 
Genomics, Ebersberg, Germany. All the primers and probes were ordered from Sigma 
Aldrich, St. Louis, USA and TIB MOLBIOL, Berlin, Germany respectively. 
 
Name Forward primer  
(5’-3’) 
Reverse primer 
 (5’-3’) 
Amplicon 
(bp) 
Probe sequence 
HPV16 E7 TTTGCAACCAGAGACAACT
GAT 
TGTTGCAAGTGTGACTCTACG
CT 
153 AGAGCCCATTACAATATTG
TA 
 
 
2.4. Antibodies 
Antibody Host 
species 
Application 
(Dilution) 
Company (City, Country) 
E1C mAb mouse  ELISA (1:5) WB 
(1:5), IF (1:3) 
Genomics and Proteomics core facility, 
Monoclonal antibodies, DKFZ 
(Heidelberg, Germany) 
Goat anti-Mouse pox mouse WB (1:10,000) Dianova GmbH (Hamburg, Germany) 
6x-His mAb mouse Hybridoma clone 
supernatant 
Genomics and Proteomics core facility, 
Monoclonal antibodies, DKFZ 
(Heidelberg, Germany) 
Polyubiquitin mAb 
(D9D5) 
rabbit  WB (1:1000) Cell Signaling Technology 
(Massachusetts, USA) 
Flag mAb mouse  WB (1:500) Sigma Aldrich (St. Louis, USA) 
Tag mAb* mouse  ELISA (1:50) Dr. Michael Pawlita lab, DKFZ 
(Heidelberg, Germany) 
Alexa 594 mouse  WB (1:500) Thermo Fisher Scientific (Eugene, USA) 
 
 
mAb – monoclonal antibody, WB – Western blot, IF – Immunofluorescence 
*- Tag mAb used was the cell culture supernatant from KT3 hybridoma cell line219,220. 
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2.5. Enzymes 
Enzyme Company (City, Country) 
EcoRV - HF New England Biolabs (Massachusetts, USA) 
SmaI New England Biolabs (Massachusetts, USA) 
T4 DNA ligase New England Biolabs (Massachusetts, USA) 
T7 RNA polymerase Fermentas (St. Leon-Rot, Germany) 
 
 
2.6. General buffers and solutions 
Buffer Ingredients 
Blocking buffer (Immunocytochemistry) PBS+0.1% Triton X-100 
2% Horse serum 
Blocking buffer (ELISA) 2 mg/mL casein in PBS-Tween® 
10% Blocking milk (Western blot) 5 g milk powder 
50 mL PBS-Tween 
Coating buffer (ELISA) 4 parts NaHCO3 
1 part Na2CO3 
Adjust pH to 9.6 
Coating medium (ELISA) 10 µL Glutathion-casein 
10 mL coating buffer 
DNA-loading buffer 0.02% Xylene Cyanol 
40% (w/v) Sucrose in bidest. H2O 
Storage at -20⁰C 
50x Electrophoresis-buffer (TAE) 2 M Tris, pH 7.8 
0.25 M NaAc (water free) 
0.05 M EDTA 
Add 8L bidest. H2O 
Storage at RT 
50% Glycerol 25 mL glycerol (100%) 
25 mL H2O  
Autoclave 
LB-Agar LB medium 
1.5% (w/v) Bacto-Agar 
Autoclave, storage at 4⁰C 
LB medium 10 g (1% (w/v)) Bacto-Tryptone 
5 g (0.5% (w/v)) Bacto-yeast extract 
10 g (1% (w/v)) NaCl 
Add 1L bidest. H2O 
Adjust pH to 7.5 with 5M NaOH 
Autoclave, storage at 4⁰C 
3.7% Paraformaldehyde 18.5 g paraformaldehyde 
500 mL 1X PBS 
PEI Add 0.16 g to 400 mL water 
Adjust pH to <2  
Stir the solution for 3h 
Adjust pH to 6.9 - 7.1 
Make upto 500 mL with water 
Sterile filter and storage at -20°C 
1X Phosphate Buffered Saline (PBS) 124 mM NaCl 
22 mM Na2HPO4 
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10 mM KH2PO4 
Adjust to pH 7.4 
Autoclave, storage at RT 
PBS+30 mM Glycine 1.1 g Glycine 
500 mL 1X PBS 
PBS+0.1% Triton X-100 500 µL Triton X-100 
499.5 mL 1X PBS 
PBS-Tween® 0.5 mL Tween 20® 
1 L 1X PBS 
10X Running buffer (Western blot) 
 
151.5 g Tris 
720 g Glycine 
50 g SDS 
Make it to 1X by the addition of deionized water 
Substrate buffer 0.1 M CH₃COONa (sodium acetate) 
Adjust pH to 6.0 
Substrate solution (ELISA) 100 µL tetramethylbenzidine 
2 µL H2O2 
10 mL substrate buffer 
Stop solution (ELISA) 1M H2SO4 
T4 DNA ligase buffer (10X) New England Biolabs (Massachusetts, USA) 
Transfer buffer (Western blot) 
 
4.84 g Tris 
2.92 g Glycine 
Adjust pH to 9.2 with NaOH 
Add 200 mL Methanol 
Make it up to 1L with deionized water 
 
 
2.7. Reagents 
Reagent Company (City, Country) 
Agarose GIBCO Life Technologies (Paisley ,Scotland) 
Ampicillin Roche (Mannheim, Germany) 
Bacto-Agar Becton Dickinson, Sparks (MD, USA) 
Bovine Serum Albumin (BSA) PAA Laboratories GmbH (Linz, Austria) 
Bradford reagent Carl Roth (Karlsruhe, Germany) 
DMEM – low glucose Sigma Aldrich (Steinheim am Albuch, Germany) 
DMEM – high glucose Sigma Aldrich (Steinheim am Albuch, Germany) 
1 kb DNA ladder New England Biolabs (Massachusetts, USA) 
EDTA Acros Organics (Geel, Belgium) 
Ethanol (Absolute) Sigma Aldrich (Steinheim am Albuch, Germany) 
Fetal Bovine Serum (FBS) Gibco, Thermo Fisher Scientific (Eugene, USA) 
Fluorescence mounting medium (Dako) Agilent Technologies (California, USA) 
Glycerol (100%), water free Carl Roth (Karlsruhe, Germany) 
Ham’s F-12 nutrient mixture GIBCO Life Technologies (Paisley ,Scotland) 
Horse serum (IF) GIBCO Life Technologies (Paisley ,Scotland) 
Hygromycin B Roche (Mannheim, Germany) 
Isopropanol Sigma Aldrich (Steinheim am Albuch, Germany) 
ß-Mercaptoethanol AppliChem GmbH (Darmstadt, Germany) 
Methanol Sigma Aldrich (Steinheim am Albuch, Germany) 
Milk powder GERBU Biotechnik GmbH (Heidelberg, Germany) 
Mitomycin C Sigma Aldrich (Steinheim am Albuch, Germany) 
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MS2 RNA Roche (Mannheim, Germany) 
Paraformaldehyde Carl Roth (Karlsruhe, Germany) 
Polyethylenimine (PEI) Polysciences GmbH (Hirschberg an der 
Bergstraße, Germany) 
Penicillin/Streptomycin Gibco, Thermo Fisher Scientific (Eugene, USA) 
PEQ green  
Protease inhibitor (cOmplete™, EDTA-free 
Protease Inhibitor Cocktail ) 
Roche (Mannheim, Germany) 
Puromycindihydrochloride Santa Cruz Biotechnology (Dallas, USA) 
RNA ladder “low range” New England Biolabs (Frankfurt am Main, 
Germany) 
RNase away spray Molecular Bioproducts (San Diego, USA) 
Sodium dodecyl sulfate (SDS)  
Sulphuric acid (96%) Carl Roth (Karlsruhe, Germany) 
TE buffer, RNase-free, 1X 
(10 mMTris-HCl, 1mM EDTA, pH 8.0) 
Acros Organics (Geel, Belgium) 
Tris-base Sigma Aldrich (Steinheim am Albuch, Germany) 
Triton-X-100 Carl Roth (Karlsruhe, Germany) 
Trypsin-EDTA (0.25%) Sigma Aldrich (Steinheim am Albuch, Germany) 
Tween® 20 Sigma Aldrich (Steinheim am Albuch, Germany) 
Water, DNase/RNase-free  Invitrogen (Carlsbad, USA) 
 
 
2.8. Kits 
Kit Company (City, Country) 
Dual-Luciferase® Reporter Assay Kit Promega (Madison, USA) 
ECL Select™ Western Blotting Detection Reagent GE Healthcare (Chicago, USA) 
LightCycler® 480 Probes Master Roche (Mannheim, Germany) 
LightCycler®480 RNA Master Hydrolysis Probes Roche (Mannheim, Germany) 
QIAshredders QIAGEN (Hilden, Germany) 
QIAquick Gel Extraction Kit Qiagen (Hilden, Germany) 
QIAGEN Plasmid Midi Kit Qiagen (Hilden, Germany) 
QIAGEN Plasmid Mini Kit Qiagen (Hilden, Germany) 
RNeasy Mini Kit QIAGEN (Hilden, Germany) 
 
 
2.9. Consumables 
Consumable Company (City, Country) 
Bottle top filter (500 mL) Corning Incorporated (Corning, USA) 
Cell culture dish (10 cm) Corning Incorporated (Corning, USA) 
Cell culture flasks (T25, T75, T150) Techno Plastic Products (TPP) AG, 
(Trasadingen, Switzerland) 
Cell culture (Falcon® ) plates (6-well, 24-well, 96-
well) 
Corning (Wiesbaden, Germany) 
Cryogenic vials (Nalgene®) Thermo Scientific (Eugene, USA) 
Disposable syringe (2 mL, 5 mL, 10 mL, 50 mL) Terumo (Tokyo, Japan) 
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Electroporation cuvette Steinbrenner Laborsysteme GmbH (Wiesenbach, 
Germany) 
Examination gloves (Microflex®) Ansell Health Care (Brussels, Belgium) 
Falcon tubes (15 mL and 50 mL) Greiner Bio-one (Frickenhausen, Germany) 
Filter tips (TipOne®) (10 µL, 20 µL, 200 µL, 1000 
µL) 
STARLAB (Hamburg, Germany) 
LightCycler® 480 Multiwell plate 96, white Roche Applied Science (Mannheim, Germany) 
LightCycler®480 Sealing foil Roche Applied Science (Mannheim, Germany) 
Low retention tubes (Nucleic acid extraction and 
storage) 
Kisker Biotech GmbH & Co. KG (Steinfurt, 
Germany) 
Microplates (96-well, Chimney well, white, 
lumitrac) (Dual-luciferase reporter assay) 
Greiner Bio-one (Frickenhausen, Germany) 
Microscopic slides Thermo Scientific (Eugene, USA) 
Neubauer counting chamber BRAND GmbH + Co KG (Wertheim, Germany) 
Nitrocellulose membrane GE Healthcare (Chicago, USA) 
Nunc Polysorp 96-well plates Thermo Scientific (Eugene, USA) 
Parafilm Bemis Company (Wisconsin, USA) 
Reaction tubes (1.5 mL and 2 mL) Eppendorf (Hamburg, Germany) 
Reagent reservoirs (50 mL) Corning (Wiesbaden, Germany) 
Waste plastic bags nerbe plus GmbH (Winsen, Germany) 
 
 
2.10. Instruments 
Instrument Company (City, Country) 
Agarose gel electrophoresis chamber, gel tray 
and combs 
Renner (Dannstadt, Germany) 
Cell culture hood The Baker Company (Sanford, USA) 
Cell observer SD microscope Zeiss (Jena, Germany) 
4° centrifuge Eppendorf (Hamburg, Germany) 
Centrifuge (Biofuge, cell culture) Heraeus (Hanau, Germany) 
Centrifuge (Megafuge 1.0 R, cell culture) Heraeus (Hanau, Germany) 
Centrifuge (Sorvall RC 6 Plus) Thermo Scientific (Eugene, USA) 
Chemiluminescence western blot detection 
system (Chemocam Imager) 
Intas Science Imaging Instruments GmbH 
(Göttingen, Germany) 
DNA gel cutting instrument  Herolab GmbH laboratory equipment (Wiesloch, 
Germany) 
Eclipse Ti fluorescence inverted microscope  Nikon (Minato, Japan) 
Gel documentation system (Gel Doc EZ) Bio-Rad Laboratories (Hercules, USA) 
Gene Pulser Electroporation device Bio-Rad Laboratories (Hercules, USA) 
Ice machine (automatic ice maschines AF30) Scotsman (Milan, Italy) 
37⁰C Incubator (Cell culture) LabotectLabor-Technik-Göttingen GmbH 
(Rosdorf, Germany) 
Leica DM IL Inverted laboratory microscope Leica microsystems (Wetzlar, Germany) 
LSM 710 confocal microscope Zeiss (Jena, Germany) 
Luminometer Biotek (Vermont, USA) 
Microwave oven Mikromat AEG (Nuernberg, Germany) 
Multichannel pipette (20-200 µL) BRAND GmbH + Co KG (Wertheim, Germany) 
MultiskanTM FC microplate photometer Thermo Scientific (Eugene, USA) 
Nanodrop™ 1000 spectrophotometer Thermo Scientific (Wilmington, USA) 
Neubauer chamber Carl Roth (Karlsruhe, Germany) 
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pH meter inoLab® (Weilheim, Germany) 
Pipetboy Integra Biosciences (Fernwald, Germany) 
Pipettes (2 µL, 10 µL, 20 µL, 200 µL, 1000 µL) Gilson International France (Villiers-le-Bel, 
France) 
Power supply (Agarose gel electrophoresis and 
SDS-PAGE) 
Consort (Turnhout, Belgium) 
QIAgility QIAGEN (Hilden, Germany) 
Skyline digital rocking shaker DRS-12 (at 4⁰C) ELMI (Riga, Latvia) 
Stuart™ see-saw rocker Fisher Scientific (Loughborough, UK) 
Shaker at 37⁰C INFORS AG (Bottmingen, Switzerland) 
Shaker at RT Heidolph (Schwabach, Germany) 
Thermomixer Eppendorf (Hamburg, Germany) 
  
Vortexer (Vortex Genie) Bender & Hobein GmbH Laboratory Chemicals 
(Bruchsal, Germany) 
Water bath (Cell culture) JULABO GmbH (Seelbach, Germany) 
 
 
2.11. Computer programs and online softwares 
Program/Software Company (City,Country) or Website 
BLAST NCBI http://www.ncbi.nlm.nih.gov/BLAST/ 
EMBL-EBI Clustal Omega https://www.ebi.ac.uk/Tools/msa/clustalo/ 
GraphPad Prism®6 GraphPad Software, Inc. (La Jolla, USA)  
Nucleotide NCBI http://www.ncbi.nlm.nih.gov/nuccore/ 
Primer 3 web http://primer3.ut.ee/ 
Zen microscope software Zeiss (Jena, Germany) 
 
 
2.12. Services 
Service Website 
DKFZ Genomics and Proteomics core facility – 
Light Microscopy 
https://www.dkfz.de/en/bildgebung/index.html 
DKFZ Genomics and Proteomics core facility – 
Antibodies 
https://www.dkfz.de/gpcf/antibodies 
DKFZ Genomics and Proteomics core facility – 
Cellular Tools/Vector & Clone Repository 
https://www.dkfz.de/gpcf/isogenic-cell-lines 
DKFZ Genomics and Proteomics core facility – 
Mass Spectrometry based Protein Analysis 
https://www.dkfz.de/gpcf/mass-spectrometry 
Multiplexion GmBH http://www.multiplexion.de/ 
Eurofins Genomics https://www.eurofinsgenomics.eu/ 
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3. Methods 
 
3.1. Cell culture 
 
3.1.1 Maintenance of cell lines 
CaSki, SiHa, MRI-H186, MRI-H196, HPK-1A, C33A and HEK-293T cells were cultured in 
DMEM containing low glucose supplemented with 10% FBS and 1% 
penicillin/streptomycin. NIH-3T3 cells were grown in DMEM containing high glucose 
supplemented with 10% FBS and 1% penicillin/streptomycin. All cell lines were cultured 
in a 37⁰C incubator with 5% CO2. 
Confluent grown cells were splitted 1:4 or 1:5. For this, the growth medium was removed 
from the cell culture flask and 1X PBS was added to wash the cells and remove the 
residual growth medium from the flask. To harvest the adherent cells, Trypsin-EDTA was 
added and the cells were incubated at 37⁰C from 2-10 minutes depending on the cell line. 
Afterwards, pre-warmed growth medium was added to the cells to stop trypsinisation and 
the cells were harvested in a Falcon tube. Finally, the required volume of cells was 
transferred back to the flask and appropriate amount of pre-warmed growth medium was 
added depending on the cell culture flask. The cell culture flask was then incubated at 
37⁰C incubator with 5% CO2 until further use. 
 
3.1.2. Culturing of W12 cells 
The protocol for culturing of W12 cells was adopted from Dr. Paul F. Lambert laboratory, 
McArdle Laboratory for Cancer Research, University of Wisconsin-Madison. All the 
materials required for the preparation various cell culture reagents for W12 cells221 are 
given in the supplementary information 9.4.. 
W12-epi and W12-int cells cells were grown on mitomycin C treated NIH-3T3 cells, which 
acted as feeder cells. NIH-3T3 cells were grown in 3T3 cell medium in a T-150 flask and 
were fed two times per week. For the preparation of feeder layer, the growth medium was 
aspirated from a confluent T-150 flask and 200 µL 50X mitomycin C mixed in 10 mL 3T3 
cell medium was added to the cells. The cells were incubated 37⁰C incubator with 5% 
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CO2 for 2h. Afterwards, 3T3 cell medium and mitomycin C were aspirated from the flask 
and the cells were washed with 1X PBS two times. To detach the cells from the bottom, 
2 mL 0.25% Trypsin-EDTA solution was added to the flask and incubated for 1 min at RT.  
1/4th of the cells were seeded to a new T-150 flask and were incubated at least 2 h to 24 
h in W12 medium before the W12 cells were seeded onto them 
For the thawing of W12 cells, 1x106 cells were thawed onto prepared NIH-3T3 feeder cells 
in W12 medium in a T-150 flask. The W12 cells were fed every two days and small clones 
of cells were observed after 1 week of culturing. A confluent T-150 flask of W12 cells were 
obtained after 2 weeks of culturing.  
For passaging W12 cells, the medium was aspirated from the confluent flask. To remove 
NIH-3T3 feeder cells, 5 mL 0.02% EDTA solution was added and placed in the 37°C 
incubator for 10 min. The flask was tapped on the sides to remove the attached feeder 
cells. 0.02% EDTA solution was removed and the cells were washed with 1X PBS to 
completely remove the feeder cells. To detach the W12 cells, 2 mL 0.25% Trypsin-EDTA 
solution was added to the flask and incubated at 37°C for 10 min. The cells were re-
suspended in W12 medium by pipetting up and down to obtain a single cell suspension. 
After counting, around 1x106 cells were seeded onto a new T-150 flask. 
 
3.1.3. Freezing and thawing of cell lines 
To freeze cells, the culture medium was removed and cells were rinsed once with 1x PBS. 
Then Trypsin-EDTA was added to detach the cells from the culture flask. After incubation 
at 37°C, trypsinisation is stopped by the addition of growth medium and the cells were 
centrifuged at 1500 rpm for 5 min to remove trypsin containing supernatant. The cells 
were resuspended in 1 ml freezing medium and immediately transferred to cold cryotubes 
and were placed in freezing box (The freezing box should be cold in order to maximize 
the number of viable cells which go to freezing). This facilitates a constant freezing rate 
of -1°C/ min and is stored in -80°C overnight and can be shifted from the freezing box to 
another storage box. 
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The cells frozen at -80°C in a cryotube are thawed by quickly transferring it in warm growth 
medium in a 15 mL Falcon tube to dilute the toxic DMSO of the freezing medium. The 
cells were then centrifuged at 1500 rpm for 5 min. The supernatant was removed thereby 
removing the toxic DMSO and the cell pellet is dissolved in fresh warm growth medium. 
The cells were then seeded to appropriate culture dishes. 
 
 
3.1.4. Determination of cell number 
In order to count the cells before seeding for various experiments, manual cell counting 
by Neubauer chamber was employed. After harvesting the cells from the cell culture flask, 
10 µL of cells was taken in a 1.5 mL Eppendorf tube and mixed with 90 µL of Trypan blue 
to make a 1:10 dilution of the cells. Then roughly 10 µL of the cell dilution was pipetted 
onto the counting grid of the Neubauer chamber. The cells distributed on the counting 
grid were counted with the help of an optical microscope and cell counter. The cells 
present in the 4 corner squares on the counting grid were counted for calculation. The 
total number of cells harvested from the cell culture flask is calculated using the below 
formula. 
Total no: of cells = (total cells counted from 4 squares / 4) x 104 x 10 x total volume in 
which cells are suspended   
 
                                                                             
where 104 is the multiplication factor of the chamber and 10 is the dilution factor of the 
cells in Trypan blue. 
 
3.2. Generation of E1C monoclonal antibody (mAb) 
A monoclonal Ab specific for the fusion peptide generating by E1C splicing was generated 
using hybridoma technology in collaboration with the Antibodies unit of the Genomics and 
Proteomics core facility at DKFZ. In hybridoma technology, lymphocytes isolated from the 
mouse immunized with the antigen of interest are fused with myeloma cells to generate 
hybridomas. These hybridomas are then cultured and clones secreting antibody of 
desired specificity are selected and expanded. 
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For the generation of E1C mAbs, an E1C peptide was designed for mouse immunization 
(see Results 4.2.1.1.).Three rounds of immunization were performed in four mice, 2 
BALB/c and 2 C57black6N with an interval of 7-9 days. 20 µg of E1C peptide was injected 
intramuscularly on both the hind legs of each mouse per immunization. After the 
immunizations, the sera of all the mice together with pre-serum from one mouse were 
tested for the presence of E1C Abs in an ELISA with E1C peptide as antigen and in 
western blot using E.coli lysate overexpressing GST-E1C and HeLa cellular lysate 
overexpressing GFP-E1C fusion proteins. The mouse in which the serum contained E1C 
Abs was selected to perform fusion. The B and T lymphocytes were isolated from the 
lymph nodes of the popliteal fossa (knee pit) of the mouse and were fused with Sp2/0 
cells, which is a B cell myeloma cell line from BALB/c mouse. Polyethylene glycol was 
used for the fusion of the cells and afterwards the fused cells were plated on a 96-well 
plate and incubated at 37⁰C and 5% CO2 for 4 – 7 days. Supernatants of growing clones 
on the plate were screened by ELISA and western blot to identify the E1C Ab producing 
clone. E1C Ab positive clones obtained from the screening were cloned for two more 
rounds and further screened to finally obtain E1C Abs from a stable single sub-clone. 
Antibody was purified from about 1L of cell culture supernatant using Protein A 
Sepharose® beads.  
 
3.3. Transient transfection of HEK-293T cells 
The overexpression of E1C to detect the E1C protein and the overexpression of various 
plasmids to study their effects on HPV16 URR activity by luciferase assay were achieved 
by transient transfection using polyethylenimine (PEI). Appropriate number of HEK-293T 
cells was seeded 24h prior to transfection. The cells need to be 70% confluent at the time 
of transfection. The following table summarizes the amount of each component of the 
transfection mix that was used in the case of a 24 well plate or a 10 cm dish transfection.  
Plate/Dish No: of cells 
seeded for 
transfection 
Water 
(µL) 
Plasmid 
DNA  
DMEM  PEI 
(µL) 
DMEM+5% 
FBS  
24 well plate 75000 8.3 600 ng 125 µL 1.7  500 µL 
10 cm dish 1.5x106 62 10 µg 1.5 mL 31 8.5 mL 
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For the preparation of transfection mix, water, plasmid DNA, DMEM and PEI were added 
to a 1.5 mL Eppendorf tube (24 well plate transfection) or a 15 mL Falcon tube (10 cm 
dish transfection) in the same order. The transfection mix was vortexed for 10s and 
incubated at RT for 10 min. Afterwards, DMEM+5% FBS medium was added carefully to 
the transfection mix and pipetted gently one time up and down for the even mixing of the 
PEI-DNA complex. The growth medium from the cells was removed and the PEI-DNA 
complex was added. The plate/ dish was gently moved back and forth and sideways for 
the even distribution of PEI-DNA complex in the wells/ dish. The transfection mix was 
removed from the cells 12-14 h post transfection and pre-warmed growth medium was 
added. The cells were analyzed 48h post transfection.  
 
3.4. Stable transfection of W12-epi, W12-int, CaSki and SiHa cells 
In order to study the effects of E1C overexpression on HPV16 transcript levels, stable 
transduction of HPV16-containing cell lines by lentiviral vector particles transfection was 
employed. The production of lentiviral particles and lentiviral transduction were performed 
in co-operation with Cellular Tools/Vector & Clone Repository unit of DKFZ Genomics 
and Proteomics core facility. 
For the cloning of E1C gene to a lentiviral vector, E1C gene flanked by attL recombination 
sites was cloned into a pMX plasmid (Thermo Fischer Scientific). Using Gateway 
recombination technology, the E1C construct was shuttled in a lentiviral expression vector 
fusing an internal ribosomal binding site (IRES) at the C-terminus. The pMX plasmid 
contains a kanamycin resistance marker and lentiviral expression vector consists of a 
puromycin resistance marker. 
For the generation of lentiviral particles201, the lentiviral expression constructs (LV and 
LV-E1C) were co-transfected with 2nd generation viral packaging plasmids VSV.G 
(Addgene #14888) and psPAX2 (Addgene #12260) in HEK293FT cells (Thermo Fischer 
Scientific, Germany). The supernatant containing virus was removed 48 h post 
transfection and cleared by centrifugation at 500 g for 5 min. To remove cell debris, the 
supernatant was passed through a 0.45 μm filter 
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In order to study the effects of E1C overexpression on HPV16 transcripts, stable 
transfection by lentiviral transduction was employed. Appropriate no: of W12-epi, W12-
int, CaSki and SiHa cells was seeded to a 6-well plate, 24 h prior to transduction. An 
additional well of cells was also seeded which will not be transduced and which acted as 
the ‘control well’ later for antibiotic selection of transduced cells. The cells need to be 70% 
confluent at the time of transduction. 24 h post seeding, cells were transduced with 
lentiviral particles with the aid of 10 μg/mL polybrene (Merck, Germany). Virus containing 
medium was replaced with puromycin selection medium 24h post transduction. The cells 
were subjected to puromycin selection until the cells in the ‘control well’ are all dead. 
Afterwards, the cells were harvested for gene expression analysis by RT-qPCR. 
 
3.4.1. Dose response kill curve for puromycin selection 
A puromycin kill curve was performed to determine the minimum concentration required 
to kill non-transduced W12-epi, W12-int, CaSki and SiHa cells. Cells were seeded in 96-
well plate to be 50% confluent. Growth medium was removed and selection medium 
(growth medium + puromycin) was added. A range of puromycin concentrations from 0.5 
– 10 µg/mL were used. The negative control was cells supplemented with growth medium 
without any puromycin. The cells were monitored under microscope daily for three days 
after puromycin addition and observed the percentage of surviving cells. The minimum 
puromycin concentration used for each cell line was the lowest concentration that killed 
100% of cells in three days. The lowest puromycin concentrations determined for all the 
cell lines were – W12-epi (700 ng/mL), W12-int (800 ng/mL), CaSki (500 ng/mL) and SiHa 
(700 ng/mL). 
 
3.5. Proteasome inhibition of cells by MG132 
To enhance detection of overexpressed E1C protein in HEK-293T cells and endogenous 
E1C protein in CaSki and SiHa cells, proteasome inhibition by MG132 was employed. 
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3.5.1. MG132 tolerance test of cell lines 
Appropriate no: of HEK-293T, CaSki and SiHa cells were seeded onto a 24-well plate so 
that the cells will be 70% confluent 24 h later. Different MG132 concentrations ranging 
from 0 µM – 20 µM were applied on the cells 36 h post seeding, to determine the 
maximum MG132 concentration tolerated by each cell line. The cells were monitored 
under the microscope for cell death or morphology differences every 2 h for 10 h. All the 
cell lines were showed to tolerate 10 µM MG132 concentration. 
 
3.5.2. Proteasome inhibition by MG132 
HEK-293T cells were seeded onto 10 cm dishes so that the cells will be 70% confluent at 
the time of transfection. The cells were transfected with p2 and p2-E1C to two 10 cm 
dishes each by PEI transfection. The transfection medium was changed 12 h post 
transfection. 42 h post transfection, one pair of p2- and p2-E1C-transfected dishes were 
treated with DMSO and the second pair were treated with 10 µM MG132 for 6 h. 
Afterwards, the cells were analyzed for E1C protein detection by western blot and 
immunofluorescence. 
CaSki and SiHa cells were also processed the same way except that they were not 
transfected with p2 or p2-E1C, because the aim was to detect the endogenous E1C 
protein in these cell lines after proteasome inhibition by MG132. 
 
 
3.6. Dual-luciferase reporter assay (DLRA) 
In order to study the effect of E1C on HPV16 URR, DLRA was employed. Reporter 
systems are widely used in molecular biology to study gene expression, promoter activity, 
transcription factors etc.. DLRA employs the simultaneous expression and measurement 
of two reporters in one assay and thereby improves assay accuracy. Out of the two 
reporters, the ‘experimental’ reporter is associated with the different experimental 
conditions and the ‘control’ reporter is used for normalization of the experiment. This 
normalization helps in minimizing experimental variabilities caused by transfection 
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efficiency or differences in pipetting volumes224. The optimal seeding cell number for 
HEK-293T cells to be 70% confluent in a well of a 24-well plate 24 h post seeding was 
determined to be 75,000 cells. 500 – 600 ng of total plasmid DNA was determined to be 
the optimal total DNA transfected to the cells to avoid DNA overdose toxicity. p-HPV16-
URR-FLuc, p-TATAbox-RLuc, p-EV, p-HPV16-E2, p-HPV16-E1C, p-HPV16-E1C-RNA 
mut and p-HPV16-E1C-Pro mut were the plasmids transfected by PEI transfection. Here,  
p-HPV16-URR-FLuc was the experimental reporter and p-TATAbox-RLuc was the control 
reporter. Post 48 h transfection, growth medium was removed and the cells were washed 
with 1X PBS. 100 µL 1X passive lysis buffer was added to the cells and the plate was 
kept on a rocker with gentle rocking to mediate cell lysis. After 20 min of lysis, the cells 
were observed under the light microscope to confirm complete dissolution of the cell 
structure. Afterwards, the cells were harvested and stored at -80⁰C till the luciferase 
activity measurement. 
 
 
3.6.1. Measurement of luciferase activity 
The samples were taken out from -80⁰C and were thawed at room temperature. After 
proper mixing, 20 µL of the samples were added to the wells of 96-well microplates. Firefly 
luciferase and renilla luciferase substrates were prepared using the Dual-luciferase® 
reporter assay kit according to the manufacturer’s instructions. Luciferase activities were 
measured in a luminometer  using Gen5TM software. To measure the luciferase activities, 
50 µL of firefly luciferase substrate was added and waited 30s before the measurement 
of firefly luciferase activity. Afterwards, 50 µL of renilla luciferase substrate was added 
and waited 30s before the measurement of renilla luciferase activity.  
 
 
3.7. Molecular biological methods 
 
3.7.1. Agarose gel electrophoresis 
Agarose Gel Electrophoresis is a method to separate a mixed population of DNA in a 
matrix of agarose. The DNA fragments are separated by size. An electric field is applied 
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to move the negatively charged DNA molecules in the agarose gel matrix. Smaller DNA 
molecules run faster leaving behind larger DNA molecules. The concentration of agarose 
prepared depends upon the size of the desired DNA fragment and varies in between 
0.5%-1.5%. The concentration of the agarose is inversely proportional to the size of the 
DNA fragment to be separated. Agarose was prepared by boiling it in 1X TAE buffer. After 
agarose was completely dissolved in TAE buffer, PEQ green was added which is a DNA 
intercalating agent and help in the visualization of DNA upon UV illumination. After proper 
mixing, the melted agarose was poured onto gel casting trays previously set with combs. 
After the gel was set, it was slowly transferred to the electrophoretic tanks filled with 1X 
TAE. DNA samples were mixed with 6X loading dye and pipetted into the gel slots. A 1kb 
ladder was added at the extreme ends of the gel as size standard. Separation of DNA 
fragments was made possible by applying 100V and the gel was analyzed later under UV 
light. 
 
 
3.7.2. DNA purification 
The correct DNA band identified by agarose gel electrophoresis was excised under UV 
light after taking right protection by wearing a helmet and nitrile gloves. The DNA present 
in the excised bands was purified using QIAquick Gel Extraction Kit according to the 
manufacturer’s instructions. 
 
 
3.7.3. Restriction d igestion 
In order to clone the desired DNA fragment into plasmid vector, both vector and inserting 
DNA fragment should have same restriction sites. For this purpose, both the vector and 
the insert should be enzymatically digested. Therefore, DNA (vector or insert), restriction 
enzyme, enzyme buffer and ddH2O were mixed and digested for 2 h at 37οC. Afterwards, 
the digested mixture was subjected to agarose gel electrophoresis for analyzing the 
accuracy of digestion. The correct products were excised and purified as described 
earlier. The concentration of the purified samples were measured using NanoDrop™ 1000 
spectrophotometer. 
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3.7.4. Ligation 
To integrate the digested insert into the digested vector, which were enzymatically 
digested with the same restriction enzymes, ligation method was used. For optimal 
ligation reaction, a 1:3 vector: insert ratio was used. The formula which was used to 
calculate the amount of insert to be used is as follows: 
 
ng of vector x kb size of insert   X molar ratio of insert 
             kb size of vector              vector 
 
In a total volume of 20 μl, 1 μl of T4 DNA ligase, 2 μl of ligation buffer and respective 
amounts of vector and insert were used. The ligation was performed at room temperature 
for 10 min.  Afterwards, the ligation mixture was heat inactivated at 65°C for 10 min. Then 
the ligation mixture was kept on ice and used 5 µL for transformation into 
electrocompetent E. coli BL21 cells. This ligation protocol was based on the New England 
Biolabs kit and manual. Two ligation mixes were prepared – control ligation mix and 
experimental ligation mix. To the control ligation mix, only the purified digested vector was 
added, and to the experimental ligation mix, both vector and insert were added.   
 
 
3.7.5. Transformation 
Electrocompetent E.coli BL21 were thawed for 2-3 min on ice. The prepared ligation 
mixture/ diluted midiprep or miniprep (with final amount 100 ng) was added to the bacteria, 
mixed quickly and transferred to precooled Trafo-cuvette. Afterwards the transformation 
was performed with electroporation device. Soon after the electroporation of the plasmid 
inside the bacterial cells, 200 µL LB medium was added to the Trafo-cuvette, mixed 
quickly and added to a 1.5 mL Eppendorf tube. Then the bacteria was incubated at 37°C 
for 1 h with shaking at 1400rpm in a thermomixer. Afterwards, the bacterial suspension 
was spread on LB agar plates containing ampicillin antibiotic as the plasmids possess 
ampicillin resistance gene. The plates were incubated overnight at 37οC. 
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3.7.6. Plasmid DNA purification 
If the transformation was successful, i.e. if the experiment plates had many colonies and 
control plates had null or very few colonies, then the purity of cloned plasmids was 
checked by performing minipreps followed by sequencing. The colonies were picked from 
the experimental plates and put in 2 mL LB medium containing ampicillin antibiotic and 
cultured overnight at 37οC in a shaking incubator. Minipreps were performed the following 
day using the QIAGEN Plasmid Mini Kit according to the manufacturer’s manual. If 
cloning was successful, then midipreps were prepared. Transformation was again carried 
out with the positive clone and one clone was picked and put in 5 mL LB ampicillin medium 
containing ampicillin antibiotic and cultured overnight at 37οC in a shaking incubator. 
Midipreps were performed the following day using QIAGEN Plasmid Midi Kit according to 
the manufacturer’s manual. 
  
 
3.7.7. Sequencing 
After doing minipreps, the DNA samples were sent for sequencing to Eurofins Genomics, 
Ebersberg, Germany. The primers for sequencing were either selected from the primer 
database of Eurofins Genomics or were ordered from them. Sequencing results were 
analyzed using Clustal Omega multiple sequence alignment program. 
 
 
3.8. Quantification of gene expression 
 
3.8.1. RNA extraction 
Cells harvested were stored at -80⁰C till RNA was extracted. Total RNA extraction was 
performed using the RNeasy Mini Kit (QIAGEN) including DNaseI treatment according to 
the manufacturer’s instructions. RNA was eluted in 30 µL RNase-free water and the 
concentration was measured using NanoDrop™ 1000 spectrophotometer at 260 nm. 
Extraction controls were also added during RNA extraction to check for RNA carry-over 
contamination. 
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3.8.2. Reverse transcriptase quantitative PCR (RT-qPCR) 
RT-qPCR was performed to determine the expression levels of E6*I, E1^E4, E1C, E7 and 
ubC transcripts in CaSki, SiHa, W12-epi and W12-int cell lines after the overexpression 
of E1C. Roche cobas® z 480 analyzer system and LightCycler® 480 RNA Master 
Hydrolysis Probes were used for this purpose. Primers and probes used for amplification 
are described in Materials 2.3.. E6*I, E1^E4 and ubC transcripts were measured in a 
triplex RT-qPCR and E1C and E7 transcripts were measured in a singleplex RT-qPCR 
separately. Table below describes the different steps and the conditions used for the 
singleplex and triplex RT-qPCRs. 
 
 Temperature (°C) Time No: of cycles 
PCR step Singleplex Triplex Singleplex Triplex Singleplex Triplex 
Reverse transcription 63 63 5 min 10 min 1 1 
Denaturation 95 95 30 s 30 s 1 1 
Amplification 95,65,72* 95,60,72* 10 s, 40 s, 
1 s* 
10 s, 30 s, 
1 s* 
50 50 
Cooling 40 40 10 s 10 s 1 1 
 
*- amplification temperatures and times correspond to each other in the given order. 
 
3.8.3. Standard curves and quantification of transcripts 
A dilution series of 106 to 101 copies of in vitro transcripts of E6*I, E1^E4 and ubC 
transcripts together and E1C transcript separately were prepared in the background of 20 
ng/μL MS2 RNA. Also, a dilution series of 106 to 101 copies of full-length HPV16 DNA 
were prepared in 50 ng/μL human placenta DNA, for the quantification of E7 transcript 
levels. Dilution series of each transcript was amplified and the standard curves were 
plotted with the copy numbers of transcripts and the corresponding crossing point (Cp) 
values obtained. The absolute copy numbers of transcripts in unknown samples were 
calculated from the  standard curves. During the RT-qPCR, apart from standards and 
samples, water controls and extraction controls were also applied in duplicates to check 
for PCR and RNA contaminations respectively. 
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3.9. Protein analyses 
 
3.9.1. Preparation of cell lysates 
Cell lysates were prepared for detection and quantification of proteins by performing SDS-
PAGE and Western blot. The cells were harvested and washed two times with 1X PBS. 
Afterwards, the cells were lysed by adding 100 µL CSK I lysis buffer and incubated on ice 
for 20 min. The cells were then centrifuged at 13,000 rpm in a table top centrifuge at 4⁰C 
for 10 min. The supernatant, which is the cell lysate was collected in fresh 1.5 mL 
eppendorf tubes and stored at -80⁰C until further use. 
 
3.9.2. Bradford Assay 
Bradford assay was performed in Nunc Polysorp 96-well plates to measure the protein 
concentration in cell lysates. For this, the Bradford reagent was diluted 1:4 in autoclaved 
bidest H2O. A 1:8 BSA dilution series ranging from 0.25 mg/mL – 8 mg/mL was used as 
the standard. 1 µL of BSA standard and sample each were added to the wells of the 96-
well plate in duplicates. Afterwards, 200 µL of diluted Bradford reagent was added using 
a multichannel pipette and mixed thoroughly by pipetting up and down 10 times without 
the formation of bubbles. Then the plate was incubated for 5 min at RT. The protein 
concentration of the cell lysates was measured at 595 nm in a MultiskanTM FC microplate 
photometer using SkanIt software.  
 
3.9.3. SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
In order to separate the denatured proteins based on their molecular weight, SDS-PAGE 
was performed.  The cell lysates stored at -80⁰C were thawed on ice. Appropriate volume 
of thawed cell lysate was mixed with water and 4X SDS so that the final concentration of 
the SDS becomes 1X. The cell lysate was then incubated at 95⁰C for 5 min to disrupt any 
protein-protein interactions. Afterwards the cell lysates was loaded onto lab-made gels 
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and run in 1X running buffer at 200V until the bromophenol blue reached the bottom of 
the gel. The separating and stacking gels were prepared in the lab and the concentration 
of the acrylamide in the separating gel was dependent on the size of the protein of 
interest. Prestained Protein Ladder, Broad Range (10-230 kDa) (New England Biolabs) 
or Spectra™ Multicolor Low Range Protein Ladder (Thermo Fisher Scientific) were used 
as protein markers to estimate the size of the separated proteins. 
 
3.9.4. Western blot (WB) 
For the detection of proteins by specific antibodies, the separated proteins were blotted 
onto nitrocellulose membranes. A sandwich was prepared inside a cassette, before kept 
inside the transfer block. The components of the sandwich were dipped in transfer buffer 
before being placed on the cassette.  The order of the sandwich components placed 
inside the cassette were as follows – Sponge ->Whatman filter paper -> nitrocellulose 
membrane -> gel on which the proteins were separated ->Whatman filter paper -> 
Sponge. Remove the trapped air bubbles in the sandwich by rolling a glass pipette on 
top. The proteins were then blotted onto the membrane at 250 mA for 35 min. After the 
blotting, the nitrocellulose membrane was blocked in 10% blocking milk for 1h. The 
membrane was washed with PBS-Tween three times for 10 min afterwards. The 
membrane was then incubated in primary Ab overnight at 4°C. Unbound primary Ab was 
removed by washing with PBS-Tween three times for 10 min. The membrane was then 
incubated in secondary Ab coupled to Horse Radish Peroxidase for 2h at RT. Unbound 
secondary Ab was removed by washing with PBS-Tween three times for 10 min. For the 
detection of proteins, Amersham™ ECL Select™ Western Blotting Detection Reagent 
(GE Healthcare) was used. Equal volumes of ECL Select ™ Luminol solution and ECL 
Select ™ Peroxide solution were mixed and applied onto the membrane. The membrane 
was incubated for 1 min at RT and developed by INTAS chemocam imager suitable for 
chemiluminescence imaging. 
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3.9.5. Immunocytochemistry 
For the visualization and localization of HPV16 E1C protein, immunofluorescence (IF) 
staining was utilized. Cover slips were placed inside 10 cm dishes at first, followed by 
seeding of 1x106 HEK-293T cells. 24 h post seeding, HEK-293T cells were transfected 
by PEI reagent as described previously. 48 h post transfection, the growth medium was 
removed from the cells and the cells were fixed by adding 3.7% paraformaldehyde for 10 
min at RT. Afterwards, the cells were washed with 1X PBS three times for 5 min each. 
Each cover slip was placed in a well of a 6-well plate and performed the following steps 
except for the staining steps with gentle horizontal oscillation in a see-saw rocker. The 
cells were washed with PBS+30 mM Glycine for 5min at RT to quench paraformaldehyde. 
The cells were then permeabilized with PBS+0.1% Triton X-100 for 10 min at RT. 
Afterwards, blocking buffer was added to the cells and incubated at RT for 45 min. The 
cells were then washed three times with 1X PBS for 5 min each. A parafilm sheet was 
kept inside an aluminium foil covered box and 30 µL drop of E1C Ab diluted in blocking 
buffer was placed on the parafilm sheet. Depending on the number of cover slips to be 
stained, several 30 µL drops were placed. The cover slips were placed on the E1C Ab 
drops with cells touching the Ab solution and incubated for 2 h at RT in dark. The cover 
slips were then placed back in the wells of 6-well plate and washed three times for 5 min 
each with PBS+0.1% Triton X-100. For the secondary Ab staining and washing 
afterwards, same procedure like E1C Ab staining was followed. The secondary Ab used 
was Alexa Fluor™ 594. The cells were again washed with 1X PBS for 5 min. Afterwards, 
the cells were rinsed in deionized water and dried by placing on a Whatman filter paper. 
The cover slips were then mounted on glass slides using fluorescence mounting medium  
and dried at RT overnight and stored at 4°C from next day onwards. For the visualization 
of stained E1C protein, confocal microscopy using Zeiss LSM 710 ConfoCor 3 was 
employed and the data was analyzed using Zen (Black edition) software from Zeiss, 
Germany. 
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3.9.6. Mass spectrometry (MS) 
Proteins have been loaded on SDS-gel, which ran only a short distance of 0.5 cm. After 
Commassie staining the total sample was cut out unfractionated and digested with 
Trypsin as described by Shevchenko et al. (Shevchenko, Andrej, et al. "In-gel digestion 
for mass spectrometric characterization of proteins and proteomes." Nature protocols 1.6 
(2006): 2856.) carried out on the DigestProMSi robotic system (INTAVIS Bioanalytical 
Instruments AG). 
Samples digested with trypsin were loaded on a cartridge trap column, packed with 
Acclaim PepMap300 C18, 5µm, 300Å wide pore (Thermo Fisher Scientific) and separated 
in a 180 min gradient from 3% to 40% ACN on a nanoEase MZ Peptide analytical column 
(300Å, 1.7 µm, 75 µm x 200 mm, Waters) and a UltiMate 3000 UHPLC system. 
Furthermore, eluting peptides have been analyzed by an online coupled Q-Exactive-HF-
X mass spectrometer (Thermo Fisher Scientific) running in a data depend acquisition 
mode where one full scan was followed by up to 12 MSMS scans of eluting peptides. 
Data analysis was carried out by MaxQuant (version 1.6.0.16, Tyanova, Stefka, 
TikiraTemu, and Juergen Cox. "The MaxQuant computational platform for mass 
spectrometry-based shotgun proteomics." Nature protocols 11.12 (2016): 2301) using an 
organism specific database extracted from Uniprot.org under default settings. 
Identification FDR cutoffs were 0.01 on peptide level and 0.01 on protein level. Match 
between runs option was enabled to transfer peptide identifications across raw files based 
on accurate retention time and m/z. 
Quantification was done using a label free quantification approach based on the MaxLFQ 
algorithm (see Cox J.et al., Accurate Proteome-wide Label-free Quantification by Delayed 
Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ. Mol Cell 
Proteomics, 2014, 13, pp 2513-2526). A minimum of 2 quantified peptides per protein 
was required for protein quantification. 
Data have been further processed by in-house compiled R-scripts to plot data and the 
Perseus software package (version 1.6.2.5) using default settings for filtering, imputation 
of missing values and statistical analysis (Tyanova, Stefka, and Juergen Cox. "Perseus: 
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A Bioinformatics Platform for Integrative Analysis of Proteomics Data in Cancer 
Research." Cancer Systems Biology. Humana Press, New York, NY, 2018. 133-148.). 
 
3.9.7. Enzyme-linked immunosorbent assay (ELISA) 
96-well Nunc Polysorp plates were coated with coating medium (100 µL/well) and 
incubated overnight at 4°C the day before performing ELISA. On the following day, the 
coating medium was discarded from the plate wells thoroughly and incubated with 
blocking buffer (180 µL/well) for 1 h at 37°C. Afterwards, the blocking buffer was 
thoroughly removed bacterial lysate dilution series (2 µg/µL lysates in blocking buffer; 100 
µL/well) containing desired overexpressed protein (GST-Tag or GST-E1C-Tag) was 
added to the plate wells. The plate was then incubated for 1 h at RT on a shaker. The 
bacterial lysate was then removed and washed three times with PBS-Tween® (200 
µL/well). Afterwards, desired primary Ab diluted in blocking buffer, anti-Tag (1:50 dilution) 
or anti-E1C (1:5 dilution) (100 µL/well) was added and incubated for 1 h at RT in the dark. 
Then the plate was washed for three times with PBS-Tween® (200 µL/well) after removing 
the primary Ab. Then goat anti-mouse pox secondary Ab diluted in blocking buffer 
(1:10,000 dilution, 100 µL/well) was added and incubated for 1 h at RT in the dark. Then 
the plate was washed for three times with PBS-Tween® (200 µL/well) after removing the 
secondary Ab. Afterwards, 3,3’,5,5’-tetramethylbenzidine chromogenic substrate solution 
(100 µL/well) was added to the plate wells and the peroxidase enzyme substrate reaction 
was stopped after 2-8 min by adding stop solution (50 µL/well). The absorbance was 
measured at 450 nm in the Multiskan™ FC microplate photometer. 
GST-E1C-Tag ELISA (Results 4.2.1.2.) used in the screening of E1C Ab producing 
hybridoma clones was performed according to the above mentioned protocol and is also 
described Sehr et al., 2001228. The anti-IgG ELISA performed for determining the subtype 
of E1C mAb was a sandwich ELISA. Here, the ELISA plates were coated with anti-IgG 
antibodies (Jackson ImmunoResearch Laboratories, Inc., Cambridgeshire, UK) as the 
capture antibody followed by the addition of hybridoma clone supernatants. Anti-IgG 
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antibodies conjugated with horseradish peroxidase were used as the secondary 
antibodies (Jackson ImmunoResearch Laboratories, Inc., Cambridgeshire, UK).   
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4. Results 
 
4.1. Effects of E1C overexpression  
 
4.1.1. Effects of E1C overexpression on HPV16 transcripts 
 
For testing the effect of E1C overexpression on HPV16 transcripts, E6*I, E1^E4 and E7 
transcripts were quantified in four different HPV16-positive cell lines i.e. W12-epi, W12-
int, CaSki and SiHa. E1C was overexpressed using LV-E1C lentiviral vector as described 
in Methods 3.4.. Corresponding control cells were transduced with LV lentiviral vector. 
After the selection of transduced cells by puromycin treatment, they were harvested and 
RNA was extracted. The extracted RNA from LV- and LV-E1C- transduced cells were 
subjected to a triplex RT-qPCR for the quantification of E6*I, E1^E4 and the 
housekeeping transcript ubC transcripts and to two singleplex RT-qPCRs for the 
quantification of E1C and E7 transcripts. The PCR programming conditions for both triplex 
and singleplex RT-qPCRs are explained in Methods 3.8.2.. The data obtained after RT-
qPCRs were analyzed using LightCycler® 480 software and the quantification of all the 
transcripts were performed from the standard curves generated using the dilution series 
of corresponding in vitro transcripts.  
 
A total of eight lentiviral transductions were performed for E1C overexpression in W12-
epi and W12-int cell lines and five transductions in CaSki and SiHa. Transductions 
number 1 and 5 of W12-epi were excluded from data analysis, because of a mistake 
performed in the puromycin selection protocol and because the LV-E1C transduction did 
not work respectively. The details of no: of cells harvested post puromycin selection, total 
amount of RNA harvested, total no: of RT-qPCRs performed on each sample are given 
in supplementary information 9.5.. Tables 4.1. to 4.8. provide details about the copies per 
PCR obtained for E6*I, E1^E4, E7 and ubC for all the four cell lines in all the LV and LV-
E1C transductions. They also summarize the ratio of copies per PCR for each transcript 
obtained in LV-E1C transduction relative to LV transduction (LV-E1C/LV ratio). E6*I 
E1^E4 and ubC copies per PCR were observed to be higher in transductions 6 – 8 for 
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W12-epi, 5 – 8 for W12-int, 2 – 5 for CaSki and SiHa, whereas E7 copies per PCR were 
more or less equivalent across transductions in all the cell lines (Tables 4.1. to 4.8.). 
However, the variation in LV-E1C/LV ratios was observed to be much less. E1C RNA 
levels post transduction were in the range of 4 – 12 copies/cell. No E1C RNA copies were 
found in LV-transduced cells.  
 
Because RNA levels varied between transductions, median LV-E1C/LV ratios were 
calculated and values outside of 2x median and 0.5x median were defined as outliers and 
excluded from statistical analysis. The ubC LV-E1C/LV ratios for all the transductions in 
all the cell lines were inside the range of 0.5x median and 2x median except for the third 
transduction in W12-epi (Table 4.2.). 
 
 
Table 4.1. E6*I and E1^E4 copies per PCR for LV and LV-E1C transductions in W12-epi.  
LV-E1C/LV denotes the ratio of corresponding transcripts in LV-E1C- to LV- transduced cells. 
The values in red indicate outliers.  
 
 
 
 
The statistical analysis was performed on the LV-E1C/LV ratios of E6*I, E1^E4 and E7 
transcript levels from all the transductions in all the cell lines by paired t test and two-
Transduction
LV LV-E1C LV-E1C/LV LV LV-E1C LV-E1C/LV
2 75,000 72,500 0.97 2,025,000 1,472,500 0.73
3 9,600 52,800 5.50 68,000 561,600 8.26
4 17,600 41,600 2.36 164,000 518,400 3.16
6 2,277,500 3,930,000 1.73 1,805,000 903,750 0.50
7 868,750 1,013,750 1.17 1,815,000 1,568,750 0.86
8 893,750 1,103,750 1.23 1,775,000 1,265,000 0.71
E6*I E1^E4
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tailed p values were calculated. In W12-epi, E6*I (p = 0.12) and E7 (p = 0.30) levels in 
LV-E1C-transduced cells were not significantly different compared to LV-transduced cells 
(Figure 4.1. (A) and (C)). However, E1^E4 levels were significantly reduced (p = 0.03) 
with a mean of 30% (Figure 4.1. (B)). 
In W12-int, E6*I (p = 0.75) and E7 (p = 0.33) levels in LV-E1C-transduced cells were not 
significantly different (Figure 4.1. (A) and (C)). E1^E4 levels were significantly reduced (p 
= 0.02) with a mean of 20% (Figure 4.1. (B)) when the value from third transduction was 
not considered and with a mean of 10% with no statistical significance (p = 0.25) when 
the value from third transduction was considered.  
Table  4.2. E7 and ubC copies per PCR for LV and LV-E1C transductions in W12-epi. 
LV-E1C/LV denotes the ratio of corresponding transcripts in LV-E1C- to LV- transduced cells. 
The values in red indicate outliers.  
 
 
 
 
In CaSki, E6*I (p = 0.26) and E7 (p = 0.38) levels in LV-E1C-transduced cells were not 
significantly different (Figure 4.1. (A) and (C)). However, E1^E4 levels were significantly 
reduced (p = 0.02) with a mean of 20% (Figure 4.1. (B)) when the value from fifth 
transduction was not considered and with a mean of 10% with no statistical significance 
(p = 0.43) when the value from fifth transduction was considered. In SiHa, E6*I (p = 0.18) 
Transduction
LV LV-E1C LV-E1C/LV LV LV-E1C LV-E1C/LV
2 52,500 37,500 0.71 878,750 1,282,500 1.46
3 800 84,000 105.00 18,400 72,800 3.96
4 24,000 60,800 2.53 32,800 80,800 2.46
6 55,000 80,000 1.45 1,011,250 846,250 0.84
7 73,750 70,000 0.95 2,287,500 2,301,250 1.01
8 68,750 86,250 1.25 1,942,500 1,973,750 1.02
E7 ubC
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and E7 (p = 0.55) levels in LV-E1C-transduced cells were not significantly different (Figure 
4.1. (A) and (C)). 
Table 4.3. E6*I and E1^E4 copies per PCR for LV and LV-E1C transductions in W12-int.  
LV-E1C/LV denotes the ratio of corresponding transcripts in LV-E1C- to LV- transduced cells. 
The values in red indicate outliers.  
 
 
 
Table 4.4.  E7 and ubC copies per PCR for LV and LV-E1C transductions in W12-int. 
LV-E1C/LV denotes the ratio of corresponding transcripts in LV-E1C- to LV- transduced cells. 
The values in red indicate outliers.  
 
 
 
Transduction
LV LV-E1C LV-E1C/LV LV LV-E1C LV-E1C/LV
1 318,750 555,000 1.74 3,500,000 6,816,250 1.95
2 233,750 243,750 1.04 5,008,750 4,653,750 0.93
3 342,500 430,000 1.26 4,495,000 5,802,500 1.29
4 497,500 322,500 0.65 7,037,500 4,335,000 0.62
5 21,771,250 20,708,750 0.95 30,366,250 23,783,750 0.78
6 21,847,500 17,770,000 0.81 25,866,250 22,502,500 0.87
7 4,662,500 4,055,000 0.87 17,171,250 13,812,500 0.80
8 5,723,750 1,270,000 0.22 22,282,500 3,538,750 0.16
E6*I E1^E4
Transduction
LV LV-E1C LV-E1C/LV LV LV-E1C LV-E1C/LV
1 107,500 275,000 2.56 472,500 335,000 0.71
2 90,000 95,000 1.06 2,036,250 1,998,750 0.98
3 327,500 382,500 1.17 572,500 417,500 0.73
4 515,000 325,000 0.63 802,500 402,500 0.50
5 212,500 160,000 0.75 1,953,750 1,748,750 0.90
6 217,500 232,500 1.07 2,067,500 1,925,000 0.93
7 331,250 237,500 0.72 8,827,500 9,287,500 1.05
8 363,750 95,000 0.26 7,580,000 7,525,000 0.99
E7 ubC
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Table 4.5. E6*I and E1^E4 copies per PCR for LV and LV-E1C transductions in CaSki.  
LV-E1C/LV denotes the ratio of corresponding transcripts in LV-E1C- to LV- transduced cells. 
The values in red indicate outliers.  
 
 
 
 
Table 4.6 E7 and ubC copies per PCR for LV and LV-E1C transductions in CaSki. 
LV-E1C/LV denotes the ratio of corresponding transcripts in LV-E1C- to LV- transduced cells. 
 
 
 
 
 
Transduction
LV LV-E1C LV-E1C/LV LV LV-E1C LV-E1C/LV
1 470,000 377,500 0.80 7,380,000 5,845,000 0.79
2 2,780,000 2,662,500 0.96 4,770,000 4,096,250 0.86
3 372,500 1,830,000 4.91 508,750 2,917,500 5.73
4 1,060,000 857,500 0.81 5,218,750 3,962,500 0.76
5 886,250 947,500 1.07 3,915,000 4,756,250 1.21
E6*I E1^E4
Transduction
LV LV-E1C LV-E1C/LV LV LV-E1C LV-E1C/LV
1 547,500 505,000 0.92 2,645,000 2,547,500 0.96
2 55,000 70,000 1.27 189,368,750 167,791,250 0.89
3 12,500 25,000 2 138,728,750 151,351,250 1.09
4 150,000 120,000 0.80 55,616,250 57,818,750 1.04
5 117,500 125,000 1.06 53,875,000 68,370,000 1.27
E7 ubC
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Table 4.7. E6*I and E1^E4 copies per PCR for LV and LV-E1C transductions in SiHa.  
LV-E1C/LV denotes the ratio of corresponding transcripts in LV-E1C- to LV- transduced cells. 
 
 
 
 
Table 4.8. E7 and ubC copies per PCR for LV and LV-E1C transductions in SiHa.  
LV-E1C/LV denotes the ratio of corresponding transcript in LV-E1C- to LV- transduced cells. 
 
 
 
 
 
Transduction
LV LV-E1C LV-E1C/LV LV LV-E1C LV-E1C/LV
1 195,000 290,000 1.49
2 6,081,250 5,648,750 0.93
3 5,246,250 6,982,500 1.33
4 1,728,750 1,741,250 1.01
5 1,673,750 1,827,500 1.09
E1^E4 transcript not present in SiHa cell line
E6*I E1^E4
Transduction
LV LV-E1C LV-E1C/LV LV LV-E1C LV-E1C/LV
1 400,000 365,000 0.91 615,000 845,000 1.37
2 37,500 80,000 2.13 27,322,500 33,992,500 1.24
3 100,000 70,000 0.70 25,396,250 36,045,000 1.42
4 300,000 312,500 1.04 17,096,250 12,240,000 0.72
5 265,000 295,000 1.11 11,448,750 11,682,500 1.02
E7 ubC
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Figure 4.1. Ratios of HPV16 transcript levels in LV-E1C to LV transductions from different cell lines. LV-E1C/LV 
ratios are displayed with outliers excluded as defined in tables 4.1. - 4.8.. A) and C) show E6*I and E7 transcripts in 
W12-epi, W12-int, CaSki and SiHa cells respectively. B) shows E1^E4 transcript in W12-epi, W12-int and CaSki 
respectively. Mean together with standard deviation is shown for all the data points. 
 
A) 
B) 
C) 
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4.1.2. Effects of E1C overexpression on host or cellular proteome 
In order to identify the cellular proteome changes in E1C overexpressed cells, MS was 
employed. For this purpose, LV-E1C-transduced W12-epi, W12-int, CaSki and SiHa cells 
together with their corresponding LV-transduced cells as controls were utilized. For W12-
epi and W12-int, cells from third, fourth, seventh and eighth lentiviral transductions and 
for CaSki and SiHa, cells from first, fourth and fifth lentiviral transductions were used 
(details of transductions are explained in Results 4.1.).  
In total, 77883 peptides and 4899 proteins were identified by MS. The Perseus software 
was used for the statistical data analysis218. To check for statistically significant changes 
in the protein quantities in LV-E1C-transduced cells, Two-sample t-tests with log2 () 
transformed LFQ values were used after replacing missing values based on normal 
distribution. A permutation based false discovery rate threshold of 0.05 was used. S0, 
which gives the minimal fold change, was set to 0.1. This means that although a protein 
shows a good p-value, it would not be significant if the S0 is below 0.1.  
The results from the Two-sample t-tests are displayed as volcano plots (Figure 4.2.). X-
axis represents the t-test difference, which is equivalent to building a ratio between protein 
expressions in LV-E1C- to LV- transduced cells. Y-axis shows the p values, which 
determine the significance of the t-test differences for each protein. If the p value for a 
given protein was below 0.05, then it is considered as statistically significantly changing. 
S0 value helped to exclude the very significant hits, which showed almost no or zero t-
test difference. All red data points below the black lines are non-significant. When the 
Two-sample t-tests were analyzed, no statistically significant changes in the protein 
quantities were observed in LV-E1C-transduced W12-epi, W12-int and SiHa cells 
compared to corresponding LV-transduced cells (Figure 4.2. (A), (B) and (D)). However, 
in LV-E1C-transduced CaSki cells, PDIA3 protein was found to be significantly changing 
when compared to LV-transduced cells (Figure 4.2. (C)). PDIA3 protein showed a t-test 
difference of 1.05 which is the log2 expression and 21.05 gives the fold change, which 
means PDIA3 protein was two fold upregulated in LV-E1C-transduced CaSki cells. When 
Two-sample t-tests were performed for all the cell lines together, i.e. LV-E1C-transduced 
versus LV-transduced, no statistically significant hits have been found (Figure 4.2. (E)).  
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Figure 4.2. Proteomic changes in LV-E1C- vs. LV-transduced cells represented using volcano plots. X-axis 
shows the two sample t-test difference of protein quantities between LV-E1C- and LV- transduced cells and Y-axis 
shows the log10p values of the t-test differences of W12-epi (A), W12-int (B), CaSki (C), SiHa (D) and for all the cell 
lines together (E).  
 
 
4.2. Detection of E1C protein 
 
4.2.1. Generation of E1C mAb 
A murine mAb specific for the detection of E1C protein was generated using hybridoma 
technology (see Methods 3.2.). The procedure involved design of antigen i.e. an E1C 
specific peptide, mouse immunization, production of hybridomas from the lymphocytes of 
mouse with the highest Ab titer and screening and cloning of hybridomas. 
 
E) 
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4.2.1.1. Design of an E1C peptide for mouse immunization 
A short peptide of 10 aa length (E1C sp) was designed for immunizing mice to generate 
E1C mAb (Figure 4.4. (B)). E1C sp spanned the splice junction-derived peptide fusion of 
the putative E1C protein (Figure 4.4. (A)), and thus confers E1C specificity against E1fl 
protein. The first 5 aa of the putative E1C protein are from the amino terminus of E1 and 
the last 77 aa from the carboxy terminus of E1 (Figure 4.3.). To elicit significant antibody 
responses, 2 mg of chemically synthesized E1C sp was conjugated via a C-terminally 
added cysteine to keyhole limpet hemocyanin (KLH), a large carrier protein. KLH is a 
copper-containing glycoprotein, with a molecular weight of 3.9x105 Da excluding the 
glycosylation. Because molluscs are phylogenetically distant from mammals, KLH is less 
likely to immunologically cross-react with human or mouse proteins. A total of 5 mg E1C 
sp was synthesized by Peptide Speciality Laboratories GmbH, Heidelberg, 
(www.peptid.de), out of which 2 mg was coupled with KLH and 3 mg was uncoupled. 
 
Figure 4.3. Schematic diagram of E1C transcript and protein. The diagram shows the HPV16 genome and the 
coding regions of the E1C transcript and protein. The regions marked in red in the E1 open reading frame are present 
in the E1C transcript. The splice junction 880^2582 of the E1C transcript is also shown. The regions marked in red in 
the E1C transcript encode the putative E1C protein (HPV16 genome edited from Höfler et al., 2015). 
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5’- ATGGCTGCCTGCAGATTCTAGGTGGCCTTATTTACATAATAGATTGGTG 
GTGTTTACATTTCCTAATGAGTTTCCATTTGACGAAAACGGAAATCCAGTGTA 
TGAGCTTAATGATAAGAACTGGAAATCCTTTTTCTCAAGGACGTGGTCCAGA 
TTAAGTTTGCACGAGGACGAGGACAAGGAAAACGATGGAGACTCTTTGCCA 
ACGTTTAAATGTGTGTCAGGACAAAATACTAACACATTATGA – 3’ 
 
MADPADSRWPYLHNRLVVFTFPNEFPFDENGNPVYELNDKNWKSFFSRTWSR     
LSLHEDEDKENDGDSLPTFKCVSGQNTNTL 
 
Figure 4.4. E1C cDNA and protein sequences. A) cDNA sequence of E1C showing the start (ATG, highlighted in 
green) and stop (TGA, highlighted in yellow) codons and the splice junction ‘GA’ (highlighted in red) embedded in the 
blue sequence coding for the 10 aa long E1C sp used for immunization. B) Sequence of the putative E1C protein 
showing the splice junction-derived peptide fusion ‘AD’ in red and the 10 aa long E1C sp used for mouse immunization 
in blue. 
 
4.2.1.2. Mouse immunization, fusion and cloning 
The sera from the E1C sp-immunized mice were tested for the presence of E1C Abs. For 
this purpose, lysates from E. coli overexpressing GST-E1C and GST-E1fl fusion proteins 
and from HeLa cells overexpressing GFP-E1C fusion protein were applied to gel 
electrophoresis and transferred to the WB membranes. E.coli lysate overexpressing GST 
protein and HeLa cellular lysate acted as corresponding negative controls. Expected 
bands of 35 and 36 kDa corresponding to GST-E1C and GFP-E1C fusion proteins 
respectively were visible in the blots stained with immune sera from C57black6N, but not 
from BALB/c mice (Figure 4.5. (A)). An additional prominent 25-28 kDa band was 
observed in the GST-E1C lane, probably a product of N- or C-terminal fusion protein 
degradation or premature translation stop shortly after the E1C specific peptide sequence 
(Figure 4.5. (A)). No bands were visible in the control lanes without E1C peptide sequence 
A. 
B. 
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and also not in the GST-E1fl protein lanes as well, confirming the E1C-specificity of the 
antibodies. GST protein and HeLa cellular lysate lanes. In addition, no bands around 70 
kDa were visible in the GST-E1fl protein lanes as well, confirming the specificity of E1C 
antibodies produced. The blot stained with pre-serum taken before immunization served 
as a negative control for sera staining and no bands were visible except for one around 
35 kDa (Figure 4.5. (A)) which is unexpected and remains unexplained. 
E1C-immunized mouse C57black6N-1 was chosen for fusion. A total of 370 primary 
hybridoma clones were screened for the presence of E1C Abs. Screening was performed 
using a standard mAb screening ELISA established in the monoclonal antibody core 
facility with E1C sp as antigen. Six clones were tested positive for the presence of E1C 
Abs, which were then confirmed by GST-E1C-Tag ELISA and WB with GST-E1C and 
GFP-E1C fusion proteins.Both GST-E1C and GFP-E1C fusion proteins were visible in 
the blots stained with cell culture supernatant of the six clones (Figure 4.5. (B)). After two 
sub-cloning rounds of these 6 clones and testing 277 supernatants one sub-clone (61/1/2) 
which showed highest reactivity in GST-E1C-Tag ELISA and reacted in WB (Figure 4.5. 
(C)) and IF (Figure 4.13. (B)) was chosen for the production of E1C mAb. In GST-E1C-
Tag ELISA, the mean absorbance measured for GST-E1C antigen stained with E1C mAb 
was 0.85 and GST-Tag antigen (positive control) stained with α-Tag mAb was 1.03. Thus, 
E1C mAb showed more than half of the reactivity when compared to the positive control.  
After performing an anti-IgG ELISA, E1C mAb was found to be of IgG1 subtype (data not 
shown). Optimal working dilutions of the purified E1C mAb were determined in dilution 
series and found to be 1:5 for ELISA (lowest concentration giving at least half of the 
maximal signal intensity as that of positive control) and WB and 1:3. Thus, a monoclonal 
antibody suited for the specific detection of HPV16 E1C protein was successfully 
produced. 
 
4.2.2. Detection of overexpressed E1C protein 
The newly generated E1C mAb was utilized for the detection of the small putative 9 kDa 
E1C protein overexpressed without additional protein fusions in HEK-293T and W12 cells.  
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Figure 4.5. E1C antibody reactivity in western blot. Western blot lanes contain lysates from E. coli overexpressing 
GST-Tag (GST), GST-E1C (p.E1C), or GST-E1fl (p.E1fl) fusion protein and lysates from HeLa cells without (e.ctrl) or 
with (e.E1C) GFP-E1C fusion protein overexpression. Prestained Protein Ladder, Broad Range (10-230 kDa) was used 
B) 
C) 
pre-serum BALB/c - 1 BALB/c - 2 C57Black6N - 1 C57Black6N - 2 
 
A) 
66 
 
as size marker in all blots. A) Reactivity of mouse pre-serum and immune sera of E1C sp-immunized BALB/c and 
C57Black6N mice (2 each). B) Reactivity of supernatants of 6 hybridoma clones (#61, #94, #115, #159, #174 and #179) 
from E1C sp-immunized mice. C) Reactivity of the finally selected E1C hybridoma sub-clone 61/1/2. GST and GST-
E1C denote the E. coli lysates overexpressing GST-Tag and GST-E1C fusion proteins. Non-transfected denotes HeLa 
cells without any protein overexpression and GFP-E1C denotes HeLa cells overexpressing GFP-E1C fusion protein. 
 
When the western blots were performed under standard conditions, E1C protein was not 
detectable in p2-E1C-transfected HEK-293T cellular lysates while the 36 kDa GFP-E1C 
protein was visible in p1-His-GFP-E1C-transfected HEK-293T cellular lysates (data not 
shown). After literature survey and several personal communications with expert 
colleagues at DKFZ, the WB protocol was modified to enhance the detection of small 
proteins and the 10 kDa ABCB5 protein carrying a 6x-His tag was used as positive control. 
The polyacrylamide gels were enlarged to around 30 cm x 30 cm to allow good separation 
of small proteins, the loading well capacity was increased to around 50 µL to increase the 
amount of loaded protein. Protein transfer was performed using a transfer buffer without 
SDS and at lower current for shorter time (250 mA for 30 min) to reduce the loss of E1C 
protein through the nitrocellulose membrane.  
 
4.2.2.1. Production and purification of ABCB5 
Bacterial lysate overexpressing truncated ABCB5 protein was purified by affinity 
chromatography. The different eluates obtained during the purification process are Eluate 
1 to Eluate 7. The concentrations of the eluates are measured using a NanoDrop™ 
spectrophotometer at 280 nm and ranged between 0.85 – 0.11 mg/mL (Table 4.9.) and 
were tested for the presence of ABCB5 by WB (Figure 4.6.). All the eluates contained 
ABCB5 protein, where Eluates 1 – 4 contained more protein compared to Eluates 5 – 7 
(Figure 4.6.). Thus, a positive control protein for the detection of 9 kDa E1C protein was 
successfully established.  
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Table 4.9. Protein concentrations of the eluates from ABCB5 purification. 
Eluate Concentration of eluate (mg/mL) 
Eluate 1 0.85 
Eluate 2 0.33 
Eluate 3 0.15 
Eluate 4 0.84 
Eluate 5 0.13 
Eluate 6 0.12 
Eluate 7 0.11 
 
 
 
Figure 4.6. Testing of all the eluates from ABCB5 purification in WB. 50 ng of Eluate 1 to eluate 7 were applied to 
WB from left to right. The blot was stained with α-His Ab. NE-8 is a purified 6x-His tagged protein of 8 kDa which was 
loaded as the positive control and 50 ng of NE-8 was loaded. α-His control was a HeLa cellular lysate containing a His-
tagged protein, which served as the positive control for α-His Ab, and 20 µg was applied. Spectra™ Multicolor Low 
Range Protein Ladder was used as the marker. 
 
4.2.2.2. Testing the sensitivity of the modified WB protocol for the detection of 
small proteins 
The sensitivity of WB protocol for small proteins was tested to analyze the least amount 
of purified protein detected with the protocol. 
The sensitivity test was performed using ABCB5 and GFP-E1C fusion protein. Eluate 1 
of ABCB5 (Table 4.9.) was chosen for the sensitivity test. For the preparation of GFP-
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E1C fusion protein, HeLa cells were transfected with p1-His-GFP-E1C plasmid by PEI 
transfection. The samples were prepared for WB as described in Methods section 3.9.4.. 
A 1:10 dilution series ranging from 330 – 0.0033 ng were used to prepare ABCB5 samples 
whereas a dilution ranging from 10 – 0.1 µg was used for GFP-E1C sample. ABCB5 blot 
was stained with α-His Ab and GFP-E1C blot with α-E1C Ab. 
ABCB5 band was observed at 10 kDa in 330 ng and 33 ng lanes and not in the rest of 
the lanes (Figure 4.7. (A)). For GFP-E1C, 36 kDa bands were observed in 10 µg and 5 
µg lanes and not in the rest of the lanes (Figure 4.7. (B)). Therefore, the sensitivity or the 
detection limits of the modified WB protocol were 33 ng of purified ABCB5 protein. GFP-
E1C protein from p1-His-GFP-E1C-transfected HeLa cellular lysate could be detected in 
a minimum of 5 µg total lysate protein. Hence the WB protocol was capable of detecting 
33 ng of small proteins of size 10 kDa and E1C in 5 µg of cellular lysate protein. 
 
4.2.2.3. Detection of overexpressed E1C protein in HEK-293T cells 
For the detection of overexpressed E1C protein in HEK-293T cells, E1C and GFP-E1C 
were overexpressed using p2-E1C and p1-His-GFP-E1C plasmids in HEK-293T cells by 
PEI transfection. The negative control samples were HEK-293T cells transfected with the 
corresponding empty vector backbones, p2 and p1-His-GFP. 
 
4.2.2.3.1. E1C mRNA quantification in p2-E1C-transfected HEK-293T cells 
RNA was extracted from p2- and p2-E1C-transfected HEK-293T cells according to the 
protocol described in Methods 3.8.1.. The overexpressed E1C mRNA was quantified by 
singleplex RT-qPCR as explained in Methods 3.8.2.. 100 ng of RNA was applied to the 
PCR. The absolute E1C mRNA copies were analyzed using a 106 – 100 copies/µL dilution 
series of p2-E1C plasmid (Figure 4.8.).  
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Figure 4.7. Sensitivity of protein detection in the modified WB protocol. A) Different amounts of ABCB5 protein 
(Eluate 1) were applied to WB and detected by 6x-His immunostaining. B) Different amounts of total lysate protein from 
HeLa cells overexpressing GFP-E1C fusion protein were applied to WB and detected by E1C immunostaining. 
Spectra™ Multicolor Low Range Protein Ladder was used as the marker. 
 
 
The sensitivity of the PCR was 103 copies/µL and the specificity of the PCR was tested 
by applying 106 copies/µL of p2 plasmid. No Cp values were detected for p2 plasmid. The 
efficiency of the PCR was 2.54. Both the standards and samples were applied as 
duplicates. 
The total no: of E1C mRNA copies per PCR was calculated from the following formula: 
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Total no: of E1C mRNA copies per PCR =2.71828182845904^((a-b)/c) 
Where, a = average Cp value of the sample duplicates, b = constant from the standard 
curve, c = natural log of slope  
The total no: of cells applied to the PCR was 5000 and was calculated under the 
assumption that one mammalian cell consists of 20 pg RNA. 9.24x107was the total 
number of E1C mRNA copies detected per PCR in p2-E1C-transfected HEK-293T RNA 
sample and no E1C mRNA copies were detected in p2-transfected HEK-293T RNA 
sample. Therefore, the absolute no: of E1C mRNA copies per cell for p2-E1C-transfected 
HEK-293T cells was calculated as 1.85x104. 
 
 
Figure 4.8. Standard curve for q-PCR amplification of p2-E1C plasmid DNA. X-axis was plotted with copies/µL and 
y-axis with Cp values. The slope is calculated from the curveas natural log and is given on the top right hand side. 
Efficiency of the PCR is calculated from base-10 log of slope, Efficiency = 10(-1/slope lg (x)). R2 is the correlation coefficient. 
 
4.2.2.3.2. E1C protein detection in p2-E1C-transfected HEK-293T cells 
For the detection of overexpressed E1C protein in HEK-293T cells, WB samples were 
prepared from cellular lysates of p2-, p2-E1C-, p1-His-GFP-, and p1-His-GFP-E1C-
transfected HEK-293T cells.  GFP-E1C protein from p1-His-GFP-E1C-transfected HEK-
293T cells acted as the positive control for E1C mAb staining and 50 ng of ABCB5 (in 
combination with α-His staining) for 10 kDa protein detection (Figure 4.9.).  
A 9 kDa band corresponding to E1C protein was not detectable in the p2-E1C-transfected 
HEK-293T cellular lysate, whereas a 36 kDa GFP-E1C protein band was visible in the 
p1-His-GFP-E1C-transfected HEK-293T cellular lysate (Figure 4.9.). 
y = -1,071ln(x) + 35,614
R² = 0,984
0
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Figure 4.9. Detection of overexpressed E1C protein in HEK-293T cells by WB. Lysates of HEK-293T cells (100 µg 
total lysate protein) transfected with p2 (denoted as – in the p2-E1C row), p2-E1C (denoted as + in the p2-E1C row), 
p1-His-GFP (denoted as – in the p1-His-GFP-E1C row) and p1-His-GFP-E1C (denoted as + in the p1-His-GFP-E1C 
row) were applied to the western blot together with 50 ng ABCB5, loaded in the lane left to the Spectra™ Multicolor 
Low Range Protein Ladder. 
 
4.2.2.4. Detection of overexpressed E1C protein in W12-epi and W12-int cells 
For the detection of overexpressed E1C protein in W12-epi and W12-int cells, E1C was 
overexpressed using LV-E1C plasmid by lentiviral transduction. The negative control 
samples were cells transfected with the corresponding empty vector LV. 
 
4.2.2.4.1. E1C mRNA quantification in LV-E1C-transduced W12-epi and W12-int 
cells 
RNA was extracted from LV- and LV-E1C-transduced W12-epi and W12-int cells. The 
overexpressed E1C mRNA was quantified by singleplex E1C RT-qPCR. 100 ng of RNA 
was applied to the PCR. The absolute E1C mRNA copies were analyzed using a 106– 
100 copies/µL dilution series of LV-E1C plasmid (Figure 4.10.). The sensitivity of the PCR 
was 10copies/µL and the specificity of the PCR was tested by applying 106copies/µL of 
LV plasmid. No Cp values were detected for LV plasmid. The efficiency of the PCR was 
2.11. Both the standards and samples were applied as duplicates. 
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The total no: of cells applied to the PCR was 5000. 7.7x104was the total number of E1C 
mRNA copies detected per PCR in LV-E1C-transduced W12-epi RNA sample and 
4.3x104copies per PCR in LV-E1C-transduced W12-int RNA sample. No E1C mRNA 
copies were detected in LV-transduced W12-epi and W12-int RNA samples. Therefore, 
the absolute no: of E1C mRNA copies per cell was calculated as 16 for LV-E1C-
transduced W12-epi cells and 9 for LV-E1C-transduced W12-int cells. 
 
 
Figure 4.10. Standard curve for q-PCR amplification of LV-E1C plasmid DNA. X-axis was plotted with copies/µL 
and y-axis with Cp values. The slope is calculated from the curve as natural log and is given on the top right hand side. 
Efficiency of the PCR is calculated from base-10 log of slope, Efficiency = 10(-1/slope lg (x)). R2 is the correlation coefficient. 
 
4.2.2.4.2. E1C protein detection in LV-E1C-transduced W12-epi and W12-int cells 
For the detection of overexpressed E1C protein in W12-epi and W12-int cells, WB 
samples were prepared from cellular lysates of LV- and LV-E1C-transduced W12-epi and 
W12-int cells. GFP-E1C protein from p1-His-GFP-E1C-transfected HEK-293T cells acted 
as the positive control for E1C mAb staining and ABCB5 for 10 kDa protein detection 
(Figure 4.11.). 
A 9 kDa band corresponding to E1C protein was not detectable in the LV-E1C-transduced 
W12-epi and W12-int cellular lysates, whereas a 36 kDa GFP-E1C protein band was 
visible in the p1-His-GFP-E1C-transfected HEK-293T cellular lysate (Figure 4.11.). 
 
y = -1,341ln(x) + 39,871
R² = 0,9944
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Figure 4.11. Detection of overexpressed E1C protein in W12 cells by WB. Lysates of HEK-293T cells (30 µg total 
lysate protein) transfected with p2 (denoted as – in the p2-E1C row), p2-E1C (denoted as + in the p2-E1C row), p1-
His-GFP (denoted as – in the p1-His-GFP-E1C row) and p1-His-GFP-E1C (denoted as + in the p1-His-GFP-E1C row) 
were applied to the western blot together with ABCB5, loaded in the lane left to the Spectra™ Multicolor Low Range 
Protein Ladder. 
 
 
4.2.2.5. Detection of overexpressed E1C protein after proteasome inhibition 
 
4.2.2.5.1. Detection of overexpressed E1C protein after proteasome inhibition: 
Western blot 
In order to detect the overexpressed E1C protein after proteasome inhibition, HEK-293T 
cells were treated with and without the proteasome inhibitor MG132 for 6 h prior to their 
harvest at 12, 24 and 48 h post transfection with p2 and p2-E1C. Afterwards, cellular 
lysates were prepared and applied to WB.  
A 9 kDa band corresponding to E1C protein was detectable 48 h post transfection when 
treated with MG132 in the p2-E1C-transfected HEK-293T cells (Figure 4.12. (3B) and 
(3D)), and not in the cases of cells harvested post 12 and 24 h transfection (Figure 4.12. 
(1B) and (2B) respectively). No 9 kDa band was visible in the p2-E1C-transfected HEK-
293T cells which were not treated with MG132 and were harvested at 12, 24 and 48 h 
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post transfection (Figure 4.12. (1A), (2A), (3A) and (3C). 36 kDa GFP-E1C protein band 
was visible in all the samples.  
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Figure 4.12. WB detection of overexpressed E1C protein after proteasome inhibition. HEK-293T cell lysates (100 
µg total lysate protein) transfected with p2 (denoted as – in the p2-E1C row), p2-E1C (denoted as + in the p2-E1C row), 
p1-His-GFP (denoted as – in the p1-His-GFP-E1C row) and p1-His-GFP-E1C (denoted as + in the p1-His-GFP-E1C 
row) and treated with (1B, 2B, 3B, 3D) and without MG132 (1A, 2A, 3A,3C) have been applied to the western blot 
together with 50 ng ABCB5, which is loaded in the left lane to the Spectra™ Multicolor Low Range Protein Ladder. 1A 
and 1B are blots of lysates prepared post 12h transfection, 2A and 2B post 24h transfection and 3A, 3B, 3C and 3D 
post 48h transfection. 3A and 3B blots were exposed for 1 min during development and 3C and 3D for 5 min. 1A – 2B 
blots were exposed for 5 min. The red frame on the blots marks the region where the endogenous 9 kDa E1C protein 
would migrate to. E1C band was observed in 3B and 3D blots where p2-E1C transfected HEK-293T cellular lysates 
were loaded. 3D blot had a more intense E1C band compared to 3B blot. Also, GFP-E1C bands were intense in p1-
His-GFP-E1C-transfected HEK-293T cellular lysates with MG132 treatment compared to the ones without treatment. 
All blots of lysates without MG132 treatment showed no 9 kDa protein. 
 
3C) 
3D) 
48 h – 5 min exposure 
48 h – 5 min exposure 
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E1C RNA was also quantified in p2 and p2-E1C-transfected and MG132-treated HEK-
293T cells by singleplex E1C RT-qPCR. 100 ng of total RNA were applied to the PCR, 
the equivalent of 5000 cells. All cells overexpressed E1C and the abundance of E1C RNA 
increased with the increase in harvest time point from 12 to 48 h post transfection (Table 
4.10). MG132-treated cells showed half the number of E1C RNA copies/cell as compared 
to DMSO-treated cells at 12 h and 24 h time points.  
 
Table 4.10. E1C RNA copies/cell in p2-E1C-transfected and MG132 treated HEK-293T cells. 
 E1C RNA copies/cell 
HEK-293T cells p2-E1C (12h) p2-E1C (24h) p2-E1C (48h) 
DMSO 6x104 2x105 4x105 
MG132 6x104 1x105 2x105 
 
 
4.2.2.5.2. Detection of overexpressed E1C protein after proteasome inhibition: 
Immunofluorescence 
In order to detect overexpressed E1C protein in p2-E1C-transfected and MG132-treated 
HEK-293T cells by IF, HEK-293T cells were treated with DMSO or MG132 for 6 h prior to 
their harvest at 48 h post transfection with p2 or p2-E1C. Afterwards, cells were fixed with 
3.7% PFA and prepared for IF as described in Methods 3.9.5..  
Before proceeding to E1C protein detection, the IF protocol was tested for the detection 
of small proteins of about 9 kDa size. For this purpose, HEK-293T cells transfected with 
pcDNA3.1(+) and pcDNA3.1(+)-CASIMO were analysed by IF. pcDNA3.1(+)-CASIMO 
encodes CASIMO protein tagged at the C-terminus with a Flag epitope and is of 9 kDa 
size192. CASIMO protein was successfully detected in the cytoplasm using α-Flag Ab 
(Figure 4.13. (A)). Thus, the IF protocol was suitable for the detection of E1C protein. As 
a positive control, HEK-293T cells transfected with p1-His-GFP and p1-His-GFP-E1C 
were also analyzed by IF. The cells were stained with α-E1C mAb and GFP-E1C protein 
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was found to be localized in the cytoplasm (Figure 4.13. (B)). When p2- and p2-E1C-
transfected HEK-293T cells were stained with α-E1C mAb, E1C protein was found to be 
localized in the cytoplasm in the case of MG132-treated p2-E1C transfected HEK-293T 
cells and not in the p2-transfected HEK-293T cells (Figure 4.13. (C)). However, not all 
GFP-positive cells were stained positive for E1C. When ten images of MG132 treated p2-
E1C transfected HEK-293T cells were analyzed from one microscopic cover slip, only 31 
cells were found to be E1C-positive out of 175 GFP-positive cells. i.e. only 20% of the p2-
E1C transfected cells were stained positive for E1C in IF. 
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Figure 4.13. IF detection of overexpressed E1C protein after proteasome inhibition. A) HEK-293T cells transfected 
with pcDNA3.1(+) (left image) and pcDNA3.1(+) –CASIMO (right image) and stained with DAPI and α-Flag Ab are 
shown. Nuclei were stained blue and CASIMO protein was stained red (right image). B) HEK-293T cells transfected 
with p1-His-GFP (top panel) and p1-His-GFP-E1C (bottom panel) stained with DAPI and α-E1C Ab are shown. Nuclei 
were stained blue and GFP-E1C fusion protein visualized through green and red channels can be seen under ‘GFP’ 
and ‘E1C’ in p1-His-GFP-E1C panel. C) HEK-293T cells transfected with p2 (top panel) and p2-E1C (bottom panel) 
stained with DAPI and α-E1C Ab are shown. Nuclei were stained blue and E1C protein visualized through red channel 
is visible under ‘E1C’ in p2-E1C panel. As p2 and p2-E1C also encodes for GFP protein, GFP-positive cells are shown 
under ‘GFP’. A merge of all the channels can be seen under ‘merge’ in both B) and C). 
 
4.2.2.5.3. Detection of overexpressed E1C protein after proteasome inhibition: 
Mass Spectrometry 
In order to detect overexpressed E1C protein in cells by MS, cellular lysates were 
prepared from p2-E1C-transfected HEK-293T cells with and without MG132 treatment 
prior to their harvest 12, 24 and 48 h post transfection. Lysate from p1-His-GFP-E1C 
transfected HEK-293T cells harvested 48 h post transfection without MG132 pre-
treatment was used as positive control. Afterwards, cells were subjected to MS analysis 
as described in Methods 3.9.6.. 
A total of 69,796 peptides and 4574 proteins were identified by MS. Out of which four 
peptides of varying length and specific for HPV16 E1 or E1C protein sequence were 
identified. LFQ intensity which is a proxy for protein abundance was calculated taking all 
C) 
p2 
p2-E1C 
DAPI GFP E1C merge 
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the four peptides together in all the cellular lysates as described in Methods 3.9.6.. A E1fl- 
or E1C–specific peptide was detected, in p2-E1C-transfected and MG132-treated HEK-
293T cells harvested 12, 24 and 48 h post transfection (Figure 4.14.) with intensities at 
least 50 times lower than in p1-His-GFP-E1C-transfected cells. No E1fl- or E1C-specific 
peptide was detected in p2-E1C transfected HEK-293T cells without MG132 and 
harvested 12 and 48 h post transfection while in cells harvested 24 h post transfection, a 
signal close to the sensitivity threshold was detectable (Figure 4.14.).  
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Figure 4.14. MS detection of overexpressed E1C protein after proteasome inhibition. Trypsin-digested lysates of 
HEK-293T cells transfected with p2-E1C or p1-His-GFP-E1C, harvested 12, 24 and 48 h post transfection with or 
without MG132 pretreatment were applied to MS analysis. Y axis shows the combined abundance (LFQ intensity) of 
four HPV16 E1- and E1C-specific peptides. 
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4.2.3. Detection of endogenous E1C protein in HPV16-positive cell lines 
 
4.2.3.1. Endogenous E1C RNA in HPV16-positive cell lines 
The absolute endogenous mRNA copies per cell were quantified for E1C by singleplex 
E1C RT-qPCR and for E6*I by the triplex RT-qPCR in HPV16 positive cell lines CaSki, 
SiHa, MRI-H186, MRI-H196, HPK-1A, W12-epi and W12-int (Table 4.11). RNA of the 
HPV16 negative cervical carcinoma cell line C33A served as negative control and as 
excepted no E6*I and E1C transcripts were identified. In the HPV16 positive cells E1C 
RNA was found in very low levels ranging from 0.0004 to 0.014 copies/cell, whereas E6*I 
RNA was found highly abundant ranging from 19 to 849 copies/cell.  
 
Table 4.11. E1C and E6*I transcript copies/cell in HPV16-positive cell lines. 
 Copies/cell 
Transcript CaSki SiHa MRI-H186 MRI-
H196 
HPK-1A W12-epi W12-int C33A 
E1C 0.014 0.001 0.001 0.003 0.0004 0.0005 0.0004 - 
E6*I 849 122 294 661 121 19 197 - 
 
 
4.2.3.2. Endogenous E1C protein in HPV16-positive cell lines 
In order to detect the endogenous E1C protein, cell lysates of cultured (without MG132 
treatment) HPV16 positive cell lines CaSki, MRI-H186, MRI-H196, HPK-1A were 
analysed in E1C western blot together with lysates from p2-E1C- (MG132-treated) and 
p1-His-GFP-E1C-transfected HEK-293T cells harvested post 48 hours transfection as 
positive controls (Figure 4.15.). Cellular lysate from C33A, which is a HPV16 negative 
cervical cancer cell line, was used as negative control. No endogenous HPV16 E1C 
protein was detected in the MG132 non-treated HPV16 positive cell lines (Figure 4.15.). 
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To detect the endogenous E1C protein by IF, CaSkiand SiHacells were cultured for three 
days and treated with DMSO and MG132 for 6 hours prior to fixation by 3.7% PFA on the 
fourth day. The fixed CaSki and SiHa cells were prepared for IF analysis afterwards. 
Endogenous E1C protein was not detectable in both DMSO and MG132 treated CaSki 
and SiHa cells (Figure 4.16.). 
 
Figure 4.15. WB detection of endogenous E1C protein in HPV16 positive cell lines. Cell lysates from CaSki, MRI-
H186, MRI-H196, HPK-1A and C33A were applied to the E1C western blot. Lysates of HEK-293T cell transfected with 
p2-E1C (with MG132 treatment) and p1-His-GFP-E1C and harvested 48 h post transfection served as positive controls. 
The red frame marks the region on the blot where the endogenous 9 kDa E1C protein would migrate. 
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Figure 4.16. IF detection of endogenous E1C protein in CaSki and SiHa cells. DMSO and MG132 treated CaSki 
(top panel) and SiHa (bottom panel) cells stained with α-E1C Ab. Nuclei were stained blue and E1C protein was not 
visible when visualized through red channel both in DMSO and MG132 treated cells. Pictures are merged images of 
DAPI and E1C immunostaining. 
 
 
4.3. Effect of E1C on HPV16 URR** activity 
Potential effects of E1C RNA and/or protein on the HPV16 upstream regulatory region 
(URR) in the absence or presence of HPV16 E2 (E2) were analysed by a dual luciferase 
reporter assay (DLRA) in HEK-293T cells co-transfected with p-HPV16-URR-FLuc 
reporter plasmid, p-TATAbox-RLuc control plasmid and different experimental plasmids 
such as p-EV, p-HPV16-E2, p-HPV16-E1C, p-HPV16-E1C-RNA mut and p-HPV16-E1C-
Pro mut. In the DLRA, the Renilla luciferase activity of co-transfected p-TATAbox-RLuc 
control plasmid is thought to provide a measure for transfection efficiency and the 
measured raw Firefly luciferase activity of the p-HPV16-URR-FLuc reporter should be 
normalized by the renilla activity. In the course of the DLRA experiments, it became 
obvious that presence of the p-TATAbox-RLuc control plasmid affected the p-HPV16-
URR-FLuc reporter activity, so a second set of experiments was performed without the 
control plasmid. 
** - HPV16 URR and HPV16 E2 are designated as URR and E2 hereafter in the ‘Results’ 
section. 
 
4.3.1. Selection of HEK-293T cells for DLRA 
To identify a cell line which supports basal transcription from p-HPV16-URR-FLuc 
reporter plasmid DLRA was initially performed in C33A, NIH-3T3 and HEK-293T cells. As 
C33A and NIH-3T3 cells are hard-to-transfect cells, they were transfected using calcium 
phosphate while PEI was used for HEK-293T. 
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C33A cells in numbers ranging from 75,000 – 200,000 were transfected p-HPV16-URR-
FLuc and firefly luciferase activity expressed as relative luminescence units (RLU) was 
measured 48 h post transfection . Mean RLU signals ranged from 671 for 75,000 cells to 
352 for 200,000 cells with a maximum of 777 for 125,000 cells (Figure 4.17. (A)) while 
non-transfected C33A cells showed 0 RLU for 75,000 and 9 for 200,000 cells. 
For NIH-3T3 and HEK-293T cells, a seeding cell density for 70% confluency on the day 
of transfection of 40,000 and 75,000 cells, respectively, had been determined previously. 
The Mean RLU signals were 1,150 for NIH-3T3 and 11,736 for HEK-293T cells (Figure 
4.17. (B)) while non-transfected cells showed a mean RLU of 16 and 5, respectively. 
Since HEK-293T cells showed the highest basal FLuc activity they were selected for 
further DLRAs. 
 
 
Figure 4.17. Firefly luciferase activities measured for C33A, NIH-3T3 and HEK-293T cells by DLRA. A) No: of 
C33A cells seeded is plotted on the x-axis and the firefly luciferase activity measured is plotted on the y-axis. B) Firefly 
luciferase activities measured for NIH-3T3 and HEK-293T cells are plotted. Mean together with standard deviation is 
shown for all the data points. 
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4.3.2. Time point determination for the measurement of firefly luciferase activity  
To further optimize DLRA, the best time point for the measurement of FLuc activity after 
transfection of 639 ng p-HPV16-URR-FLuc in HEK-293T cells was determined. FLuc 
activities were measured 12, 24 and 48 h post transfection. 
The mean RLU signals increased from 362 at 12 h, and 2302 at 24 h to 11,736 at 48 h 
(Figure 4.18.). Non-transfected cells at all 3 time points showed 23 or less RLU. Since, 
the 48 h time point showed the maximum FLuc activity it was chosen for further 
experiments. 
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Figure 4.18. Time point determination for firefly luciferase activity measurement in HEK-293T cells by DLRA.12 
h, 24 h and 48 h time points are plotted on the X-axis and the firefly luciferase activity measured is plotted on the Y-
axis. Mean together with standard deviation is shown for all the data points. 
 
4.3.3. Determination of a control plasmid for DLRA 
In order to determine a proper control plasmid, both p-SV40-RLuc and p-TATAbox-RLuc 
plasmids encoding renilla luciferase (RLuc) were tested in DLRA. Transfection of a control 
plasmid together with the reporter and other experimental plasmids is essential for the 
normalization of reporter activity, which could vary depending on transfection efficiency. 
The aim was to find out the least amount of control plasmid and thereby the best feasible 
reporter-control plasmid amount combination for co-transfection which avoids the 
occurrence of trans effects between promoter elements.  
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At first, 2.5, 5 and 10 ng of p-SV40-RLuc or p-TATAbox-RLuc plasmids were transfected 
in HEK-293T cells and RLuc activities were measured. In general, RLuc activities from p-
SV40-RLuc were higher than from p-TATAbox-RLuc. Also, mean RLU signals increased 
with increase in amount of plasmid 12,450 with 2.5 ng, 45,969 with 5 ng and 46,829 with 
10 ng p-SV40-RLuc (Figure 4.19. (A)) and from 212 with 2.5 ng, 385 with 5 ng and 430 
with 10 ng p-TATAbox-RLuc (Figure 4.19. (B)). Since 2.5 ng of both p-SV40-RLuc and p-
TATAbox-RLuc plasmids showed the lowest, but robustly measurable RLuc signals, this 
amount was chosen to test the combination of p-HPV16-URR-FLuc reporter and p-SV40-
RLuc or p-TATAbox-RLuc control plasmids for DLRA. 
 
 
Figure 4.19. Determination of a control plasmid for DLRA in HEK-293T cells. Amounts of p-SV40-RLuc (A) and p-
TATAbox-RLuc (B) plasmids in ng are plotted on the X-axis and the renilla luciferase activity measured is plotted on 
the Y-axis. Mean together with standard deviation is shown for all the data points. 
 
For testing the combination of the reporter and control plasmids, 75,000 HEK-293T cells 
were co-transfected with 500 ng of p-HPV16-URR-FLuc and 2.5 ng of p-SV40-RLuc or p-
TATAbox-RLuc, Each plasmid was also transfected separately for measuring the 
respective luciferase signals without any promoter trans effects. 
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Co-transfection of p-HPV16-URR-FLuc with p-SV40-RLuc (Figure 4.20. (A)) lowered the 
mean FLuc RLU signal to 875 relative to 1742 for p-HPV16-URR-FLuc alone. The mean 
RLuc RLU signal in co-transfection increased to 83,383 relative to 16,717 for p-SV40-
RLuc alone. Co-transfection with p-TATAbox-RLuc (Figure 4.20. (B)) reduced the mean 
FLuc RLU signal to 1024. The mean RLuc RLU signal for p-TATAbox-RLuc alone was 23 
and in co-transfection, increased to 308.  
 
 
Figure 4.20. Testing the combination of reporter and control plasmids for DLRA in HEK-293T cells. Combinations 
of p-HPV16-URR-FLuc and p-SV40-RLuc (A) and p-HPV16-URR-FLuc and p-TATAbox-RLuc (B) plasmids were tested 
in DLRA. X-axis indicates the transfected plasmid(s) and in brackets, the luciferase analysed. RLU values are plotted 
on the Y-axis. Bars indicate arithmetic mean and standard deviation. In A) the mean renilla RLU for co-transfection is 
an underestimation because it was calculated from two data points only, since the luminometer showed ‘OVRFLW’ 
during measurement of two other samples (which means the renilla signals were beyond the measurement threshold 
of the luminometer). 
 
Thus, FLuc activity was reduced 50% by co-transfection with p-SV40-RLuc and 41% with 
p-TATAbox-RLuc. Co-transfection with p-HPV16-URR-FLuc increased RLuc activity of p-
SV40-RLuc by 398% and that of p-TATAbox-RLuc by 1239%. Since the promoter trans 
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effect on FLuc was less in co-transfections with p-TATAbox-RLuc, this control plasmid 
was used in subsequent experiments. 
  
4.3.4. Effect of E2 on URR activity 
Alloul and Sherman63 for HPV16 have shown with a chloramphenicol acetyltransferase 
reporter assay that an expression construct for E2 represses and one for E1C activates 
URR activity. They have also shown that co-transfection of E1C reduces the repressive 
effect of E2, owing to the simultaneous activation by E1C. Before proceeding to determine 
in a more sensitive assay like DLRA whether E1C protein or E1C RNA activates URR, I 
decided to test first the repressive effect of E2 on URR. 
HEK-293T cells were transfected with p-HPV16-URR-FLuc, p-TATAbox-RLuc and p-
HPV16-E2 or empty p-EV plasmids. In the total of ten experiments the mean RLU signal 
of both FLuc and RLuc activity for non-transfected cells was 15 or less. In p-EV co-
transfected cells the mean FLuc RLU signal ranged from 2423 to 6238 and with co-
transfected p-HPV16-E2 the signal was always reduced, ranging from 1389 to 5179 
(Figure 4.21. (A)). In summary, in these 10 experiments E2 reduced FLuc activity 
significantly (p = 0.0001) by about 35% (Figure 4.21. (B)), indicating that E2 in 
concordance with the data obtained by Alloul and Sherman63 also in this experimental 
design, represses HPV16 URR. 
However, in all experiments with p-HPV16-E2 transfected HEK-293T cells, RLuc activities 
of the control plasmid were also repressed compared to p-EV (Figure 4.22.). Mean RLuc 
RLU signals ranged between 160 and 2167 for the p-EV co-transfected cells and 55 - 907 
for the p-HPV16-E2 co-transfected cells (Figure 4.22.). Therefore, only raw FLuc data 
without normalization by RLuc data were considered in the analysis of effects of E2 on 
URR activity. As a further consequence, in further DLRA esperiments, co-transfections 
were performed with and without p-TATAbox-RLuc and firefly luciferase activities in both 
cases were analyzed separately. p-HPV16-URR-FLuc and p-TATAbox-RLuc were also 
transfected separately and in combination to analyze the background signals and 
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corresponding data of all the DLRA performed is given in the supplementary information 
9.6..  
  
 
 
Figure 4.21. Measurement of firefly luciferase activity in p-HPV16-E2 co-transfected HEK-293T cells. A) HEK-
293T cells were co-transfected with p-HPV16-URR-FLuc and p-TATAbox-RLuc and p-EV or p-HPV16-E2. Mean and 
SD of raw FLuc RLU signals of 10 independent experiments are shown. B) Mean and SD of the FLuc RLU values of 
p-EV and p-HPV16-E2, respectively, from the 10 individual experiments shown in (A).  The two-tailed p value of 0.0001 
was calculated by paired t test 
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Figure 4.22. Measurement of renilla luciferase activity in p-HPV16-E2 co-transfected HEK-293T cells. HEK-293T 
cells were co-transfected with p-HPV16-URR-FLuc and p-TATAbox-RLuc, and p-EV or p-HPV16-E2. Mean and SD of 
raw RLuc RLU signals of 9 independent experiments are shown. Experiment 4 was excluded from the analysis because 
of outlier renilla signals obtained in the duplicates with both p-EV and p-HPV16-E2 (For data see supplementary 
information 9.6..) 
 
 
4.3.5. Effect of E1C and E1C mutants on URR activity 
In order to study by DLRA the effect of E1C on URR, HEK-293T cells were transfected in 
4 independent experiments with p-HPV16 URR-FLuc, p-TATAbox-RLuc and p-HPV16-
E1C or p-EV plasmids. Mean FLuc RLU signals in non-transfected cells were 1.5 - 15 
and 0 – 8 for RLuc. With p-EV mean FLuc RLU signals were 2423 - 6238 and 4332 – 
7444 with p-HPV16-E1C (Figure 4.23 (A)). Mean RLuc RLU signals were 160 – 2167 with 
p-EV and 150 - 1177 with p-HPV16-E1C (for RLuc data see supplementary information 
9.6.).  
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The results demonstrated significant (p = 0.0005) activation of about 42% of the HPV16 
URR by E1C (Figure 4.23. (B)) indicating that E1C, also in this experimental design,  
activates the HPV16 URR. 
 
 
Figure 4.23. Measurement of firefly luciferase activity in p-HPV16-E1C co-transfected HEK-293T cells. A) HEK-
293T cells were co-transfected with the reporter and control luciferase plasmids and with p-EV or p-HPV16-E1C. Mean 
and SD of raw FLuc RLU signals of 4 independent experiments are shown. B) Mean and SD of the raw FLuc RLU 
values of p-EV and p-HPV16-E1C, respectively, from the 4 individual experiments shown in (A). The two-tailed p value 
of 0.0001 was calculated by paired t test. 
 
In parallel, additional four p-HPV16-E1C co-transfection experiments were carried out in 
duplicates without the addition of p-TATAbox-RLuc. Mean FLuc RLU signals were 3306 
– 5084 with p-EV and 4667 – 6731 with p-HPV16-E1C (Figure 4.24 (A)). Here again E1C 
caused a significant (p = 0.0003) activation of about 29%. 
FLuc activities measured in the presence of both p-EV and p-HPV16-E1C and with and 
without p-TATAbox-RLuc co-transfection are summarized in Table 4.12.. The ratio of 
FLuc activity without p-TATAbox-RLuc to the activity with p-TATAbox-RLuc calculated for 
each experiment varied only 0.97 and 1.37 for p-EV and 0.87 to 1.1 for p-HPV16-E1C so 
that the data were combined for statistical significance analysis. A two-tailed p value of 
<0.0001 was obtained by paired t test and a mean activation of 35% of FLuc activity was 
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observed from the total eight experiments (Figure 4.24. (C)).Taken together these results 
indicate that E1C activates the HPV16 URR and are in concordance with the data 
obtained by Alloul and Sherman63. 
 
Table 4.12. Summary of firefly luciferase activity measured for p-HPV16-E1C co-transfected HEK-293T cells 
with and without p-TATAbox-RLuc co-transfection. FLA – Firefly luciferase activity 
 
 
In order to analyze whether it is the E1C RNA or E1C protein that activates URR, two 
mutant E1C expression plasmids were constructed. p-HPV16-E1C-RNA mut transcribes 
a random sequence with the same size and GC content as that of E1C RNA and in p-
HPV16-E1C-Pro mut the first three E1C codons are replaced by TGA, TAG and TAA stop 
codons to abolish translation of E1C protein. 
HEK-293T cells were co-transfected with p-HPV16 URR-FLuc, with or without p-
TATAbox-RLuc and with p-HPV16-E1C or p-HPV16-E1C-RNA mut or p-HPV16-E1C-Pro 
mut or p-EV plasmids. Two experiments each were performed with and without p-
TATAbox-RLuc. Since the FLuc activity variation with and without p-TATAbox-RLuc 
transfection was negligible, the data from all four experiments were combined and 
analyzed together.  
Experiment 
No: 
FLA with p-TATAbox-
RLuc transfection 
(RLU) 
FLA with p-TATAbox-
RLuc transfection 
(RLU) 
Ratio of FLA without to with p-
TATAbox-RLuc transfection 
 p-EV p-HPV16-E1C p-EV p-HPV16-E1C p-EV p-HPV16-E1C 
1 3246 4505 4004 4971 1.23 1.1 
 2996 4472 4116 4865 1.37 1.08 
2 5531 7599 5610 6632 1.01 0.87 
 4661 7288 4558 6829 0.97 0.93 
3 2725 4455 3308 4787 1.21 1.07 
 3251 4208 3304 4546 1.01 1.08 
4 4037 4325 3948 4632 0.97 1.07 
 3511 5640 4370 5445 1.24 0.96 
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Figure 4.24. Measurement of firefly luciferase activity in p-HPV16-E1C co-transfected HEK-293T cells without 
p-TATAbox-RLuc transfection. A) HEK-293T cells were co-transfected with p-HPV16-URR- and p-EV or p-HPV16-
E1C. Mean and SD of raw FLuc RLU signals of 4 independent experiments are shown. B) Mean and SD of the raw 
FLuc RLU values of p-EV and p-HPV16-E1C, respectively, from the 4 individual experiments shown in (A). The two-
tailed p value of 0.0003 was calculated by paired t test. C) All FLuc values of p-EV and p-HPV16-E1C co-transfected 
cells from (A) and Figure 4.23. (A) are combined in a bar graph to evaluate the statistical significance. The two-tailed p 
value of 0.0001 was calculated by paired t test. 
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In non-transfected cells the mean raw FLuc RLU signal was 12.5, and 4.5 for RLuc. In p-
EV-transfected cells mean FLuc RLU signals were 2988 - 4159, 4332 – 5039 with p-
HPV16-E1C, 3917 - 4676 with p-HPV16-E1C-RNA mut and 4693 - 6207 with p-HPV16-
E1C-Pro mut (Figure 4.25 (A)). (For mean RLuc RLU signals see supplementary 
information 9.6.)  
With p-HPV16-E1C, a significant (p = 0.0007, two-tailed, paired t test) mean FLuc 
activation of 35% was observed, a significant (p = 0.003) mean activation of 19% with p-
HPV16-E1C-RNA mut and a significant (p = 0.0001) mean activation of 33% with p-
HPV16-E1C-Pro mut (Figure 4.25. (B)). Thus, E1C but also both p-HPV16-E1C-RNA mut 
and p-HPV16-E1C-Pro mut appeared to activate the HPV16 URR. 
 
4.3.6. Effect of co-transfection of E1C and E2 on URR activity 
In order to study the effect of E1C in combination with E2 on URR by DLRA, HEK-293T 
cells were co-transfected with p-HPV16 URR-FLuc, p-TATAbox-RLuc (in 4 of the 8 
experiments), p-HPV16-E2, and p-EV or p-HPV16-E1C plasmids. The data from all eight 
experiments were combined and analyzed together.  
In non-transfected cells, mean RLU signals for FLuc were 1.5 - 15 and 0 – 8 for RLuc. 
With p-EV alone, mean FLuc RLU signals were 2988 – 5096, 2265 – 3770 with p-HPV16-
E2 alone, 4332 – 7444 with p-HPV16-E1C alone, 1077 – 3242 with p-HPV16-E2 and p-
EV, and 1351 – 4082 with p-HPV16-E2 and p-HPV16-E1C (Figure 4.26. (A)). (For RLuc 
RLU signals see supplementary information 9.6.)  
A significant (p < 0.0001, two-tailed, paired t test) mean reduction of FLuc activity of 24% 
was observed with p-HPV16-E2 alone, a significant (p < 0.0001) mean activation of 35% 
with p-HPV16-E1C alone, and a significant (p = 0.0124) mean activation of 19% with p-
HPV16-E2 and p-HPV16-E1C combined (Figure 4.26. (B)). Thus, E1C co-transfected 
with E2 reduced the repressive effect of E2, which is in accordance with the data obtained 
by Alloul and Sherman63. 
 
95 
 
 
 
Figure 4.25. Measurement of firefly luciferase activity in p-HPV16-E1C-RNA mut and p-HPV16-E1C-Pro mut co-
transfected HEK-293T cells. A) HEK-293T cells were co-transfected with one of the expression plasmid p-EV, p-
HPV16-E1C, p-HPV16-E1C-RNA mut or p-HPV16-E1C-Pro mut and the reporter plasmid p-HPV16-URR-FLuc with or 
without the control plasmid p-TATAbox-RLuc. Mean and SD of raw FLuc RLU signals of 4 experiments are shown. B) 
Mean and SD of the raw FLuc RLU values obtained with p-EV, p-HPV16-E1C, p-HPV16-E1C-RNA mut or p-HPV16-
E1C-Pro mut, respectively, from the 4 individual experiments shown in (A). The two-tailed p values were calculated by 
paired t test.  
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Figure 4.26. Measurement of firefly luciferase activity in p-HPV16-E1C and p-HPV16-E2 co-transfected HEK-
293T cells. A) HEK-293T cells were co-transfected with reporter plasmid p-HPV16-URR-FLuc and with or without the 
control plasmid p-TATAbox-RLuc as well as with the expression plasmids p-EV (EV), p-HPV16-E2 (E2) and p-HPV16-
E1C (E1C) alone or in combinations. Mean and SD of raw FLuc RLU signals of 8 experiments (4 with and 4 without p-
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TATAbox-RLuc) are shown. (B) Mean and SD of the raw FLuc RLU values obtained with EV, E2, E1C, EV+E2 and 
E2+E1C, respectively, from the 4 individual experiments shown in (A). The two-tailed p values were calculated by 
paired t test.  
 
In order to analyze whether it is the E1C RNA or E1C protein that is capable of reducing 
the repressive effect of E2 on URR, HEK-293T cells were transfected with p-HPV16 URR-
FLuc, p-TATAbox-RLuc (in 2 of the 4 experiments), p-HPV16-E2, either p-HPV16-E1C, 
p-HPV16-E1C-RNA mut or p-HPV16-E1C-Pro mut plasmids. The data from all four 
experiments were combined for statistical analysis.  
In non-transfected cells, mean RLU signal was 12.5 for FLuc and 4.5 for RLuc. With p-
EV alone, the FLuc RLU signals were 2988 – 4159, 2333 – 3672 with p-HPV16-E2 alone, 
4332 – 5039 with p-HPV16-E1C alone, 1077 – 1590 with p-HPV16-E2 and p-EV 
combined, 1390 – 1975 with p-HPV16-E2 and p-HPV16-E1C combined, 1526 – 2067 
with p-HPV16-E2 and p-HPV16-E1C-RNA mut combined, and 1772 – 2499 with p-
HPV16-E2 and p-HPV16-E1C-Pro mut combined (Figure 4.27. (A)). (For RLuc RLU 
signals see supplementary information 9.6.)  
In comparison to p-EV, a significant (p = 0.0042, two-tailed, paired t test) mean FLuc 
reduction of 17% was observed with p-HPV16-E2 and a significant (p = 0.0007) activation 
of 35% with p-HPV16-E1C. In the presence of p-HPV16-E2 and compared to p-EV, p-
HPV16-E1C significantly (p = 0.0007) activated FLuc by 24%, p-HPV16-E1C-RNA mut 
significantly (p = 0.0052) activated by 32% and p-HPV16-E1C-Pro mut significantly (p = 
0.0028) activated by 69% (Figure 4.27. (B)). 
Thus, not only p-HPV16-E1C but also both E1C mutants, p-HPV16-E1C-RNA mut and p-
HPV16-E1C-Pro mut, reduced the repressive effect of co-transfected E2 on the HPV16-
URR. 
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Figure 4.27. Measurement of firefly luciferase activity in p-HPV16-E2, p-HPV16-E1C-RNA mut and p-HPV16-E1C-
Pro mut co-transfected HEK-293T cells. A) HEK-293T cells were co-transfected with the reporter plasmid p-HPV16-
URR-FLuc and with or without the control plasmid p-TATAbox-RLuc (2 experiments each) in combination with either 
p-EV (EV), p-HPV16-E1C (E1C) or p-HPV16-E2 (E2) alone or p-HPV16-E2 together with either p-EV, p-HPV16-E1C, 
p-HPV16-E1C-RNA mut (E1C rm or p-HPV16-E1C-Pro mut ((E1C pm). Mean and SD of raw FLuc RLU signals of 4 
experiments with duplicate samples are shown. B) Mean and SD of the raw FLuc RLU values obtained from the co-
transfections indicated below the x-axis in the 4 individual experiments shown in (A). The two-tailed p values were 
calculated by paired t test. 
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5. Discussion 
 
 
5.1. Rationale 
The aim of this thesis was the characterization of the diagnostically relevant HPV16 E1C 
transcript (splice 880^2582). Schmitt and colleagues152 had analyzed the HPV16 
transcriptome including 10 spliced and 5 fl transcripts to identify novel RNA patterns for 
the grading of LSIL and HSIL, by NASBA-Luminex assay152,153,158-160 (see Introduction 
section 1.4.1.1.). One of the important findings of this study was the identification of the 
frequent upregulation of E1C transcripts in HSIL and CxCa patients when compared with 
NIL/M. E1C transcript’s prevalence gradually increased from NIL/M to CxCa. The study 
used the transcript ratio of E1C to L1 (splice 3632^5639) for the differentiation of <=LSIL 
and >= HSIL and found it to be diagnostically useful as the results were in concordance 
with the clinical grading of these lesions153. 
Another study which showed the diagnostic relevance of E1C transcript was from Höfler 
and colleagues85. They developed new HPV16 RNA patterns using RT-qPCR technology 
for the detection of the 3 spliced transcripts E6*I, E1^E4 and E1C for the discrimination 
of mild and severe lesions and thereby improving the positive predictive value of HPV 
DNA testing in screening settings. When the prevalence of E1C transcript was analyzed, 
it was found to be 3% or lower in NIL/M, CIN0 and CIN1, 17% in CIN2, 54% in CIN3 and 
22% in CxCa. The study described E1C as a specific, but insensitive marker for the 
differentiation of ≤CIN1 and ≥CIN385.  
Alloul and Sherman63 studied a transcription regulating activity on the HPV16 LCR/URR 
of a’-type HPV16 mRNA (E1C) which contains the 880/2581 splice. They found that E1C 
cDNA can activate the LCR in a dose-dependent fashion and together with E2 cDNA can 
reduce the repressive effect of E2 on LCR activity. This is the only study so far that had 
shed some light to the functional side of E1C. 
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Based on these studies, my thesis aimed (i) to further understand the role of E1C in 
regulating transformation specific HPV16 transcripts E6*I, E1^E4 and E7, (ii) to analyse 
whether E1C effects are mediated by E1C RNA or E1C protein and (iii) to corroborate the 
findings of LCR activation by E1C cDNA from Alloul and Sherman using a more sensitive 
and better quantifiable assay like DLRA. 
 
5.2. Effect of E1C overexpression on HPV16 transcripts 
Experiments on silencing of E1C transcripts in HPV16 positive cell lines was purposefully 
avoided as the endogenous E1C mRNA levels  present in the cell lines were found to be 
very low and were in the range of 0.0004 – 0.014 copies/cell. So the rationale was not to 
further knock down the already lowly abundant E1C transcript which might fail to detect 
the subsequent changes, e.g. in HPV16 transcript levels. Therefore, E1C overexpression 
experiments were performed by lentiviral transduction. Lentiviral transduction was chosen 
over transient transfection because there would not be an over-dosage of E1C transcripts 
in stably transduced cells; in line with this expectation the E1C transcript levels found in 
the lentivirally transduced cells was approximately 10 copies/cell. In contrast, in the case 
of transient transfection, say, by PEI in HEK-293T cells, the overexpressed E1C RNA 
level reached approximately 1.85x104 copies/cell which is roughly 2000 times more than 
lentiviral transduction. In addition, in clinical specimens, the number of E1C copies per 
HPV-infected cell is estimated in the range from 1 – 20147. Therefore, E1C overexpression 
by lentiviral transduction was the overexpression system closest to the physiological 
status. 
W12-epi and W12-int cell lines were two out of the four cell lines chosen for E1C 
overexpression. The parental W12 cell line was established from a LSIL patient162. W12-
epi and W12-int are two of the many clones generated from the parental W12 cell line in 
the Dr. Paul F. Lambert lab163. The HPV16 genome is integrated in almost 85% of HPV16 
positive CxCas161. As the HPV16 genome is present as episomes in W12-epi, this cell 
line represents an early stage of transformation and is a good material to analyze the viral 
and cellular events that could trigger the transformation pathway further. Since the HPV16 
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genome is integrated in W12-int cells, this cell line is thought to be closer to the fully 
transformed CxCa stage. The other two cervical carcinoma-derived cell lines, CaSki and 
SiHa also have integrated HPV16 genomes. CaSki has around 400-600 complete and 
SiHa has one incomplete HPV16 genome(s) present per cell and thus are at the two 
extremes with respect to HPV16 genome copy numbers164,165. Therefore, the four cell 
lines chosen were assumed to be a good representation of HPV16 transformation stages 
and suited to test E1C overexpression effects on HPV16 transcripts. 
The HPV16 transcripts E6*I, E1^E4 and E7 were analyzed upon E1C overexpression in 
W12-epi, W12-int, CaSki and SiHa because of their functional roles in cell cycle 
progression and transformation. The prevalence of HPV16 E6*I was found to be 8% in 
NIL/M and rising to more than 95% in CIN3 and CxCa85. Zhi-Ming Zheng’s lab has studied 
HPV16 E6 splicing in depth. They have shown that E6*I transcripts which are spliced from 
226 nt at the 5’ to 409 nt at the 3’ are abundant in CaSki and SiHa cells166. They have 
also shown that the majority of the E7 proteins are translated from E6*I mRNAs166 in 
these cells. The E6*I splice is present only in high-risk HPVs and not in low-risk ones167-
169. This could mean that E6*I might have a role in viral oncogenesis, another alternative 
suggestion being a role in viral life cycle completion170. Another group that has studied 
about both HPV16 E6*I transcript and protein is Penelope Duerksen-Hughes and 
colleagues. They have shown that HPV16 E6*I overexpression in SiHa cells increased 
the expression of p53 and sensitized the cells to apoptosis175. They have also observed 
a reduction in tumor formation in mice when HPV16 E6*I overexpressing SiHa cells were 
injected compared to the control mice. This is the first study which demonstrated a 
biological activity for E6*I175.  
The prevalence of HPV16 E1^E4 was found to be 6% in NIL/M, increasing to >90% in 
CIN1and CIN2 and slightly decreasing to 83% in CIN3 to a substantial decline of 33% in 
CxCa85. HPV16 E1^E4 protein was found to be abundantly present in the upper 
epithelium in productive infections171. It has also been found to associate with cytokeratin 
networks in keratinocytes leading to its collapse172,173. HPV16 E1^E4 can also bind to a 
DEAD box RNA helicase, also known as E4-DBP and change its ATPase activity. Davy 
and colleagues have shown that HPV16 E1^E4 can affect cell cycle progression by 
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causing the cells to arrest in the G2 phase of the cell cycle171. HPV16 E7 protein is one of 
the two viral oncoproteins. It binds and degrades the cellular tumor suppressor protein 
pRb, induces genome instability and has immortalization and transformation functions. 
E1C overexpression in stably lentivirally transduced W12-epi, W12-int, CaSki and SiHa 
cell lines has not changed E6*I and E7 expression. This means the transformation 
pathways that are affected by altered E6*I and E7 expression levels are not further 
affected by overexpressed E1C levels. Although E1C is described as a specific marker 
for ≥CIN3 cases85, the occurence of the transcript in severe lesions seems to have no 
transformation promoting roles and works independent of E6*I and E7 transcript levels. 
Alternatively, as E6*I protein possesses an anti-oncogenic function, an increase in E6*I 
expression could inhibit cell proliferation and vice versa. Therefore, it is tempting to 
speculate that E1C expression maintains the cell cycle progression in CxCa cell lines by 
maintaining the homeostatic levels of E6*I and E7. However, this hypothesis demands 
further investigation.  
The E1^E4 expression was reduced 20 - 30% in E1C overexpressing W12-epi, W12-int 
and CaSki cells. Dave and colleagues171 have previously demonstrated the ability of 
HPV16 E1^E4 protein to inhibit cell proliferation. Also, it may be possible that this ability 
of E1^E4 is required to inhibit cell division during the virus life cycle. Therefore, a lower 
E1^E4 RNA expression induced by E1C could be to prevent the cells from G2 arrest171 
and maintain cell cycle progression in these cells. However, it is not clear how E1^E4 
transcription and splicing is targeted. It might be an HPV genome integration-independent 
mechanism as E1^E4 RNA expression was reduced in both W12-epi and W12-int cells 
upon E1C overexpression. It will be also interesting to look at the E1^E4 protein 
expression upon E1C overexpression. The C-terminal region of the E1C protein contains 
the E1 helicase domain which has ATPase activity. HPV16 E1^E4 protein is known to 
change the ATPase activity of a RNA helicase protein171. So far the data point towards 
an indirect role of E1C in transformation by not changing the RNA expression levels of 
the major transformation transcripts such as E6*I and E7 and by reducing E1^E4 levels, 
thereby aiding the cells to remain in proliferative stage. As next steps, it would be 
interesting to look at the entire HPV16 as well as cellular transcriptomes to analyze the 
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changes in the RNA expression profiles of both virus and host upon E1C overexpression. 
This would shed more light on the other key players that orchestrate either upstream or 
downstream of E1C to execute its functions. 
When the E1C overexpressed W12-epi, W12-int, CaSki and SiHa cells were analysed to 
identify cellular proteome changes, no significant changes were observed except in the 
case of CaSki cells, where PDIA3 protein was found to be two fold upregulated in E1C 
overexpressed CaSki cells. Since it is just one protein out of the 4899 proteins analysed 
in MS, this result demands reproduction and further verification by WB. It will also be 
interesting to examine PDIA3 RNA levels in E1C overexpressed CaSki cells. PDIA3 
belongs to protein disulfide isomerase (PDI) family of proteins. PDI proteins are important 
for the proteostasis in endoplasmic reticulum229. However, several studies have 
demonstrated the altered expression of PDI proteins in various cancers, for e.g., PDIA3 
has been reported to be upregulated in primary ductal breast cancer230. Another PDI 
protein, AGR2 which is highly expressed in ovarian and prostate cancers, can stimulate 
the proliferation and metastasis of cancer cells231. Accordingly, PDI inhibitors have shown 
to enhance apoptosis in cancer cells232. Zhang and colleagues have shown that 
interrupting the interation between endoplasmic reticulum oxidoreductin-1α and PDI 
proteins can suppress cervical cancer progression233. Since PDIA3 was also observed to 
be upregulated in E1C overexpressed CaSki cells, it will be intriguing to look at the 
upstream and downstream components of PDIA3 pathway that are involved in 
tumorigenesis. 
 
5.3. Detection of E1C protein 
Usually viruses with small genomes as that of HPV (8 kb) use multiple strategies to 
increase the coding capacity of the genome to meet their various needs in the completion 
of life cycle. Alternative splicing of mRNA is one of the mechanisms used by HPV to 
synthesize multiple proteins. Some of the proteins from alternatively spliced HPV mRNAs 
that have been closely studied are E1^E4, E8^E2C and E6*I. As described in Chapter 
4.2., E1^E4 protein plays a role in the productive life cycle of HPV. Also, HPV11 and 
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HPV16 E1^E4 can induce G2 arrest171. The spliced E8^E2C fusion protein from HPV31 
has a negative regulatory effect on viral transcription and replication176,177. As there is 
increasing and compelling evidence of biologically active proteins from alternatively 
spliced products of HPV, I decided to look for the translated product of the spliced E1C 
transcript, i.e. E1C protein. E1C protein is of 9 kDa size and consists of 82 aa, of which 
the first 5 aa are from the N-terminus and the remaining 77 aa are from the C-terminus of 
E1. 
A mAb was generated by hybridoma technology for the detection of E1C protein in various 
immunological assays such as ELISA, WB and IF. The mAb generated is directed against 
the splice junction-derived peptide sequence of E1C to ensure the unique E1C specificity 
of the antibody. The newly generated E1C mAb could not detect overexpressed HPV16 
GST-E1fl fusion protein in E. coli, but detected the overexpressed GST-E1C fusion 
protein in E. coli in ELISA and WB, and detected overexpressed GFP-E1C fusion protein 
in HEK-293T cells in WB and IF. Thus, a functional E1C-specific mAb was successfully 
generated.  
However, for the detection of overexpressed untagged E1C protein in WB, the standard 
WB protocol had to be modified due to the very small size of E1C. The first WBs were run 
with mini SDS gels of 20 µL well volume capacity and loaded with a maximum of 20 µg 
lysates. The transfer of proteins from gels to nitrocellulose membrane was performed at 
a current of 200 mA for 1h using a SDS containing transfer buffer. When 20 µg of p2-
E1C- and p1-His-GFP-E1C-transfected HEK-293T cellular lysates were run in a WB 
under these conditions, only a 36 kDa band corresponding to GFP-E1C fusion protein 
was visible and not the 9 kDa E1C protein. Therefore, the next step was to ensure the 
detection of a comparably small protein in WB. To this end, a truncated version of ABCB5, 
the ATP Binding Cassette Subfamily B Member 5 protein was used. The N-terminally His-
tagged truncated ABCB5 is of 10 kDa size and thus suited as a size detection threshold 
for the WB protocol and as proxy for  the detectability of the 9 kDa E1C protein. The 
truncated ABCB5 was overexpressed in E. coli and purified by affinity chromatography. 
In addition, the WB protocol was modified to use bigger gels with 50 µL well volume 
capacity and the protein transfer conditions were changed to 250 mA for 30 minutes using 
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a transfer buffer without SDS. The absence of SDS and the shorter transfer time ensured 
that small proteins do not migrate too fast and get lost through the membrane. The 
modified WB protocol conditions were also tested for the sensitivity of both purified 
ABCB5 protein and p1-His-GFP-E1C-transfected HEK-293T cellular lysate. The purpose 
of this sensitivity test was to analyze the detection limit of the modified WB protocol in 
terms of protein amounts. Results showed that 33 ng of purified ABCB5 and 5 µg of p1-
His-GFP-E1C-transfected HEK-293T cellular lysate were detectable with the modified 
WB protocol. This means that it could be possible to detect E1C in lysate of p2-E1C- 
transfected HEK-293T cells with the newly modified WB protocol.  
For the detection of overexpressed E1C protein in p2-E1C-transfected HEK-293T cells, 
the modified WB protocol was used together with 50 ng of ABCB5 and 100 µg of p1-His-
GFP-E1C-transfected HEK-293T cellular lysate. 100 µg protein amount was also loaded 
for p2-E1C-transfected HEK-293T cellular lysate. However, only 10 kDa ABCB5 and 36 
kDa GFP-E1C bands were visible and not the 9 kDa E1C band. There could be several 
reasons for not detecting E1C protein out of which I tested the following three: 1) 
insufficient E1C transcription from the E1C cDNA sequence present in p2-E1C plasmid 
2) insufficient E1-Alpha promoter activity to transcribe the E1C cDNA sequence in p2-
E1C plasmid 3) instability of E1C protein by treatment with MG132 proteasome inhibitor. 
E1C transcription from E1C cDNA sequence in p2-E1C plasmid followed by transfection 
in HEK-293T cells was tested by E1C RT-qPCR. The E1C copies per cell were quantified 
to be 18,500. This means that the transfection was successful and there was no blockade 
present to transcribe the E1C cDNA. HEK-293T cells are easy-to-transfect cells as also 
demonstrated here by the high number of E1C RNA copies per cell measured. This also 
indicated that the overexpressed E1C mRNA was stable and abundantly present at least 
until 48 h post transfection.  
Next, I tested for E1-Alpha promoter activity for its capability in transcribing E1C cDNA. 
The p2 plasmid has the same vector sequence as that of p2-E1C except that the E1C 
cDNA sequence is replaced with Gaussia luciferase cDNA sequence in p2. This means 
E1C cDNA sequence in p2-E1C plasmid and Gaussia luciferase cDNA sequence in p2 
are driven by the E1-Alpha promoter. Gaussia luciferase activity was measured in p2-
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transfected HEK-293T cells and was comparable to the positive control (data not shown). 
This means that E1-Alpha promoter is capable of driving the E1C RNA expression in p2-
E1C-transfected HEK-293T cells. 
The third parameter that has been tested as potential reason for not detecting E1C protein 
in p2-E1C-transfected HEK-293T cells was to check for instability of the putative E1C 
protein. This means that although E1C protein is translated from the highly overexpressed 
E1C RNA, the protein is not stable and gets degraded immediately upon translation. The 
involvement of the ubiquitin-proteasome pathway in the regulation of various cellular 
processes such as oncogenesis, cell cycle progression, apoptosis, protein quality control 
etc. has been well studied178. This pathway in mammalian cells is responsible for the 
degradation of both short- and long-lived proteins179,180.  The main targets of this pathway 
are proteins that are incorrectly folded or damaged181. A protein is targeted for 
degradation by poly-ubiquitinylation which serves as a tracking signal for the proteasome. 
Hence, I decided to test whether in p2-E1C-transfected HEK-293T cells, that could 
translate E1C from the abundant E1C RNA, the E1C protein might be degraded by the 
proteasome pathway. 
There are various proteasome inhibitors available which target multiple active sites of the 
proteasome like chymotrypsin-like, trypsin-like or caspase-like sites178. MG132 is a 
reversible inhibitor and belongs to the peptide aldehyde class. It can enter cells rapidly 
and the inhibitor effect can be rapidly reversed by removing MG132 from the cells182. In 
addition, MG132 is more potent and selective for proteasome rather than other cellular 
proteases compared to other peptide aldehyde inhibitors183. MG132 is also available at 
low cost and owing to all these characteristics, it is the favorite candidate to study the 
involvement of proteasome in a biological process in cell culture systems 178. Hence, I 
decided to treat p2-E1C-transfected HEK-293T cells with MG132 proteasome inhibitor to 
analyze whether the E1C protein translated is being degraded via ubiquitin-proteasome 
pathway. 12 h, 24 h and 48 h post transfection time points were chosen for harvesting 
MG132-treated cells to ensure the capture of the E1C protein soon after translation. A 9 
kDa E1C protein was detected in MG132-treated p2-E1C-transfected HEK-293T cells 
which were harvested 48 h post transfection but not 12 h and 24 h post transfection in 
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WB. However, with an apparently more sensitive method like MS, E1C protein was 
detectable in all these three cases with increasing intensity from 12 h to 48 h, which 
indicates E1C protein accumulation over time. This means E1C RNA translation started 
less than 12 h post transfection and the protein accumulated over the next 36 h. This 
means that at 48 h post transfection, there were more cells present due to cell division, 
therefore the p2- E1C plasmids were replicated accordingly and thereby more E1C RNA 
transcribed and more E1C protein translated which was prevented from degradation by 
MG132. E1C protein was found to be localized in cytoplasm after MG132 treatment in p2-
E1C-transfected HEK-293T cells in IF. However, only 20% of the p2-E1C-transfected 
cells were stained positive for E1C. This could be due to the heterogeneity in proteasome 
inhibition in different cells, which means E1C protein was visible in the cells where there 
was higher proteasome inhibition and the IF protocol might not be sensitive enough to 
detect low E1C protein amounts. However, it would be interesting to quantify the E1C 
positive staining signal intensity to understand the IF detection thresholds. 
 In summary, the proteasome inhibitor experiments show that E1C protein is unstable 
which could impair detectability of endogenous E1C protein in CxCa cell lines or ≥CIN3 
clinical cases. This could also mean that E1C executes its functions rather via RNA and 
not via protein. Accordingly, no endogenous E1C protein was detected in HPV16 positive 
cell lines CaSki, MRI-H186, MRI-H196 and HPK-1A. However, in these analyses they 
were not treated with MG132. But, the endogenous E1C RNA present in these cell lines 
are in the range of 0.0004 – 0.014, which makes the detection of E1C protein after MG132 
treatment less likely in light with the results obtained so far. 
There are several factors that determine the stability of a protein like pH, temperature, 
salt concentration, protein-protein interactions etc. A folded protein has higher stability 
than the one in its native state. Folding of a protein after its synthesis is necessary to 
acquire its functions195, for e.g. post-translational modifications on the aa sequence of the 
primary structure of a protein can alter the structure and function and also stability of the 
protein. Also, secondary structures of the protein can be unstable if there is a proline aa 
on the α-helix, because proline misses an amide H atom and therefore cannot form stable 
hydrogen bonds205. Some of the factors which affect the stability of tertiary structure of a 
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protein which means the fold of the protein are pH, temperature, van der Waals forces, 
hydrogen bonding, primary and secondary structure etc.194. With respect to quaternary 
structure, which is a complex of individual folded protein sub-units, the stability is 
determined by the conformational changes. It is known that the different stability states of 
a protein is associated with its function. The best example studied is hemoglobin, 
switching between tense and relaxed states during the oxygenation process. Deoxy-
hemoglobin is in relaxed state and oxyhemoglobin is in tense state206-208. 
Degradation of proteins is part of cellular metabolism. It has been observed that proteases 
have an increased preference for denatured proteins in vitro210-213. Accordingly, Parsell 
and Sauer209 have shown that thermal stability and sequence composition are key 
determinants to understand the susceptibility of a protein to proteolysis. Post-translational 
modifications, cellular environment and protein-protein interactions are some of the 
factors that also affect the stability of HPV proteins. Thomas et al. have shown that cellular 
E6AP is destabilised in the presence of HPV-10 and HPV-11 E6 proteins214. Chang et al. 
have shown that when HPV16 E2 is phosphorylated at serine 243, the half-life is reduced 
compared to wild type E2. However, this modification of E2 is necessary for its binding to 
cellular Brd4 protein, which facilitates the tethering of viral genome to mitotic 
chromosomes215. Selvey and colleagues have demonstrated that HPV18 E7 is a short-
lived protein with a half-life of 13.5 min in HeLa cells216. The phosphorylated form (at 
serine 33) of E7 showed longer half-life than de-phosphorylated form, when 
overexpressed in Sf21 cells216. They have also shown that the steady state levels of E7 
increased in the presence of hydrocortisone and not with progesterone, oestrogen or 
testosterone216, which means cellular hormonal environment also plays a role in the 
steady state levels of proteins. Another HPV protein which has a short half-life is HPV18 
E6*I. When untagged E6*I proteins were expressed in human 293 cells and treated with 
cycloheximide 24 h later to prevent de novoprotein synthesis, the half-life of E6*I was 
determined to be 6 h217.  
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5.4. Effect of E1C transcript and E1C protein on URR activity  
Since the HPV URR contains the regulatory elements such as promoters and enhancers 
which are required for the viral gene regulation, extensive studies have been undertaken 
to understand the effect of various viral genes on the activity of URR. Accordingly, Alloul 
et al. studied the effects on HPV16 URR of various E2 transcripts from HPV16, which 
contain E2 ORFs connected to variable upstream 5’ ORFs by alternative spliceing63. a’-
type mRNA which has the coding potential of both E2 and E1C, had a repressive effect 
on URR activity. But a mutant of a’-type mRNA truncated in the E2 ORF activated the 
URR, which they suggested might have been driven by the putative E1C protein. 
Accordingly, they showed that E1C cDNA activated the URR and suppressed the 
repression of URR by E263. I decided to confirm the URR activation by E1C together with 
E1C mutants to corroborate the findings from Alloul et al.. They had performed the 
experiments in a chloramphenicol acetyltransferase (CAT) assay, a classic method used 
in the past in many promoter studies. However, although CAT assay has a good signal-
to-background ratio, but it is a rather insensitive and time-consuming procedure requiring 
radioactivity184,185. Therefore, I decided to use DLRA, a simple 2 h procedure which is 
widely used in the last years to study the promoter activity and DNA replication of HPVs 
and has an exceptional sensitivity and wide dynamic range. 
Of the three cell lines initially tested for DLRA, HEK-293T cells, an epithelial cell line 
derived from human embryonic kidney by adenovirus immortalization and additional 
expressing SV40 T antigen, upon transfection of an HPV16-URR luciferase construct 
showed the maximum HPV16 URR activity. URR activity was lowest in human cervical 
carcinoma-derived C33A cells and only 1.5 times higher in mouse NIH-3T3 fibroblasts. 
Alloul et al. had described that the basal transcription of HPV16 URR-CAT reporter 
plasmid in NIH-3T3 and canine Cf2Th fibroblasts is higher than in C33A cells. I chose 
only HEK-293T cells for DLRA since it showed the highest URR activity and therefore will 
be possible to detect a wide range of repressed as well as activated URR signals63. 
In DLRAs, a control plasmid is always co-transfected with the reporter plasmid to allow 
normalization for transfection efficiency. Alloul et al. co-transfected a CMV-ß-
galactosidase plasmid as control plasmid for normalization. Of two control plasmids 
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tested in DLRA, p-TATAbox-RLuc was chosen over p-SV40-RLuc because of its lower 
promoter trans effect. However, when the effect of E2 on URR was analyzed, RLuc 
activities were found to be consistently repressed in ten consecutive transfections and 
therefore normalization of FLuc activites by RLuc was omitted. Only raw FLuc activities 
were used for DLRA data analysis. However, when FLuc activities were analyzed for the 
DLRAs with and without p-TATAbox-RLuc co-transfections, the variations observed were 
negligible. This indicates the consistency of the transfections and the entire DLRA 
protocol performed and therefore, analyzing URR activity without the normalization to a 
control plasmid was considered acceptable.  
E2 repressed URR activity in p-HPV16-E2 co-transfected HEK-293T cells which was in 
accordance with Alloul et al.63. In DLRA, 100 ng of p-HPV16-E2 produced a mean 
reduction of 35% in URR activity, whereas in CAT assay, Alloul et al. observed 69% 
reduction with 2000 ng of E2 plasmid co-transfected with LCR-CAT plasmid in Cf2Th 
cells, which is roughly ten times less reduction when compared to DLRA and assuming a 
linear dose-response relationship. This could be due to the different cell lines and different 
transfection efficiencies and/or higher sensitivity of DLRA. For e.g., Schenker and 
colleagues observed that the extent of repression of different HPV URRs by 
corresponding E2 proteins is cell-type dependent186.  
E1C activated URR activity in p-HPV16-E1C co-transfected HEK-293T cells which was 
in accordance with Alloul et al.63. In DLRA, 100 ng of p-HPV16-E1C increased URR 
activity by a mean of 42%, whereas in CAT assay, Alloul et al. observed 48% activation 
with 2000 ng of E1C plasmid, which is roughly 18 times less activation when compared 
to DLRA and assuming a linear dose-response relationship. This could be due to the 
same reasons as discussed for E2 above.  
Since E1C protein was found to be unstable, it was interesting to test whether URR 
activation by E1C is mediated through transcript and/or protein. p-HPV16-E1C-Pro mut 
co-transfected HEK-293T cells showed a mean URR activation of 33%. URR activation 
by p-HPV16-E1C-Pro mut indicates that E1C RNA is capable of activating URR because 
p-HPV16-E1C-Pro mut plasmid cannot encode an E1C protein. However, the mechanism 
by which E1C RNA activates URR for e.g., by URR binding needs further investigation. 
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There are studies about different cellular proteins that can bind to HPV mRNAs that 
control HPV gene expression187, for e.g., HuR binding to the late 3’-UTR of HPV16191. 
Also, it has been suggested that HPV E4 might have a role in HPV mRNA splicing 
regulation188. HPV E2 is a DNA binding protein which binds to URR to control 
transcription. There is also increasing evidence which supports the idea that E2 might 
also control HPV- and cellular-RNA splicing189 and HPV early polyadenylation190, thus 
acting as a RNA processing factor. Although there is a wealth of information about cellular 
proteins binding to HPV mRNAs or HPV proteins binding to HPV genomes, there is no 
knowledge about a HPV RNA binding to URR, and therefore this is the first study that 
hints to such a possibility. 
p-HPV16-E1C-RNA mut co-transfected HEK-293T cells unexpectedly also activated the 
URR by a mean of 19%. E1C-RNA-mut transcribes a random RNA sequence with length 
and GC content identical to E1C RNA. This could mean that URR activation by E1C RNA 
is not really E1C specific and URR could merely be activated by a RNA which possess 
the same GC content as that of E1C RNA. However, this should be tested with more 
random sequence RNAs with the same length GC content as E1C RNA.  
For E2 and E1C co-transfections, p-HPV16-E2 alone repressed URR activity by a mean 
of 17%. However, p-EV and p-HPV16-E2 together repressed by a mean of 62% 
compared to p-EV alone. This means that the addition of p-EV introduced some promoter 
trans effect causing additional URR repression apart from repression by E2. This also 
indicates susceptibility of the complex DLRA co-transfection system with subtle changes 
causing high oscillations and the need for multiple repetitions of the experiment to 
generate robust and consistent results.  
p-HPV16-E1C and p-HPV16-E2 co-transfection activated the URR by a mean of 24% 
when compared to p-EV and p-HPV16-E2 co-transfection which is the specific negative 
control. However, p-EV and p-HPV16-E2 co-transfection repressed by a mean of 54% 
when compared to p-HPV16-E2 alone. And, p-HPV16-E1C and p-HPV16-E2 together 
repressed the URR by a mean of 44% when compared to p-HPV16-E2 alone and 66% 
when compared to p-HPV16-E1C alone. Together these data show that E1C reduces the 
repressive effect of E2 on URR in E2 and E1C co-transfections and is in accordance with 
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data shown by Alloul et al.. They have observed a reduction in the E2-mediated 
transrepression of URR in E2 and E1C co-transfection experiments in Cf2Th cells in a 
dose-dependent fashion63. When E2 was co-transfected with p-HPV16-E1C-RNA mut 
plasmid, there was a mean of 40% repression of URR and 24% repression with p-HPV16-
E1C-Pro mut plasmid which are 14% and 30% lower repressions compared to E2 
transfection alone. These data again indicate that it is the E1C RNA which is activating 
URR and not E1C protein.  
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6. Outlook 
In this thesis, HPV16 E1C, which had been identified as a useful diagnostic marker 
transcript for the discrimination of low grade and high grade cervical lesions85,152, has 
been characterized. E1C was overexpressed by lentiviral transduction in four HPV16 
positive cell lines and E1^E4 transcript was found to be 20 – 30 % significantly 
downregulated. As E1^E4 protein is shown to inhibit cell proliferation171 it would be 
interesting to check for proliferation in E1C overexpressed cells by quantifying DNA 
synthesis or cellular metabolic changes or proliferation proteins such as PCNA, Ki67 or 
MCM2. The tumorigenic potential of E1C overexpressed cells could also be assessed by 
checking for clonogenicity in a colony forming assay or anchorage-independent growth 
potential in a soft agar assay193. In addition, analyzing changes in global cellular 
transcriptome under overexpressed E1C condition by microarray or RNA-seq 
technologies is also intriguing. 
Although E1C RNA can be stably overexpressed, E1C protein is found to be unstable. As 
there are several factors, which can be attributed to the instability of a protein, quinary 
interactions, cellular crowding environment or primary – secondary – tertiary – quaternary 
structure of E1C protein could be studied to understand its instability194,195.  Also looking 
for post-translational modifications such as phosphorylation, acetylation or methylation 
which can regulate protein stability is also compelling196. 
E1C RNA was found to activate HPV16 URR in a dual reporter luciferase assay. Different 
cellular RNA binding proteins have been identified that could bind to HPV16 mRNAs to 
control HPV16 gene regulation197. In this context, in order to unravel the mechanism with 
which the URR activation is mediated by E1C RNA, it would be interesting to look for E1C 
RNA interactions with cellular proteins. It is also intriguing to check whether E1C RNA 
interacts with other HPV16 proteins or is able to bind to the URR. Results from these 
experiments should provide evidence whether the URR activation by E1C RNA is a direct 
or indirect mechanism.  
Furthermore, the C-terminal module of E1fl protein from papillomaviruses was shown to 
play a role in the stabilization of E1 hexamer during viral DNA replication198-200. Therefore, 
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E1C protein overexpressed under proteasome inhibition conditions could also be 
validated for its capability to support viral DNA replication. 
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7. Abbreviations 
 
Bidest.   Bidestillatus 
BSA   Bovine Serum Albumin 
bp    base pair 
BSA   Bovine Serum Albumin 
⁰C    degree Celsius 
CIN   Cervical Intraepithelial Neoplasia 
CMV   Cytomegalovirus 
Cp    Crossing point 
CV    Coefficient of Variation 
CxCa   Cervical Cancer 
DKFZ   Deutsches Krebsforschungszentrum 
DMEM   Dulbecco’s Modified Eagle Medium 
DNA   Deoxyribonucleic acid 
E. coli   Escherichia coli 
ECL   Enhanced Chemiluminescence 
EDTA   Ethylenediaminetetraacetic acid 
e.g.   exempli gratia 
EtOH   Ethanol 
FBS   Fetal Bovine Serum 
fl    full length 
h    hour(s) 
HPV   Human Papillomavirus 
hr    high-risk 
HSIL   High-grade Squamous Intraepithelial Lesion 
i.e.    id est 
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IF    Immunofluorescence 
IRES   Internal Ribosomal Entry Site 
lr    low risk 
kb    kilo base 
LSIL   Low-grade Squamous Intraepithelial Lesion 
LV    Lentiviral 
mAb   monoclonal Antibody 
MCS   Multiple Cloning Site 
min   minute(s)    
mM   millimolar 
mRNA   messenger RNA 
MS   Mass Spectrometry 
µg    microgram(s) 
µL    microliter 
ng    nanogram(s) 
NIL/M   Negative for Intraepithelial Lesion or Malignancy 
No:   Number 
nt    nucleotide 
ORF   Open Reading Frame 
PAGE   Polyacrylamide Gel Electrophoresis 
PBS   Phosphate Buffered Saline 
PCR   Polymerase Chain Reaction 
PEI   Polyethyleneimine  
pRb   Retinoblastoma protein 
PV    Papillomavirus  
q    quantitative 
RIN   RNA Integrity Number 
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RNA   Ribonucleic acid 
rpm   rounds per minute   
RT    Room Temperature 
RT-qPCR   Reverse Transcriptase quantitative PCR 
s    second(s)   
sj    splice junction 
SV40   Simian Virus 40 
ubC   ubiquitin C   
URR   Upper Regulatory Region 
Vs.   Versus    
WB   Western blot 
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9. Supplementary Information 
 
Table 9.1. Details of plasmids containing spliced HPV16 transcripts147. 
Name Accession number Cloned region from 
reference genome 
Cloning vector 
E6*I HPV16Ra 83-795 Bluescript M13-KS  
E1^E4 HPV16R 83-795 Bluescript M13-KS 
E1C HPV16R 83-4210 Bluescript M13-KS 
HPV16 fl HPV16R 1-7904 Bluescript M13-KS 
 
 
 
 
9.2. Vector maps 
 
 
a - HPV16 sequence and base positions are numbered according to the 1996 sequence database (Los 
Alamos National  Laboratory). http://hpv-web.lanl.gov/COMPENDIUM_PDF/95PDF/1/A1-9.pdf 
 
A) 
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B) 
C) 
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Figure 9.2. Vector maps of A) pGEX-GST-Tag B) p1-His-GFP C) p2-E1C D) LV-E1C E) p-HPV16-E2 
D) 
E) 
LV-E1C 
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9.3. DNA sequence information 
 
a) HPV16 E1C 
5’- ATGGCTGATCCTGCAGATTCTAGGTGGCCTTATTTACATAATAGATTGGTGGTGTTTACATTTCCTAATGAGTTTCCAT 
TTGACGAAAACGGAAATCCAGTGTATGAGCTTAATGATAAGAACTGGAAATCCTTTTTCTCAAGGACGTGGTCCAGATTA 
AGTTTGCACGAGGACGAGGACAAGGAAAACGATGGAGACTCTTTGCCAACGTTTAAATGTGTGTCAGGACAAAATACTA 
ACACATTATGA-3’ 
 
b) GST-E1C-Tag 
5’-ATGTCCCCTATACTAGGTTATTGGAAAATTAAGGGCCTTGTGCAACCCACTCGACTTCTTTTGGAATATCTTGAAGAAAAA 
TATGAAGAGCATTTGTATGAGCGCGATGAAGGTGATAAATGGCGAAACAAAAAGTTTGAATTGGGTTTGGAGTTTCCCAATCTTC
CTTATTATATTGATGGTGATGTTAAATTAACACAGTCTATGGCCATCATACGTTATATAGCTGACAAGCACAACATGTTGGGTGGT
TGTCCAAAAGAGCGTGCAGAGATTTCAATGCTTGAAGGAGCGGTTTTGGATATTAGATACGGTGTTTCGAGAATTGCATATAGTA
AAGACTTTGAAACTCTCAAAGTTGATTTTCTTAGCAAGCTACCTGAAATGCTGAAAATGTTCGAAGATCGTTTATGTCATAAAACA
TATTTAAATGGTGATCATGTAACCCATCCTGACTTCATGTTGTATGACGCTCTTGATGTTGTTTTATACATGGACCCAATGTGCCT
GGATGCGTTCCCAAAATTAGTTTGTTTTAAAAAACGTATTGAAGCTATCCCACAAATTGATAAGTACTTGAAATCCAGCAAGTATA
TAGCATGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAATCGGATCTGGTTCCGCGTGATGGC
TGATCCTGCAGATTCTAGGTGGCCTTATTTACATAATAGATTGGTGGTGTTTACATTTCCTAATGAGTTTCCATTTGACGAAAACG
GAAATCCAGTGTATGAGCTTAATGATAAGAACTGGAAATCCTTTTTCTCAAGGACGTGGTCCAGATTAAGTTTGCACGAGGACG
AGGACAAGGAAAACGATGGAGACTCTTTGCCAACGTTTAAATGTGTGTCAGGACAAAATACTAACACATTATGAAAACCTCCCAC
ACCTCCCCCTGAACCTGAAACATAA-3’ 
 
Color code: Red – GST sequence, Black – E1C sequence, Green – Tag sequence 
 
 
c) His-GFP-E1C 
5’-ACATCACCATCACCATCACATGAGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGTGAT 
GTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGATGCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTA
CTGGAAAACTACCTGTTCCATGGCCAACACTTGTCACTACTTTCTCTTATGGTGTTCAATGCTTTTCAAGATACCCAGATCATATG
AAACGGCATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAAAGAACTATATTTTTCAAAGATGACGGGAACTACA
AGACACGTGCTGAAGTCAAGTTTGAAGGTGATACCCTTGTTAATAGAATCGAGTTAAAAGGTATTGATTTTAAAGAAGATGGAAA
CATTCTTGGACACAAATTGGAATACAACTATAACTCACACAATGTATACATCATGGCAGACAAACAAAAGAATGGAATCAAAGTT
AACTTCAAAATTAGACACAACATTGAAGATGGAAGCGTTCAACTAGCAGACCATTATCAACAAAATACTCCAATTGGCGATGGCC
CTGTCCTTTTACCAGACAACCATTACCTGTCCACACAATCTGCCCTTTCGAAAGATCCCAACGAAAAGAGAGACCACATGGTCC
TTCTTGAGTTTGTAACAGCTGCTGGGATTACACATGGCATGGATGAACTATACAAGGATGGCTGATCCTGCAGATTCTAGGTGG
CCTTATTTACATAATAGATTGGTGGTGTTTACATTTCCTAATGAGTTTCCATTTGACGAAAACGGAAATCCAGTGTATGAGCTTAA
TGATAAGAACTGGAAATCCTTTTTCTCAAGGACGTGGTCCAGATTAAGTTTGCACGAGGACGAGGACAAGGAAAACGATGGAGA
CTCTTTGCCAACGTTTAAATGTGTGTCAGGACAAAATACTAACACATTATGA-3’ 
 
Color code: Purple – ‘His’ tag sequence, Brown – GFP sequence, Black – E1C sequence 
 
 
d) HPV16-URR-FLuc 
5’-TGCAGACCTAGATCAGTTTCCTTTAGGACGCAAATTTTTACTACAAGCAGGATTGAAGGCCAAACCAAAATTTACATTAGG 
AAAACGAAAAGCTACACCCACCACCTCATCTACCTCTACAACTGCTAAACGCAAAAAACGTAAGCTGTAAGTATTGTATGTATGT
TGAATTAGTGTTGTTTGTTGTTTATATGTTTGTATGTGCTTGTATGTGCTTGTAAATATTAAGTTGTATGTGTGTTTGTATGTATGG
TATAATAAACACGTGTGTATGTGTTTTTAAATGCTTGTGTAACTATTGTGTCATGCAACATAAATAAACTTATTGTTTCAACACCTA
CTAATTGTGTTGTGGTTATTCATTGTATATAAACTATATTTGCTACATCCTGTTTTTGTTTTATATATACTATATTTTGTAGCGCCAG
CGGCCATTTTGTAGCTTCAACCGAATTCGGTTGCATGCTTTTTGGCACAAAATGTGTTTTTTTAAATAGTTCTATGTCAGCAACTA
TAGTTTAAACTTGTACGTTTCCTGCTTGCCATGCGTGCCAAATCCCTGTTTTCCTGACCTGCACTGCTTGCCAACCATTCCATTG
TTTTTTACACTGCACTATGTGCAACTACTGAATCACTATGTACATTGTGTCATATAAAATAAATCACTATGCGCCAACGCCTTACA
TACCGCTGTTAGGCACATATTTTTGGCTTGTTTTAACTAACCTAATTGCATATTTGGCATAAGGTTTAAACTTCTAAGGCCAACTA
AATGTCACCCTAGTTCATACATGAACTGTGTAAAGGTTAGTCATACATTGTTCATTTGTAAAACTGCACATGGGTGTGTGCAAAC
CGTTTTGGGTTACACATTTACAAGCAACTTATATAATAATACTAAACTACAATAATTCATGTATAAAACTAAGGGCGTAACCGAAA
TCGGTTGAACCGAAACCGGTTAGTATAAAAGCAGACATTTTATGCACCAAAAGAGAACTGCATGGAAGACGCCAAAAACATAAA
GAAAGGCCCGGCGCCATTCTATCCTCTAGAGGATGGAACCGCTGGAGAGCAACTGCATAAGGCTATGAAGAGATACGCCCTG
GTTCCTGGAACAATTGCTTTTGTGAGTATTTCTGTCTGATTTCTTTCGAGTTAACGAAATGTTCTTATGTTTCTTTAGACAGATGCA
CATATCGAGGTGAACATCACGTACGCGGAATACTTCGAAATGTCCGTTCGGTTGGCAGAAGCTATGAAACGATATGGGCTGAAT
ACAAATCACAGAATCGTCGTATGCAGTGAAAACTCTCTTCAATTCTTTATGCCGGTGTTGGGCGCGTTATTTATCGGAGTTGCAG
TTGCGCCCGCGAACGACATTTATAATGAACGTAAGCACCCTCGCCATCAGACCAAAGGGAATGACGTATTTAATTTTTAAGGTG
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AATTGCTCAACAGTATGAACATTTCGCAGCCTACCGTAGTGTTTGTTTCCAAAAAGGGGTTGCAAAAAATTTTGAACGTGCAAAA
AAAATTACCAATAATCCAGAAAATTATTATCATGGATTCTAAAACGGATTACCAGGGATTTCAGTCGATGTACACGTTCGTCACAT
CTCATCTACCTCCCGGTTTTAATGAATACGATTTTGTACCAGAGTCCTTTGATCGTGACAAAACAATTGCACTGATAATGAATTCC
TCTGGATCTACTGGGTTACCTAAGGGTGTGGCCCTTCCGCATAGAACTGCCTGCGTCAGATTCTCGCATGCCAGGTATGTCGTA
TAACAAGAGATTAAGTAATGTTGCTACACACATTGTAGAGATCCTATTTTTGGCAATCAAATCATTCCGGATACTGCGATTTTAAG
TGTTGTTCCATTCCATCACGGTTTTGGAATGTTTACTACACTCGGATATTTGATATGTGGATTTCGAGTCGTCTTAATGTATAGAT
TTGAAGAAGAGCTGTTTTTACGATCCCTTCAGGATTACAAAATTCAAAGTGCGTTGCTAGTACCAACCCTATTTTCATTCTTCGCC
AAAAGCACTCTGATTGACAAATACGATTTATCTAATTTACACGAAATTGCTTCTGGGGGCGCACCTCTTTCGAAAGAAGTCGGGG
AAGCGGTTGCAAAACGGTGAGTTAAGCGCATTGCTAGTATTTCAAGGCTCTAAAACGGCGCGTAGCTTCCATCTTCCAGGGATA
CGACAAGGATATGGGCTCACTGAGACTACATCAGCTATTCTGATTACACCCGAGGGGGATGATAAACCGGGCGCGGTCGGTAA
AGTTGTTCCATTTTTTGAAGCGAAGGTTGTGGATCTGGATACCGGGAAAACGCTGGGCGTTAATCAGAGAGGCGAATTATGTGT
CAGAGGACCTATGATTATGTCCGGTTATGTAAACAATCCGGAAGCGACCAACGCCTTGATTGACAAGGATGGATGGCTACATTC
TGGAGACATAGCTTACTGGGACGAAGACGAACACTTCTTCATAGTTGACCGCTTGAAGTCTTTAATTAAATACAAAGGATATCAG
GTAATGAAGATTTTTACATGCACACACGCTACAATACCTGTAGGTGGCCCCCGCTGAATTGGAATCGATATTGTTACAACACCCC
AACATCTTCGACGCGGGCGTGGCAGGTCTTCCCGACGATGACGCCGGTGAACTTCCCGCCGCCGTTGTTGTTTTGGAGCACG
GAAAGACGATGACGGAAAAAGAGATCGTGGATTACGTCGCCAGTAAATGAATTCGTTTTACGTTACTCGTACTACAATTCTTTTC
ATAGGTCAAGTAACAACCGCGAAAAAGTTGCGCGGAGGAGTTGTGTTTGTGGACGAAGTACCGAAAGGTCTTACCGGAAAACT
CGACGCAAGAAAAATCAGAGAGATCCTCATAAAGGCCAAGAAGGGCGGAAAGTCCAAATTGTAA-3’ 
 
Color code: Blue – HPV16-URR sequence, Black – FLuc sequence 
 
 
e) HPV16-E2 
5’-ATGGAGACTCTTTGCCAACGTTTAAATGTGTGTCAGGACAAAATACTAACACATTATGAAAATGATAGTACAGACCTACGTGA 
CCATATAGACTATTGGAAACACATGCGCCTAGAATGTGCTATTTATTACAAGGCCAGAGAAATGGGATTTAAACATATTAACCAC
CAAGTGGTGCCAACACTGGCTGTATCAAAGAATAAAGCATTACAAGCAATTGAACTGCAACTAACGTTAGAAACAATATATAACT
CACAATATAGTAATGAAAAGTGGACATTACAAGACGTTAGCCTTGAAGTGTATTTAACTGCACCAACAGGATGTATAAAAAAACA
TGGATATACAGTGGAAGTGCAGTTTGATGGAGACATATGCAATACAATGCATTATACAAACTGGACACATATATATATTTGTGAA
GAAGCATCAGTAACTGTGGTAGAGGGTCAAGTTGACTATTATGGTTTATATTATGTTCATGAAGGAATACGAACATATTTTGTGC
AGTTTAAAGATGATGCAGAAAAATATAGTAAAAATAAAGTATGGGAAGTTCATGCGGGTGGTCAGGTAATATTATGTCCTACATC
TGTGTTTAGCAGCAACGAAGTATCCTCTCCTGAAATTATTAGGCAGCACTTGGCCAACCACCCCGCCGCGACCCATACCAAAGC
CGTCGCCTTGGGCACCGAAGAAACACAGACGACTATCCAGCGACCAAGATCAGAGCCAGACACCGGAAACCCCTGCCACACC
ACTAAGTTGTTGCACAGAGACTCAGTGGACAGTGCTCCAATCCTCACTGCATTTAACAGCTCACACAAAGGACGGATTAACTGT
AATAGTAACACTACACCCATAGTACATTTAAAAGGTGATGCTAATACTTTAAAATGTTTAAGATATAGATTTAAAAAGCATTGTACA
TTGTATACTGCAGTGTCGTCTACATGGCATTGGACAGGACATAATGTAAAACATAAAAGTGCAATTGTTACACTTACATATGATA
GTGAATGGCAACGTGACCAATTTTTGTCTCAAGTTAAAATACCAAAAACTATTACAGTGTCTACTGGATTTATGTCTATATGA-3’ 
 
f) HPV16-E1C-RNA mut 
5’-GATTAATGGTATAACAGGATTAAGAAACCAATACAAAGGCTACATCCTCACTTAGATGAAAGCAAACGCAGAATAATGATTA 
CTTTTTCGATACGTGAAACATATCCCATGGTAGTCCAAAGACTTGAAAGTCTATCACCTCTAGGGCCCTTTTCTGGATATAAACG
CCAAGTTGAATCCGTATTTGGAGGTACGATGGATCAGTCTGGATGAGACGTGCTTCATTTATATCGTAAGTAGGGTCGACCAAG
AACCCAAATC-3’ 
 
g) HPV16-E1C-Pro mut 
5’-GATTAATGATAGTAACCTGCAGATTCTAGGTGGCCTTATTTACATAATAGATTGGTGGTGTTTACATTTCCTAATGAGTTT 
CCATTTGACGAAAACGGAAATCCAGTGTATGAGCTTAATGATAAGAACTGGAAATCCTTTTTCTCAAGGACGTGGTCCAGATTAA
GTTTGCACGAGGACGAGGACAAGGAAAACGATGGAGACTCTTTGCCAACGTTTAAATGTGTGTCAGGACAAAATACTAACACAT
TATGACAAATC-3’ 
 
Color code: In red, green and blue are the three stop codons 
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9.4. Materials used for W12 cell culture 
 
3T3 Cell medium 
 
 
 
 
 
 
 
 
W12 Medium  
 
Ingredients Quantity 
DMEM with high glucose 375 mL 
F12 medium 125 mL 
Fetal Bovine Serum 25 mL 
100X Hydrocortisone 5 mL 
100X Insulin 5 mL 
100X Cholera Toxin 5 mL 
100X Adenine 5 mL 
Penicillin/streptomycin 5 mL 
100X Epidermal Growth Factor 
 
5 mL 
 
 
Reagents used for W12 cell culture 
 
Reagents Composition 
0.02% EDTA Solution 
 
1L 1X PBS  
0.2 g EDTA 
Autoclave the solution 
Ham’s F-12 nutrient mixture  
Earle's Salts 
 
For 2L add: 
128 g NaCl   
8 g KCl  
74 g NaHCO3 
2.5 g NaH2PO4.H2O   
4 g MgSO4.7H2O   
0.002 g Fe(NO3)3.9H2O 
0.1 g Phenol Red 
Bring to 2L with sterile water and filter-sterilize 
HEPES Buffered Earle's Salts (HBES) 
 
25 mL 1M HEPES buffer 
100 mL Earle's Salts 
Bring to 2L with sterile water and filter-sterilize 
50X Mitomycin C 2mL HBES 
2mg mitomycin C 
8 mL 3T3 cell medium 
Filter-sterilize and store at -20°C as 1 mL aliquots.  
100X Hydrocortisone 5 mL cold 100% Ethanol 
Ingredients Quantity 
DMEM with high glucose 500 mL 
Fetal Bovine Serum 50 mL 
Penicillin/streptomycin 5 mL 
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25 mg Hydrocortisone 
This is 5 mg/mL solution.  
 
- Add 0.8 mL of 5 mg/mL hydrocortisone solution 
to 100 mL HBES containing 5% FBS.  
 
- Filter-sterilize and store at -20°C as 10 mL 
aliquots. 
100X Cholera toxin 1.2mL autoclaved Bidest H2O 
1mg Cholera toxin 
This is 10 µM solution. 
  
- Dilute 50 µL of 10 µM solution into 50 mL HBES 
containing 0.1% Bovine Serum Albumin.  
- Filter-sterilize and store at 4°C as 10 mL  
aliquots. 
100X Insulin Prepare immediately before use and never freeze. 
- Dissolve 12.5 mg insulin in 25 mL of 0.005M 
HCL.  
- Filter-sterilize with a syringe filter prewet with 
FBS. 
 
100X Adenine - Dissolve 121 mg adenine in 50 mL of 0.05M HCl 
by stirring one hour.  
- Filter-sterilize and store at -20°C in 10 mL 
aliquots. 
 
100X Epidermal Growth Factor - Dissolve 100 g vial in 10 mL sterile water. 
- Add 90 mL HBES containing 0.1% bovine 
serum albumin. 
- Filter-sterilize and store at -20°C in 10 mL 
aliquots. 
 
 
 
 
9.5. Complete transduction summary 
In the below tables, details of all transductions including transduction no:, date on which 
transduction was performed, batch of lentiviral* particles preparation used for different 
transductions of different cell lines, cell lines used, lentiviral vector transduced, total no: 
of cells harvested after completion of puromycin selection, amount of cells used for RNA 
extraction, no: of RNA extractions performed, total amount of RNA extracted, no: of PCRs 
performed, copies/cell analyzed for different HPV16 transcripts (E6*I, E1^E4, E7 and 
ubC), Ratios of these transcript copies/cell to ubC (E6*I/ubC, E1^E4/ubC and E7/ubC) 
and finally, each of these ratios in LV-E1C transductions normalized to LV transductions 
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to analyze the changes in the expression of the corresponding transcripts (E6*I LV-
E1C/LV, E1^E4 LV-E1C/LV and E7 LV-E1C/LV ) are given. 
*- LV stands for ‘Lentiviral’ in the tables. 
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9.6. Table showing the firefly and renilla luciferase signals of all the transfections. 
 
 
